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Abstract 
 
Membrane proteins constitute 30% of the human genome but represent only a small 
fraction of the known three-dimensional protein structures. In this thesis I describe the 
characterization of the membrane protein complex between sarcoplasmic reticulum 
Ca2+-ATPase (SERCA) and phospholamban (PLN). SERCA drives cardiac muscle 
relaxation by active transport of Ca2+ ions into the SR. PLN is a small membrane protein 
that consists of a helical trans-membrane domain connected to a cytoplasmic domain 
through a short loop, and inhibits SERCA through intra-membrane interactions. The 
cytoplasmic domain of PLN is in equilibrium between a helical, membrane-associated T 
state and an unfolded, membrane-dissociated R state. Here, I summarize the work to 
probe the structures of the T and R states and elucidate the role of the conformational 
equilibrium in regulation of SERCA. Using solution and solid state NMR in combination 
with biochemical assays I show that the structures of T and R state but not their relative 
populations are conserved in different lipid environments and sample conditions. 
Furthermore, the T/ R equilibrium has a central role in SERCA regulation and is crucial 
to relieve the inhibition of the enzyme. These findings provide new insights into 
SERCA/PLN function and offer a unique view of the role of conformational equilibria and 
multiple conformational states in membrane protein structure and function.               
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Chapter 1 - Introduction 
1.1 Lipid membranes 
Cells and organelles are surrounded by self-assembled phopsholipid bilayers referred to 
as membranes. Membranes create a barrier to the outside environment and are the site 
of many important cellular processes such as oxidative phosphorylation, photosynthesis 
and signaling. The majority of these functions are carried out by membrane proteins that 
are associated with or span the membrane bilayer. According to the classic “fluid mosaic 
model”, membranes can be depicted as two-dimensional entities where lipids and 
proteins can diffuse freely (1) (Figure 1). This view has later been challenged by the 
discovery of microdomains within the membrane of lipids and proteins referred to as 
“lipid rafts” and multiple anchoring interactions between membrane-associated proteins 
and the cell cytoskeleton (2). The lipid composition of the membrane varies between 
different organelles and organisms. For example, the eukaryotic endoplasmic reticulum 
(ER) membrane has an average chain length of ~18 carbons and is composed mainly of 
lipids with phosphocholine (PC) and phosphoethanolamine (PE) head groups while the 
most abundant lipids in yeast cell membranes are phosphoinositol (PI), phosphoserine 
(PS) and sphingomyelin (3). 
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Figure 1. Fluid mosaic model of lipid membranes. A.) Original model proposed by Singer 
et al. (1) B.) Revised model by Engelman(2). Figure adapted from Engelman (2). 
1.2 Membrane proteins 
Membrane proteins constitute ~30% (4) of the proteins in the human genome and more 
than 50% of the available drug targets (5). Integral membrane proteins span the 
membrane bilayer one or several times either as β-strands or as trans-membrane (TM) 
α-helices. 8 to 24 β-strands fold into cylindrical β-barrels with hydrogen bonds between 
adjacent strands and hydrophilic side chains lining the inside of the barrel (6) (Figure 
2A). This creates a hydrophilic pore through the bilayer and β-barrels mediate transport 
of compounds through the outer periplasmic membrane of prokaryotes and the outer 
membranes of mitochondria and chloroplasts of eukaryotic cells. Proteins with TM α-
helices account for the rest of the integral membrane proteins (Figure 2B). They range 
from single-spanning, hydrophobic helices to multi-helical structures with as as many as 
20 TM helices that form channels or other functional units (7). Helical TM domains have 
an abundance of amino acids with hydrophobic side chains, especially Val, Ile and Leu. 
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TM helices can therefore often be identified from the primary sequence of a protein due 
to the relative hydrophobicity of its amino acids (7).         
 
Figure 2. Membrane protein structures. A.) β-barrel exemplified by the voltage-gated 
anion channel (VDAC) (PDB ID 2K4T). B.) α-helical rhodopsin with the typical seven TM 
helix fold of G-protein coupled receptors (PDB ID 1F88). 
In the last few decades there has been a near exponential growth of the number of 
protein structures deposited in the protein database, which currently contains ~80000 
protein structures (www.pdb.org). However, membrane proteins make up only ~2% of 
these, and there are only ~ 300 unique membrane protein structures 
(http://blanco.biomol.uci.edu/membrane_proteins_xtal.html). The reason for the 
discrepancy between the number of membrane protein structures and the total number 
of known structures is that membrane proteins present a number of experimental 
challenges. They are typically difficult to over-express and frequently form inclusion 
bodies that are complicated to refold to regain the native three-dimensional protein 
structure. In addition, membrane proteins require a membrane-mimicking environment 
such as a micelle or a lipid bilayer to be solubilized. Solution nuclear magnetic 
resonance (NMR) and X-ray crystallography cannot be performed in lipid bilayers. 
Therefore, these techniques, which together contributed more than 99% of the structures 
in the PDB, are typically performed with proteins reconstituted into detergent micelles. 
Studies of detergent-solubilized protein have produced a number of groundbreaking 
results such as crystal structures of ion channels (8), G protein coupled receptors 
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(GPCRs) (9, 10) and translocons (11) and solution NMR structures of polytopic 
membrane proteins such as voltage-dependent anion channel VDAC (12), uncoupling 
protein 2 (13) and DsbB (14). However, detergent micelles are a poor mimic of the 
native membrane environment and can interfere with both protein structure and function. 
In contrast to solution NMR and X-ray crystallography, solid state NMR (ssNMR) 
experiments can be acquired in lipid bilayers and even whole cells (15). Thanks in part 
to this unique property, ssNMR has developed as a powerful tool to obtain high 
resolution structural information of membrane proteins in their natural environment (16, 
17).  
1.3 NMR spectroscopy 
Certain atomic nuclei possess a spin and can therefore populate different spin states. In 
a magnetic field these states have degenerate energies, leading to a distribution of spins 
between the states according to the Boltzmann distribution. The excitation, manipulation 
and detection of nuclear spins form the basis of NMR spectroscopy. The two main NMR 
techniques are solution NMR and ssNMR. An important difference between these 
techniques is the nature of the samples. Solution NMR samples are characterized by 
molecules that tumble rapidly in solution, for example small soluble proteins. ssNMR 
samples, on the other hand, have restricted motion, such as fibrillar proteins or a 
membrane proteins in bilayers. The motional differences have significant effects on NMR 
observables such as chemical shifts and dipolar couplings. As a consequence, solution 
NMR and ssNMR differ both in the nature of the experiments and the information that 
can be obtained from them. 
1.3.1 Chemical shifts 
The electrons surrounding a nucleus give rise to magnetic fields that can either increase 
or decrease the static field of the NMR magnet.  Each nucleus therefore experiences a 
local, “induced” field (Bind) that is slightly different than the global field B0. This effective 
magnetic field can be approximated as (18): 
𝐵𝑖𝑛𝑑 = 𝛿𝐵0 
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Where δ is a 3*3 matrix that is referred to as the chemical shift tensor and is different for 
each nucleus. The rapid molecular tumbling of a solution NMR sample gives isotropic 
chemical shift according to: 
𝛿𝑖𝑠𝑜 = 𝛿11 + 𝛿22 + 𝛿333  
Where δ11, δ22 and δ33 represent the diagonal elements of the chemical shift tensor and 
are referred to as principal values (18). Under these conditions the chemical shift has no 
orientation-dependence and is sensitive to the local environment of the nucleus. For 
example, isotropic chemical shifts of Cα nuclei are excellent probes of secondary 
structure. In ssNMR samples, chemical shift are not motionally averaged and thus 
orientation-dependent. ssNMR therefore requires specific methods to acquire high 
resolution spectra but can also provide information about the orientation of molecules in 
a sample (see section 1.3.4). 
1.3.2 Dipolar couplings 
Nuclear spins act as magnetic dipoles that generate magnetic fields in the space 
surrounding the nucleus. The interactions between neighboring nuclei give rise to dipolar 
couplings that are fundamental in NMR experiments and generally provide the main 
contribution to relaxation of the NMR signal. Under the secular approximation, the 
heteronuclear dipolar coupling (DIS) between two spins I and S is 
𝐷𝐼𝑆 = −𝜇0𝛾𝐼𝛾𝑆ℏ4𝜋𝑟𝐼𝑆3  �3 cos2 𝜃𝐼𝑆 − 12 �  
where θIS is the angle that the I-S bond vector makes with respect to the magnetic field, 
γI and γS are the gyromagnetic ratios of the two spins and rIS is the inter-nuclear distance. 
In solution NMR samples, molecules tumble rapidly in solution, leading to motional 
averaging of the dipolar couplings to zero and sharp peaks in the NMR spectrum. Still, 
their distance-dependence makes dipolar couplings very important in solution NMR 
since non-secular parts of the dipolar coupling give rise to the nuclear Overhauser effect 
(nOe), which is the central tool for structure determination of proteins by solution NMR. 
ssNMR samples have restricted motion and thus non-zero dipolar couplings. Therefore, 
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ssNMR experiments generally utilize dipolar couplings to transfer magnetization by 
cross-polarization transfers that satisfy the Hartmann-Hahn condition 
𝛾𝐼𝐵1,𝐼 = 𝛾𝑆𝐵1,𝑆 
where B1,I and B1,S are the applied radio-frequency fields on nuclei I and S, respectively. 
In ssNMR, dipolar couplings are also frequently used to get information about both 
orientation and inter-nuclear distances (see section 1.3.4). 
1.3.3 Paramagnetic relaxation enhancement  
Due to the large gyromagnetic ratio of the electron, unpaired electrons give rise to local 
magnetic fields of significantly larger magnitude than those arising from nuclei. The 
dipolar interactions with these paramagnetic centers give increased relaxation rates of 
NMR signals and increased line widths of the peaks in the NMR spectrum (Figure 3). 
This effect, often referred to as paramagnetic relaxation enhancement (PRE), can be 
used to probe distances up to ~30Å. PRE has therefore evolved as an important 
complement to the nOe, which is limited to distances ~6Å, in structure determination of 
proteins. PRE has been implemented together with other restraints to determine 
structures of soluble proteins (19) and membrane proteins (13, 20) by solution NMR. 
Recent studies have also extended this method to structure determination of small 
microcrystalline proteins by ssNMR (21).     
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Figure 3. Paramagnetic relaxation enhancement. Effect of spin label on NMR signal in 
the time domain and frequency domain. LW refers to the line width at half height. 
1.3.4 Solid state NMR 
A crucial feature of a solution NMR sample is a rapid molecular reorientation with 
rotational correlation times on the ns time scale. Detergent-solubilized membrane 
proteins tumble rapidly in solution. This gives dipolar couplings that are motionally 
averaged to zero and the chemical shift take an isotropic value. Lipid vesicles typically 
have correlation times of several µs. Under these conditions the dipolar couplings and 
chemical shifts are orientation-dependent, which leads to broad powder patterns that 
represent all possible orientations of each nucleus in the sample (Figure 4).  
 
Figure 4. O-ssNMR of membrane proteins. A.) and B.) Simulated spectra of an aligned 
TM helix with a single 15N label. C.) Characteristic powder pattern of an unaligned 
protein.  
Thus, solution NMR experiments cannot be performed in lipid vesicles and ssNMR is the 
NMR method of choice for membrane proteins in lipid bilayers. ssNMR utilizes two main 
techniques, oriented ssNMR (O-ssNMR) and magic angle spinning (MAS) ssNMR, to 
produce high resolution spectra. 
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O-ssNMR: In O-ssNMR all molecules in the sample have a uniform alignment with 
respect to the static magnetic field of the magnet. As a consequence each nucleus gives 
rise to one peak in the NMR spectrum, and the position of the peak is orientation-
dependent. The uniform alignment can be achieved by “mechanical alignment” where 
protein-containing lipid bilayers are stacked between thin glass slides. Alternatively, the 
sample can be oriented by “magnetic alignment” where proteins are reconstituted into 
bicelles, which are a mixture between short-chain and long-chain lipids that form a liquid 
crystalline phase and align spontaneously in a strong magnetic field. Orientation-
dependent NMR observables offer a unique opportunity to orient membrane proteins in 
the lipid membrane. For example, the chemical shift of the amide nitrogen in a peptide 
bond is given by: 
𝛿𝐼 = (𝛿33 − 𝛿11) sin2 𝛽 cos2(𝛼 − 17) + (𝛿11 − 𝛿22) sin2 𝛽 + 𝛿22 
where the angles α and β are defined according to figure 5 and the principal values of 
the chemical shift tensor are δ11 = 64 ppm, δ22 = 77 ppm, and  δ33 = 225 ppm. The N-H 
dipolar coupling is: 
𝐷𝐻𝑁 = −𝜇0𝛾𝐻𝛾𝑁ℏ4𝜋𝑟𝐻𝑁3  �3 cos2 𝜃𝐻𝑁 − 12 �  
where θHN is defined as the angle between the H-N bond vector and the magnetic field 
B0 and rHN is the distance between the amide nitrogen and amide proton.    
 
9 
 
Figure 5. Principal components of the 15N chemical shift tensor with respect to the 
peptide plane.  
The orientation-dependence of NMR observables is frequently utilized in two-
dimensional separated local field (SLF) experiments, such as the Polarization Inversion 
Spin Exchange at Magic Angle (PISEMA) experiment, that correlate chemical shifts and 
dipolar couplings. TM helices have 3.6 residues per helical turn and give rise to 
characteristic polarity indexed slant angle (PISA) wheels in the spectra with 3.6 peaks 
per turn of the wheel. The size and position of the PISA wheel is directly correlated to 
the angle between the helical axis and the bilayer normal and can therefore be utilized to 
orient the helix in the membrane (Figure 6). O-ssNMR has provided backbone 
structures of several membrane-spanning proteins (22, 23). In addition, a hybrid 
approach where O-ssNMR is combined with solution NMR in micelles has recently 
produced all-atom high resolution structures of both monomeric and pentameric forms of 
the membrane protein phospholamban (PLN) (24, 25). 
 
Figure 6. PISEMA spectra at different orientations of an α-helix. 
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MAS-ssNMR: In MAS-ssNMR, high resolution spectra are produced by spinning the 
sample around an axis which makes a 54.7° “magic” angle with respect to the magnetic 
field. The spinning averages out the secular contributions of the dipolar coupling and 
chemical shift, which gives isotropic chemical shifts and zero dipolar couplings (Figure 
7) since 
  
𝐷𝐼𝑆 = −𝜇0𝛾𝐼𝛾𝑆ℏ4𝜋𝑟𝐼𝑆3  � 3 cos2 54.7° − 1 2 �  = 0 
There are a growing number of multidimensional MAS-ssNMR experiments that can be 
used for assignment of chemical shifts, measurement of inter-nuclear distances and 
internal dynamics (16, 17). MAS-ssNMR has been used to determine high resolution 
structures of micro-crystallized, soluble proteins like the α-spectrin SH3 domain (26)  
and ubiquitin (27). Notable MAS studies for membrane proteins include probing the 
mechanism of potassium channel (KcsA) gating (28), determining structure of the M2 
channel of influenza virus (29), and recently the backbone structure determination of the 
GPCR CXCR1 in combination with molecular modeling (30).  
 
Figure 7. Magic angle spinning. ωb refers to the spinning frequency of the MAS rotor. 
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1.3.5 Membrane environments 
ssNMR experiments can be acquired in a range of different bilayer systems that can be 
tailored to mimic the lipid composition of native lipid membranes (Figure 8). MAS-
ssNMR allows for total flexibility in sample lipids and can be performed at a wide range 
of temperatures. For example, a recent study used lipids that mimic viral membranes to 
study the M2 channel of influenza virus (31). Similarly, mechanically O-ssNMR 
experiments can be performed in a range of bilayer conditions. Bicelles, on the other 
hand, are limited to certain mixtures of long and short-chain lipids. The long-chain lipids 
need to have predominantly saturated chains and a PC head group even if a portion can 
be exchanged with a lipid with a different head group and chain saturation. The choice of 
short-chain lipid is less stringent and several detergents including 1,2-dihexanoyl-
glycero-3-phosphocholine (DHPC), dodecylphosphocholine (DPC), Triton X-100 and 3-
[(3-Cholamidopropyl)dimethylammonio]-2-hydroxy-1-propanesulfonate (CHAPSO) can 
be utilized for bicelle formation. In addition, the q value, which is defined as the molar 
ratio of long chain to short chain lipid, needs to be sufficiently large (usually >3) to 
achieve alignment. A major advantage of bicelles compared to mechanically aligned 
bilayers is that the sample conditions (i.e pH, salt concentration) can be easily controlled 
(32). Bicelles have been successfully utilized to align a number of membrane proteins 
with as many as seven TM domains (33).   
 
Figure 8. Membrane environments for NMR experiments.        
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1.4. Cardiac muscle physiology and pathophysiology 
Cardiac muscle contraction is initiated by a calcium induced calcium release mechanism 
where depolarization of the sarcolemma membrane triggers an opening of voltage gated 
Ca2+ channels and a subsequent influx of extra-cellular Ca2+ ions into the cytoplasm of 
the cardiomyocyte (Figure 9). Ca2+ binds to ryanodine receptors (RyR) in the 
sarcoplasmic reticulum (SR) membrane causing them to open and release a larger 
amount of Ca2+. Binding of Ca2+ to troponin C causes a conformational rearrangement 
that allows actin and myosin to interact and produce force. For muscle relaxation the 
Ca2+ levels must be lowered and this is achieved either by transport out of the cell 
through Ca2+/Na+ exchangers (NCX) or by transport into the SR by SR Ca2+-ATPase 
(SERCA). The latter mechanism is responsible for ~60% of the Ca2+ depletion. SERCA 
is inhibited by PLN, which is present in molar excess of SERCA in the SR membrane 
(34). Extracellular stimuli of the β-adrenergic receptors leads to raised cAMP levels that 
triggers protein kinase A (PKA) to phosphorylate PLN and several other proteins that are 
involved in Ca2+ handling (35). Phoshorylation of PLN relieves the inhibition of SERCA 
and lead to more efficient muscle relaxation (36).  
 
Figure 9. Schematic of a cardiomyocyte, adapted from Davis et al. (35) SERCA is 
referred to as ATP. 
Defective Ca2+ handling in the cardiomyocyte leads to a pathophysiological condition. 
For example, a reduction of SERCA expression is associated with chronic heart failure, 
where the heart is unable to pump enough blood to satisfy the demands of the body 
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(37). Heart failure is one of the leading causes of death in the world and affects more 
than 2% of the population in the United States (38). Several studies have shown that 
increasing SERCA activity can restore cardiac muscle function to relieve the effects of 
heart failure (39). To this end, there are currently three separate clinical trials that utilize 
adeno-associated virus (AAV) to over-express SERCA and thereby increase the total 
Ca2+ transport into the SR (37). One of the studies reported positive results of phase I 
trials and also recently of phase II trials (40).  
Another approach to increase SERCA activity is by modulation of PLN function. This has 
been done by decreasing PLN expression using antisense RNA (41) or by delivering a 
pseudophosphorylated form of PLN where a Ser 16 to Glu (S16E) mutation mimics PKA-
mediated phosphorylation. S16E-PLN competes with endogenous PLN for binding to 
SERCA and this approach has been successfully applied to heart failure animal models 
(42).  
1.5 SERCA and PLN 
1.5.1 SERCA  
SERCA is a 110 kDa membrane protein that hydrolyses ATP to transport Ca2+ ions into 
the SR against a concentration gradient. SERCA is a P-type ATPase that is present in 
several isoforms where SERCA1a is the most prevalent in skeletal muscle and 
SERCA2a in cardiac muscle (43). The enzyme consists of a helical TM and three 
cytoplasmic domains: actuator (A), nucleotide (N) and phosphorylation (P) domains. 
ATP binds to the N domain, which results in autophosphorylation of D351 in the P 
domain, forming a high energy bond that provides the energy to transport two Ca2+ ions 
into the lumen of the SR along with counter-transport of two H+ ions (44, 45). Several 
crystal structures have been solved of SERCA, capturing different stages of the 
enzymatic cycle. Specifically, SERCA populates two major conformational states: the E2 
state with low Ca2+ affinity (46) and the E1 state with high affinity for Ca2+ (47). The 
structures show that SERCA undergoes major conformational changes in the 
cytoplasmic domain in the transition between different conformational states (Figure 10). 
However, spectroscopic as well as computational studies have concluded that some 
crystal structures likely capture extreme conformational states that are not significantly 
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populated in a membrane environment (48-50). Also, considering the high intracellular 
nucleotide concentration, the crystal structure of the E1:Ca2+ state, which has an open 
structure with large separation between A and P/N domains, is likely not physiologically 
relevant (45). 
 
Figure 10. X-ray crystallography structures of SERCA in E1 (induced by high Ca2+ 
concentration) and E2 (induced by presence of the inhibitor thapsigargin) states. 
1.5.2 PLN  
PLN is a small membrane-spanning protein that is present at a ~5-fold excess to SERCA 
in the SR membrane of cardiac muscle (34, 51). PLN is present in equilibrium between 
monomeric and pentameric forms where the monomer binds and regulates SERCA and 
the pentamer is thought to act as a storage form (52, 53). PLN inhibits SERCA by 
reducing the Ca2+ affinity of the enzyme (Figure 11). The inhibition is relieved by 
phosphorylation of PLN at S16 by PKA or at T17 by Calmodulin-dependent kinase II 
(36).  
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Figure 11. Inhibition of SERCA by PLN. Normalized ATPase activity of SERCA as a 
function of Ca2+ concentration. Half Vmax is reached at a higher Ca2+ concentration in the 
presence of PLN and the shift is measured as ∆pKCa. 
The structure of pentameric as well as monomeric PLN consists of a TM helix connected 
to a cytosplasmic domain by a short loop (24, 25) (Figure 12). The TM domain can be 
divided into the very hydrophobic domain II (residues 31-52), which resides in the 
hydrocarbon region of the bilayer and the more hydrophilic domain Ib (residues 23-30), 
which makes several contacts with the lipid head groups. The cytoplasmic domain, also 
referred to as domain Ia, contains the two phosphorylation sites, S16 and T17. The 
structure of domain Ia has been controversial. Initial solution NMR studies in organic 
solvent and detergent micelles reported an α-helical structure attached to the micelle 
surface (54, 55) while ssNMR studies in lipid bilayers suggested that domain Ia is 
unfolded and membrane dissociated (56). Furthermore, a study of pentameric PLN in 
detergent micelles determined domain Ia to be helical and oriented parallel to the 
proposed bilayer normal (57). More recently, NMR, electron paramagnetic resonance 
(EPR) and fluorescence resonance energy transfer (FRET) studies have concluded that 
in pentameric as well as monomeric PLN domain Ia is in equilibrium between a 
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membrane-associated, α-helical T state and a membrane-dissociated, unfolded R state, 
thus resolving the apparent discrepancy from the initial structural studies (58-60) (Figure 
12). The T state is the dominating conformation in dodecylphosphocholine (DPC) 
micelles and 1,2-dioleoyl-glycero-3-phosphocholine (DOPC)/ 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine (DOPE) lipid bilayers with the R state populated at <20% (60, 61). 
Phosphorylation at S16 leads to local unfolding and increased dynamics around the 
phosphorylation site and a shift in equilibrium towards the R state (58, 62, 63). Similarly, 
mutations in the loop and domain Ia of PLN can either increase or decrease the 
dynamics in the cytoplasmic region, which has been shown to correlate with SERCA 
inhibition (Figure 13). For example, a P21G mutation in the loop leads to increased 
dynamics and lowered inhibition of SERCA making this mutant a possible future 
candidate in gene therapy applications (64).                  
 
Figure 12. Structures of pentameric PLN (PDB ID 2KYV) and monomeric PLN in T (PDB 
ID 2KB7) and R states.  
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Figure 13. Structure-dynamics-function relationship for PLN mutants. Adapted from Ha 
et al. (64). 
1.5.3 The SERCA/PLN complex 
Although there are several structures of both SERCA and PLN there is still no high 
resolution structure of the SERCA/PLN complex. Extensive scanning mutagenesis 
studies have defined the TM domain of PLN as the primary inhibitory unit while the 
cytoplasmic region has a regulatory role (65). These studies also defined the side of the 
TM helix that faces SERCA in the complex and identified a stretch of residues from K397 
to K402 in the N domain of SERCA to be crucial for SERCA regulation (66). In 
agreement with this a bifunctional cross-linker was found to cross-link K3 of PLN to Lys 
400 in the N domain of SERCA (67). In addition to this single cytoplasmic cross-link, 
several cross-links have been formed between the TM domains of SERCA and PLN 
using different reagents and mutants. Cross-linking is reduced or completely abolished 
at high Ca2+ concentrations or upon phosphorylation of PLN at S16 but increased in the 
presence of nucleotide (68). This led to the conclusion that PLN inhibits SERCA by 
interacting with the E2 form of the enzyme and that S16 phosphorylation of PLN relieves 
the inhibition by dissociation of the complex. However, spectroscopic measurements and 
immuno-precipitation experiments have shown that neither high Ca2+ concentration nor 
phosphorylation dissociate PLN from SERCA (69, 70). This implies that phosphorylation 
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relieves the inhibition through a conformational rearrangement of the complex. Based on 
mutagenesis and cross-linking studies, a solution NMR structure of a monomeric mutant 
of PLN and the crystal structure of SERCA in the E2 state, a molecular model was 
proposed of the SERCA/PLN complex (Figure 14) (71). In this model, the TM domain of 
PLN binds in a groove formed by helices M2, M4, M6, and M9 of SERCA. The 
cytoplasmic domain Ia of PLN is helical and interacts with the N and P domains of 
SERCA, a position that is heavily biased by the cross-link between K3 and K400 of 
SERCA. A later study utilized backbone dihedral angle restraints derived from ssNMR 
experiments to further refine the model of the complex (72). The main difference 
between the two models is that the latter determined that domain Ib remains helical upon 
binding to SERCA.  
 
Figure 14. Molecular model of the SERCA/PLN complex. Structural coordinates were 
provided by D. H. Maclennan and C. Toyoshima. 
However, a shortcoming of these studies are that they model only one state of PLN 
bound to SERCA even if both NMR and EPR studies have shown that the T/R state 
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equilibrium of PLN is retained upon SERCA binding (58, 60). Upon interaction with 
SERCA, there is a slight shift in the equilibrium in favor of the R state. Also, anchoring of 
domain Ia to the lipid bilayer using a covalently attached lipid anchor shifts the 
equilibrium completely to the T state. Phosphorylation of S16 does not relieve the 
inhibition of lipid-anchored PLN. (58). This implies that the T/R equilibrium is important 
for PLN function. Still, the functional roles of the T and R states remain elusive.  
Additional structural information about the complex has come from cryoelectron 
microscopy studies of two-dimensional SERCA/PLN co-crystals. These studies 
produced low resolution images and indicated that PLN binds in between two SERCA 
monomers, possibly as a pentamer (73, 74). In summary, despite the large number of 
studies of the SERCA/PLN complex there is a lack of high resolution structural 
information. A high resolution structure of this membrane protein complex would be a 
major breakthrough towards the full understanding of SERCA regulation by PLN and a 
starting point for the development of novel therapies to treat heart failure. 
1.6 Objectives 
The R and T states of PLN have been detected by several different techniques but the 
functional relevance of these states has remained unclear. I hypothesized that the T/R 
equilibrium is central for PLN function and SERCA regulation. To test this hypothesis I 
used NMR spectroscopy in conjunction with other biophysical and biochemical 
techniques to probe PLN, SERCA and the SERCA/PLN complex. Specifically, I aimed to 
answer the following questions: 
• What are the structures of the T and R state in the absence of SERCA and what 
are the factors that affect the T/R equilibrium?  
• How is SERCA function and PLN regulation affected by the lipid bilayer and how 
can a SERCA/PLN complex be formed to perform NMR studies under fully 
functional conditions? 
• What is the conformation of PLN in the PLN/SERCA complex and where is the 
cytoplasmic domain located in the complex? 
• What are the other functional roles of the T/R equilibrium? 
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The answers to these questions could increase the understanding of the molecular basis 
of regulation of SERCA by PLN and the possible role of the T/R equilibrium in this 
regulation. This would contribute to the overall goal of the Veglia lab to understand the 
structural basis of muscle relaxation and could provide important information to target 
the SERCA/PLN complex in the treatment of heart failure. 
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The integral membrane protein complex between phospholamban (PLN) and 
sarcoplasmic reticulum Ca2+-ATPase (SERCA) regulates cardiac contractility. In the 
unphosphorylated form PLN binds SERCA and inhibits Ca2+ flux. Upon phosphorylation 
of PLN at Ser 16, the inhibitory effect is reversed. Although structural details on both 
proteins are emerging from X-ray crystallography, cryo-electron microscopy, and NMR 
studies, the molecular mechanisms of their interactions and regulatory process are still 
lacking. It has been speculated that SERCA regulation depends on PLN structural 
transitions (order-to-disorder, i.e. folding-unfolding). Here, we investigated PLN 
conformational changes upon chemical unfolding by a combination of EPR and NMR 
spectroscopy, revealing that the conformational transitions involve mostly the 
cytoplasmic regions, with two concomitant phenomena: 1) membrane binding and 
folding of the amphipathic domain Ia and 2) the folding/unfolding of the juxtamembrane 
domain Ib of PLN. Analysis of phosphorylated and unphosphorylated PLN with two 
phosphomimetic mutants of PLN (S16E and S16D) shows that the population of an 
unfolded state in domains Ia and Ib (T’ state) is linearly correlated to the extent of 
SERCA inhibition measured by activity assays. Inhibition of SERCA is carried out by the 
folded ground state (T state) of the protein (PLN), while the relief of inhibition involves 
promotion of PLN to excited conformational states (Ser 16 phosphorylated PLN). We 
propose that PLN population shifts (folding/unfolding) are a key regulatory mechanism 
for SERCA.  
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2.1 Introduction 
Phospholamban (PLN) is a 52-residue integral membrane protein embedded in 
the sarcoplasmic reticulum (SR) membrane of cardiac muscle (1) that reversibly inhibits 
the SR Ca2+-ATPase (SERCA), regulating calcium flux and muscle contractility (1-4).  
Although several X-ray crystallography and cryo-electron microscopy studies 
focused on SERCA have revealed important details on calcium translocation (5-9), 
structural data on the SERCA/PLN complex (10-13) are sparse and do not offer 
mechanistic details on the regulatory function of PLN.   
In the SR membrane, PLN exists as a homopentameric assembly in equilibrium 
with monomers that bind SERCA (1, 2, 4, 14). Both the monomer and pentamer adopt an 
L-shaped topology, with a cytoplasmic α-helix (domain Ia, residues 1-16) connected to a 
membrane-spanning α-helix (residues 23-52) by a short loop (residues 17-22) (15-17). 
The membrane-spanning helix has two dynamically distinct domains: domain Ib 
(residues 23-30) that is positioned at the hydrophilic portion of the lipid bilayer and 
domain II (residues 31-52) that exists in the hydrophobic interior (15, 18, 19).  
Previously, using NMR and EPR spectroscopy, we detected a conformational 
equilibrium between two major states: an ordered T state and a disordered R state (20, 
21). According to EPR, the R state population is ~16% (T state ~84%) in the absence of 
SERCA (22), and becomes slightly more populated in the presence of the enzyme (21). 
We then speculated that the regulation of SERCA by PLN occurs via conformational 
transitions between the T and R states. This hypothesis was supported by our studies on 
the structural effects of PLN phosphorylation at Ser 16 (23, 24) and NMR and functional 
studies of PLN reconstituted in different lipid mimetics (25-27). In fact, phosphorylation of 
PLN at Ser 16 by protein kinase A relieves SERCA inhibition, allowing for more efficient 
muscle relaxation (1-3, 28). We found that structurally and dynamically, phosphorylation 
causes an order-to-disorder transition, with an unwinding of domain Ia at residues 14-16 
around the phosphorylation site (16, 21, 23, 24). As a result, the phosphoryl transfer 
shifts the PLN conformational equilibrium, increasing the R state population (21). The 
latter can be exploited for the design of mutants to control SERCA function (29). It is also 
possible to rationalize the effects of phosphomimetic mutations (S16E) (29) used in gene 
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therapy (30). Although we established the foundations for a rational design of mutants 
and showed that the excited states of PLN are important for SERCA inhibition (29), we 
did not provide a quantitative interpretation of the conformational transitions of PLN 
between the ground and excited states or elucidate the structural and dynamic features 
of the excited conformations. 
Here, we used EPR and NMR spectroscopy in conjunction with biological activity 
assays to define the nature of PLN excited states and at the same time to establish a 
quantitative correlation between the population of the excited state and the extent of 
SERCA inhibition. We show that the conformational equilibrium of PLN is more complex 
than previously anticipated. We present a new model for the PLN conformational pre-
equilibrium and show a linear correlation between the loss of function (LOF) of PLN 
phosphomimetic mutants and their excited state populations.  
 
2.2 Results 
2.2.1 A four-state model of PLN conformational equilibrium 
Based on our previous studies, we hypothesized that PLN undergoes 
conformational interconversion between two states: a motionally restricted T state with 
the cytoplasmic domain absorbed on the membrane surface and a more dynamic R 
state with domain Ia detached from the membrane and mostly unfolded (20, 21, 29). To 
test this hypothesis, we monitored the chemical unfolding of PLN upon addition of 
guanidine hydrochloride (Gdn HCl) using both EPR in 4:1 DOPC:DOPE (1,2-dioleoyl-sn-
glycero-3-phosphocholine: 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine) lipid bilayers 
and NMR in DPC micelles. We utilized a synthetic (for EPR) or recombinant (for NMR) 
monomeric variant of PLN (AFA-PLN) that has the same inhibitory power and similar 
structural topology as wild-type PLN (18, 31). 
EPR spectra of TOAC (2,2,6,6-tetramethyl-piperidine-1-oxyl-4-amino-4-
carboxylic acid) spin label engineered at position 11 revealed the presence of two 
resolved peaks: one broad resonance which was assigned to the T state and a sharper 
peak assigned to the R state (Figure 1) (22). The R state is very dynamic, with an order 
parameter three-fold lower than the corresponding T state (21). To follow the chemical 
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unfolding of PLN, EPR experiments were carried out by titrating Gdn HCl into the PLN 
samples and monitoring the spectral changes of TOAC at positions 11 (domain Ia), 24 
(domain Ib), and 36 (domain II). In the absence of chemical denaturant, the populations 
of the R state were 8 and 28% for positions 11 and 24, respectively; while at position 36 
only the T state was detected (Figure 1). Addition of Gdn HCl to the PLN in vesicles 
caused the disappearance of the TOAC resonance (position 11) T statecomponent and 
a concomitant increase of the peak intensity of the R state component. This 
demonstrates a shift in the PLN conformational equilibrium toward the R state for 
domain Ia. In contrast, the TOAC spectrum for 36 remained unperturbed upon addition 
of the denaturant, and showed that while domain Ia unfolded completely, the membrane 
embedded domain II was still helical in the presence of chemical denaturant. At position 
24 (domain Ib), the addition of the Gdn HCl increased the R state population from 28 to 
34%.  
To analyze the conformational transitions at the atomic level, we monitored the 
NMR chemical shifts for both the methyl and the amide groups of PLN upon addition of 
Gdn HCl using 2D heteronuclear single quantum coherence (HSQC) spectra. As a 
reference for the unfolded R state of PLN, we used a peptide corresponding to the 
cytoplasmic residues of PLN (PLN1-20). In aqueous solutions, this peptide is soluble and 
unfolded, while in the presence of DPC (or lipid vesicles) it is helical and associated with 
the micelle surface (Figure S1)(32-35).   
Titration of Gdn HCl into a PLN sample in DPC micelles caused gradual changes 
to the chemical shifts for all of the resonances (methyls and amides) in domain Ia, loop, 
and domain Ib (Figures 2 and 3). Domain II remained mostly unperturbed with the 
exception of the C-terminal residues, which is in agreement with the results obtained 
from the EPR experiments at position 36. The chemical shifts for the PLN methyl groups 
follow trajectories that are close to linear (Figure 3), and at a high concentration of 
denaturant, overlay with those of PLN1-20 without DPC (unfolded R state) (Figure 4A).    
The deviations from linearity, however, are more apparent from the amide 
chemical shifts. In particular, amide chemical shifts of domain Ia show at least three 
different states (see triangulation of chemical shifts for I12), while more linear behavior is 
observed for resonances located in domain Ib (Figure 3, Figures S3 and S4). At high 
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Gdn HCl concentrations, amide chemical shifts in domain Ia overlap with the R state 
(Figure 4B). These results demonstrate that while EPR detects an apparent two-state 
equilibrium, the conformational states visited by PLN during chemical unfolding are at 
least three as revealed by NMR spectroscopy. The latter supports the three-state folding 
model of amphipathic helices proposed by White and co-workers (36, 37). For PLN the 
unfolding process highlights three major conformational ensembles: 1) a helical T state, 
2) a partially unfolded membrane-associated R’ state, and 3) a totally unfolded 
membrane-dissociated R state. Note that while the chemical shifts of the methyl groups 
are sensitive to environmental changes, like the EPR measurements, they only show an 
apparent two-state equilibrium. In contrast, the amide groups are more sensitive to 
secondary structural changes and therefore are able to detect the presence of the R’ 
state more clearly. 
Interestingly, the plots of the chemical shift changes as a function of the 
concentration of Gdn HCl show that residues in domains Ia and Ib have different melting 
profiles (Figure 5). Specifically, unfolding curves for residues in domain Ia have a more 
cooperative unfolding behavior than residues in domain Ib (larger Hill coefficient; 2.2 ± 
0.2 vs. 1.6 ± 0.1 (average ± standard error)) (Figure S5, Table S1). Thus, a lower 
concentration of Gdn HCl is required to induce unfolding for residues in domain Ib. This 
behavior is typical of less compact states that are likely to interconvert non-cooperatively 
(38, 39).  
Phosphorylation of PLN at Ser 16 causes a complete LOF. This state is 
responsible for calcium reuptake into the SR membrane and regulates the diastolic 
phase of the cardiac cycle. Guided by the EPR data (21), we originally interpreted 
phosphorylation of PLN at Ser 16 as a shift of the conformational equilibrium toward the 
R state (24). To test this, we compared the chemical shifts of both methyl and amide 
groups with the unfolding experiments carried out in Gdn HCl. While the methyl group 
chemical shifts of pS16-AFA-PLN are in line with the trajectories toward the unfolded R 
state, supporting an apparent two-state equilibrium, the amide group chemical shifts do 
not overlap with those from the Gdn HCl titration. This distinct state (T’ state), which is 
present in most of the resonances of domain Ia is partially unfolded as revealed by the 
13C chemical shift index (Figure 6) (23, 24), but primarily membrane attached (23, 27). 
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Upon titration with Gdn HCl, the T’ state of phosphorylated PLN is perturbed toward the 
unfolded and membrane detached R state (Figure 4, Figures S3 and S4). Note that for 
most of the resonances the unfolded states of both phosphorylated and 
unphosphorylated PLN overlap completely. However, slight differences in chemical shifts 
around the phosphorylation site were observed and are probably due to the charged 
phosphate group. Also, pS16-AFA-PLN unfolds at significantly lower Gdn HCl 
concentration than AFA-PLN (average k values of 0.7 ± 0.1  and 1.6 ± 0.1) (Figure S6), 
consistent with the partially unfolded nature of the T' state.   
Based on the above results, we can conclude that the conformational 
interconversions of PLN include at least four major states for domain Ia and two states 
for domain Ib. The folding-unfolding equilibrium of domain Ia is dictated by its 
interactions with the lipids and is regulated by phosphorylation (Figure 7). The T state 
can proceed to the R state either through the unfolded and membrane-associated R' 
state or the T' state. Domain Ib transitions between two states, folded and unfolded, 
independent of domain Ia. 
 
2.2.2 Pseudo-phosphorylated mutants of PLN and conformational equilibrium.  
To further test the presence of the excited T’ state, we monitored the effects of 
phosphomimetic mutations of PLN (S16D and S16E) by monitoring the chemical shifts of 
both methyl and amide groups. As with the unfolding studies, the methyl group chemical 
shifts follow an apparent linear trajectory toward the unfolded R state (Figure 8). In 
contrast, the amide chemical shifts of the mutants do not fall along the unfolding 
trajectory for pS16-AFA-PLN or AFA-PLN, rather they reside in intermediate positions 
between the resonances of pS16-AFA-PLN and AFA-PLN. Therefore, it is possible to 
conclude that pseudo-phosphorylation and phosphorylation promote a gradual shift in 
population toward the T’ state, consistent with previous reports that pS16 
phosphorylation leads to partial unfolding (26). 
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2.2.3 Quantitative Correlation between the population of excited state and SERCA 
inhibition 
To investigate a relationship between the population of the excited states and the 
loss of inhibitory power of PLN, we correlated structure (chemical shifts), dynamics (HX-
NOEs) (Figure S9), and water accessibility (SEA-CLEANEX) (Figure S10) with the 
extent of PLN inhibition on SERCA’s calcium affinity (inhibition; ΔpKCa) induced by the 
different mutants. Consistent with previous results (29), we found the following overall 
order of inhibition: AFA-PLN > S16E-AFA-PLN > S16D-AFA-PLN > pS16-AFA-PLN 
(Table 1). In order to link the structure to function, we adopted the approach proposed 
by Li et al. (40), correlating the average chemical shift change (corresponding to T to T’) 
for each mutant with the respective SERCA inhibitory potency. The resonances of AFA-
PLN were defined to be 100% T state, while those from pS16-AFA-PLN were set to 
100% T’ state. The structure-function correlation plot is reported in Figure 9A. The 
linearity of this plot (correlation coefficient = 0.98) indicates a direct correlation between 
the increase in the population of the T' state and the loss of inhibition. Similar 
correlations with the inhibitory potency are obtained for both the fast dynamics (ps-ns) 
and solvent accessibility (Figures 9B and C). This is in agreement with the partially 
unfolded character of the T’ state, which makes it more dynamic and solvent accessible 
than the T state and can exchange directly with the completely unfolded R state (Figure 
7). These data suggest that the promotion of PLN from the ground T state to the excited 
T’ state (and likely R state) results in LOF.  
 
2.3 Discussion 
Based on our previous investigations (16), we hypothesized that the 
conformational equilibrium of PLN is central to SERCA regulation. However, in our 
original papers both EPR and NMR studies revealed the presence of an apparent two-
state equilibrium (T and R states) (20, 21, 41). Here, we provide evidence that PLN 
exists in a pre-existing equilibrium between several conformational states, exemplified 
by the folding/unfolding equilibria of both domain Ia and Ib. For domain Ia methyl groups, 
the chemical shift trajectories for chemical unfolding follow an apparent two-state 
equilibrium in agreement with EPR data. In contrast, the trajectories for amide group 
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chemical shifts showed the presence of four conformational states, which is in 
agreement with the folding model of amphipathic helices proposed by White and co-
workers (36, 37). On the other hand, for domain Ib the folding/unfolding process involves 
a simpler two-state model, as we also found using CPMG relaxation dispersion methods 
(41). This new, more complex model agrees with recent data from the Lorigan and 
Middleton groups (25, 26), who proposed an active role of lipids in modulating PLN 
structural dynamics and SERCA inhibition. At the same time, it explains previous 
mutagenesis studies, which identified a number of sites in domain Ia of PLN that lead to 
relief of SERCA inhibition (42). Specifically, residues populating the hydrophobic face of 
the amphipathic domain Ia (V4, L7, and I12) are among these hot spots (42), which in 
the T state are residues inserted into the lipid bilayer (17). Shortening the side chain of 
these residues would likely attenuate the interactions of domain Ia with the membrane 
environment, supporting the hypothesis that lipid bilayers influence the regulatory 
process in the context of membrane-detachment and helix unfolding. Interestingly, 
attachment of a lipid anchor to the N-terminus completely shifts PLN to the T state, with 
Ser 16 phosphorylation of this lipidated PLN failing to relieve SERCA inhibition (21, 33). 
This result also strongly supports the structure-function relationship reported in Figure 9. 
It is important to stress that the relative population of states can potentially be biased by 
the choice of membrane mimic. For example, in DPC micelles the T and T’ states are 
primarily detected. However, solid-state NMR experiments in DMPC lipid bilayers found 
domain Ia to be predominantly unfolded (43). This suggests an important role of lipid 
charge, head groups and possibly bilayer curvature in influencing the conformational 
equilibria and extent of aggregation of PLN. 
Tuning PLN conformational equilibrium leads to the control of SERCA activity. 
Recently, we showed that to gain complete control over PLN inhibition, it is necessary to 
map the transition to the excited states (29). Our new data show that pseudo-
phosphorylation and phosphorylation of PLN increase the population of T’ state. Since 
the T’ state exchanges more readily with the fully unfolded R state (Figure 7), it is likely 
that the R state also increases in population. The correlation between membrane 
detachment/unfolding and SERCA inhibition (Figure 9) suggests that these states need 
to be considered in the design of new, more efficient loss-of-function PLN mutants. To 
this extent, the S16D mutation is more similar in structure and dynamics to pS16-AFA-
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PLN than is the S16E mutant. This is supported by SERCA inhibition assays that show a 
greater LOF character for S16D-AFA-PLN than S16E-AFA-PLN, and would make the 
S16D mutant a better candidate for positive inotropic therapy (44).  
An important corollary of this study is the intrinsic flexibility and versatility of the 
cytoplasmic domain of PLN that when detached from the membrane surface behaves as 
an intrinsically disordered domain that can adopt several conformations (45, 46). In the 
heart muscle, PLN interacts with several different partners to elicit its regulatory function. 
Specifically, PLN associates with the lipid bilayer, SERCA, PKA, CamKII, AKAP18δ, 
protein phosphatase 1 (PP1), HAX1, and itself in the form of a pentamer state. How can 
this protein with such a simple structure and topology bind these diverse biomolecules? 
We believe the answer is encoded in its flexibility and malleability (i.e. dynamics) that 
enable PLN to undergo conformational changes and mold into different binding sites. 
 Finally, it is worth noting that PLN can be divided into two main regions: an 
inhibitory transmembrane segment and a cytoplasmic regulatory region. The latter is 
reminiscent of the autoinhibitory elements found in Vav and LOV proteins, where an 
amphipathic helical switch is activated upon phosphorylation or light (40, 47). In the case 
of Vav and LOV, this regulatory element is covalently attached to the proteins with the 
amphipathic helix undergoing folding/unfolding transitions upon interaction with the 
protein surface. For SERCA, the reversible regulatory element is provided by PLN that is 
modulated by the folding/unfolding transitions via the lipid bilayer and phosphorylation. 
Given the high similarity between PLN and other single pass membrane protein subunits 
such as the FYXD family, it is likely that the mechanism described in this paper is a 
general one, also found in the regulation of other ion pumps.  
 
2.4 Materials and Methods 
2.4.1 Purification of PLN Protein 
Recombinant AFA-PLN, S16D-AFA-PLN and S16E-AFA-PLN were grown and 
purified as described by Buck et al. (18). PLN1-20 was expressed in E. coli and purified as 
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described by Masterson et al. (48). To obtain full phosphorylation at Ser 16, lyophilized 
AFA-PLN protein was dissolved at a concentration of 0.3 mg/ml in 20 mM MOPS buffer 
pH 7.0 containing 1%(w/v) n-octyl-β-D-glucopyranoside (OG), ATP (1 mM), and MgCl2 (1 
mM) (23). Phosphorylation was accomplished by addition of purified recombinant protein 
kinase A (49, 50) at a 1:2000 PKA:AFA-PLN molar ratio and incubated for ~12 h at 30 
ºC. After purification by reversed-phase HPLC, the pS16-AFA-PLN was lyophilized and 
stored at -20 ºC. 
2.4.2 Assay for SERCA Activity 
For SERCA activity measurements, AFA-PLN, pS16-AFA-PLN, S16E-AFA-PLN, 
and S16D-AFA-PLN were reconstituted into 4:1 DOPC:DOPE lipid bilayers. SERCA was 
purified in octaethylene glycol monododecyl ether (C12E8)  (5) and added to the lipid 
vesicle suspension containing 700:1 lipid:SERCA and 10:1 PLN:SERCA molar ratios. 
Subsequently, the samples were incubated with Biobeads (30:1 Biobeads:C12E8 by 
weight) (Bio-Rad Laboratories) to remove excess detergent. A coupled NADH assay 
was used to measure SERCA activity (hydrolysis of ATP) at 37 ºC as a function of 
calcium concentration (51). The rate of enzyme activity was measured as a decrease of 
NADH absorption at 340 nm using a Spectramax plate reader (Molecular Devices). Data 
were fit using the Hill equation to extract the maximum activity (Vmax), Hill coefficient (n), 
and calcium concentration needed to achieve half maximal activity (pKCa) (51).  
 
2.4.3 EPR spectroscopy 
 For EPR experiments, AFA-PLN with the TOAC spin label substituted at 11, 
24, or 36 was synthesized and reconstituted into lipid vesicles containing DOPC:DOPE 
(4:1, 200 lipids per PLN) (52). EPR spectra were acquired using a Bruker EleXsys 500 
spectrometer with the SHQ cavity. Samples (20 uL in a 0.6 mm i.d. quartz capillary) 
were maintained at 4 ºC using the Bruker temperature controller with a quartz dewar 
insert. The field modulation frequency was 100 kHz, with a peak-to-peak amplitude of 2 
G. The microwave power was 7.9 mW, producing moderate saturation (so that signal 
intensity was at least 50% of maximum) without significant effect on the spectral 
lineshape. EPR spectra were simulated as a sum of one or two components, each 
component produced by a population having a static random distribution of membrane 
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orientations and undergoing rotational diffusion in a restricting potential (defined by order 
parameter S) with a single rotational correlation time (21). Experimental spectra were fit 
by summing simulated components, yielding mole fractions. 
 
2.4.4 NMR Spectroscopy 
To prepare NMR samples of the AFA-PLN variants, lyophilized protein was 
dissolved in NMR sample buffer containing 20 mM NaHPO4, 120 mM NaCl, 0.01 % 
NaN3, 5 % D2O, 6 M guanidine hydrochloride (Gdn HCl), 300 mM deuterated DPC, and 
pH 6.0 uncorrected for isotopic effect. Gdn HCl was subsequently dialyzed against 1 L of 
NMR sample buffer. This procedure gave more homogenous spectral lines and avoided 
protein aggregation. All of the NMR experiments were performed on Varian VNMRS and 
Inova spectrometers operating at a 1H frequency of 600 MHz. Data were processed 
using NMRPipe (53) and viewed and analyzed in Sparky (54). Protein amide fingerprints 
were analyzed using gradient enhanced [1H,15N]-HSQC experiments (55). The data were 
acquired at 37 ºC using 1544 complex points in the direct 1H dimension and 50 to 80 
increments in the indirect 15N dimension. Gradient enhanced constant-time [1H,13C]-
HSQC experiments were utilized to measure methyl group chemical shifts. For PLN1-20 
and each AFA-PLN mutant, 8 scans were acquired at 37 ºC with 2048 complex points 
and a spectral width of 12000 Hz in the direct 1H dimension, and 64 points with a 
spectral width of 3500 Hz in the indirect 13C dimension. After Fourier transformation, the 
data were zero-filled to a final matrix size of 4096 x 2048. 
Heteronuclear [1H-15N] steady-state NOE measurements were acquired using the 
pulse sequence of Kay and co-workers (56). 2D spectra with and without a 3 s 1H 
saturation period were acquired at 37 ºC. The 1H-15N steady-state NOE value was 
obtained as the ratio between peak intensities in the saturated (Isat) and unsaturated 
(Iunsat) spectrum: [ 𝐻, 𝑁]151 𝑁𝑂𝐸 = 𝐼𝑠𝑎𝑡 𝐼𝑢𝑛𝑠𝑎𝑡⁄   (1) 
The uncertainty of the measurement was estimated for each residue from the 
relationship (56): 
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𝜎[ 𝐻, 𝑁]151 𝑁𝑂𝐸 [ 𝐻, 𝑁]151 𝑁𝑂𝐸⁄ = �((𝜎𝑠𝑎𝑡 𝐼𝑠𝑎𝑡⁄ )2(𝜎𝑢𝑛𝑠𝑎𝑡 𝐼𝑢𝑛𝑠𝑎𝑡⁄ )2)   (2) 
Where σsat and σunsat is the baseline noise in the saturated and unsaturated spectra and 
σHNNOE is the estimated error for the HNNOE values.    
 To measure the solvent exchange for amide protons, [1H,15N]-SEA-CLEANEX 
experiments  were performed (57). This pulse sequence utilizes a spin-echo filter to 
select for water magnetization followed by a mixing period to allow for exchange 
between protein and solvent (58). To eliminate NOE contributions, the CLEANEX-PM 
mixing scheme was implemented (59). Four different mixing times (30, 60, 120 and 200 
ms) were used to follow the build-up of peaks corresponding to solvent exchanging 
amide protons. A total of 64-96 scans were recorded at 37 ºC with 2048 complex points 
in the direct 1H dimension and 40 increments in the indirect 15N dimension. Spectral 
widths were 12000 and 1200 Hz in the direct and indirect dimensions, respectively. A 
shifted sine bell window function was applied to all data sets, which were zero-filled to 
4096 in both dimensions prior to Fourier transformation. 
 Gdn HCl-induced denaturation was done by titrating Gdn HCl from a 6 M stock 
solution to AFA-PLN at pH 6.0. Six additions were made to a final Gdn HCl 
concentration of 2.8 M and [1H,15N]-HSQC and [1H,13C]-HSQC spectra were acquired 
after each addition as described above. For the analysis of unfolding, spectra were 
referenced to 10 mM DSS and 15N peak shifts were plotted as a function of Gdn HCl 
concentration. The data were fit using the Hill equation: 
∆𝜕 = (𝜕𝑒𝑛𝑑 − 𝜕𝑠𝑡𝑎𝑟𝑡) [𝐺𝑑𝑛 𝐻𝐶𝑙]𝑛[𝐺𝑑𝑛 𝐻𝐶𝑙]𝑛 +  𝑘𝑛 
Where n is the Hill coefficient and k is the unfolding half point. Hill coefficients for 
residues in domain Ib of PLN (22-28) and domain Ia (3-16) were compared using a t-
test. Residue 9 was excluded since it could not be assigned and residues 2, 29 and 30 
since those fit poorly to the Hill equation. k values for domain Ia and Ib of AFA-PLN and 
pS16-AFA-PLN (residues 3-16 and 22-28) were compared with a t-test.  
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2.4.5 Structure, dynamics, function relationship 
Chemical shift changes for the different mutants were calculated according to the 
expression: 
𝛥𝛿𝑐𝑜𝑚𝑏𝑖𝑛𝑒𝑑 = �(𝛥𝛿1𝐻)2 +  (𝛥𝛿15𝑁/5)2 (6) 
where Δδcombined is the difference in chemical shift relative to AFA-PLN. Several 
resonances within the HSQC spectra (Figure S2) that have a gradual change in 
chemical shifts from AFA-PLN  S16E-AFA-PLN  S16D-AFA-PLN  pS16-AFA-PLN 
(Leu 7, Thr 8, Ala 11, Ile 12, Ala 15, Ile 18, Glu 19, Gln 22, Gln 23, Arg 25, Gln 26, Asn 
27, Leu 28, Gln 29, Asn 30) were used in the analysis. Each resonance shift was 
calculated using the following formula: 
𝑝 = 𝜔𝑚𝑢𝑡𝑎𝑛𝑡−𝜔𝐴𝐹𝐴
𝜔𝑝𝐴𝐹𝐴−𝜔𝐴𝐹𝐴
 (7) 
where ω is the combined chemical shift and p is the relative peak position for each 
species. In the formula, the AFA-PLN chemical shifts correspond to 0 and pS16-AFA-
PLN corresponds to 1. The heteronuclear NOE value was calculated as an average of 
HN NOE values for all residues in domains Ia, the loop and domain Ib (residues 2-31). 
To determine the normalized solvent exchange, peak intensities from [1H,15N]-SEA-
CLEANEX spectra were measured using the software Sparky (54). The intensities were 
corrected for the differences in sensitivity for residues in a [1H-15N]-HSQC spectrum and 
then normalized among the different PLN species (AFA-PLN, pS16-AFA-PLN, S16D-
AFA-PLN, and S16E-AFA-PLN) by assuming Glu 2 to have the same solvent exchange 
for all mutants. The averaged normalized solvent exchange value included residues in 
domains Ia, the loop, and domain Ib (2-30). Residues 15-17 were excluded from the 
analysis due to their proximity to the phosphorylated/mutated Ser 16 and residues 5, 9 
and 25 were removed due to spectral overlap. 
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PLN variant ΔpKCa 
AFA-PLN 0.20±0.02 
S16E-AFA-PLN 0.14±0.04 
S16D-AFA-PLN 0.08±0.04 
pS16-AFA-PLN 0.02±0.02 
 
Table 1. SERCA inhibition for PLN mutants. pKCa values were determined from fits to 
the Hill equation (see material and methods). Inhibition was measured from the 
difference in pKCa in the absence and presence of a 10-fold excess of PLN (ΔpKCa). 
Standard errors were calculated from the average of three measurements. 
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Figure 1. Chemical unfolding of PLN in lipid vesicles. Continuous wave EPR spectra of 
TOAC spin label engineered at positions 11 (domain Ia), 24 (domain Ib), and 36 (domain 
II). Left: EPR spectra in the absence of Gdn HCl. Right: EPR spectra in the presence of 
6 M Gdn HCl (right). 
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Figure 2. Chemical shift perturbations of AFA-PLN upon unfolding with Gdn HCl. (A) 15N 
amide and (B) 13C methyl chemical shift changes as a function of residue. Colors reflect 
the different structural domains of PLN: domain Ia (green), loop (orange), domain Ib 
(red), and domain II (blue). The asterisk indicates an overlapped resonance as a result 
of Gdn HCl unfolding. 
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Figure 3. Chemical unfolding of AFA-PLN and pS16-AFA-PLN. Representative spectra 
of methyl [1H,13C] and amide [1H,15N]-HSQC experiments for residues in domain Ia (Val 
4, Leu 7, and Ile 12) and domain Ib (Gln 26) upon Gdn HCl titration for AFA-PLN (black) 
and pS16-AFA-PLN (red). AFA-PLN and pS16-AFA-PLN peaks correspond to Gdn HCl 
concentrations of 0 M, 0.067 M, 0.178 M, 0.48 M, 0.89 M, 1.81 M and 2.79 M. The 
direction of the arrows represents the increase in Gdn HCl concentration. 
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Figure 4. Methyl and amide fingerprint spectra of PLN1-20 and unfolded AFA-PLN. (A) 
Overlay of [1H,13C]-HSQC spectra of AFA-PLN in the presence of Gdn HCl (black) and 
PLN1-20 in the absence of DPC (purple). (B) Overlay of the [1H,15N]-HSQC spectra for the 
species in reported in (A). With the exception of the terminal residues, the chemical 
shifts of the resonances of the unfolded domain Ia of AFA-PLN and PLN1-20 (in the 
absence of DPC) are very similar, showing that the PLN1-20 free peptide is a good mimic 
of the R state. 
  
49 
 
 
 
Figure 5. Unfolding of domain Ia and Ib upon titration of Gdn HCl. Plots of the 15N 
chemical shifts as a function of Gdn HCl concentration for Leu 7 and Ala 11 in domain Ia 
(left) and Gln 26 and Asn 27 in domain Ib (right). The unfolding of domain Ia is more 
cooperative than domain Ib.  
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Figure 6. 13C chemical shift index (CSI) for AFA-PLN and pS16-AFA-PLN. The chemical 
shift index is calculated as 13Cα – 13Cβ – (13Cα,RC – 13Cβ,RC), where RC stands for the 
random coil chemical shifts reported by Zhang et al (60). Consecutive positive CSI 
values indicate helix propensity. 
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Figure 7. Model of the conformational equilibrium of PLN. (Top) The T state of domain Ia 
undergoes unfolding to the R state via an intermediate T’ state or R’ state. (Bottom) 
Two-state conformational equilibrium for domain Ib.  
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Figure 8. Methyl and amide HSQC spectra for Ser 16 phosphorylated AFA-PLN and the 
pseudo-phosphorylated variants. [1H,13C] and [1H,15N]-HSQC spectra AFA-PLN (black), 
S16E-AFA-PLN (blue), S16D-AFA-PLN (grey), and pS16-AFA-PLN (red). The solid-line 
arrows point to the AFA-PLN resonance in the presence of Gdn HCl, while the dotted-
line arrow visually traces the transition from AFA-PLN (T-state) to pS16-AFA-PLN (T’-
state).  
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Figure 9. Structure-dynamics-function relationships for AFA-PLN, Ser 16 phosphorylated 
AFA-PLN, and pseudo-phosphorylated mutants. (A) Correlation between combined 15N-
HSQC chemical shift change (normalized ∆δ), averaged [1H,15N]-NOE in domain Ia and 
the loop (B), and normalized solvent exchange from SEA-CLEANEX experiments (C) 
with SERCA inhibition from ATPase assays (ΔpKCa) for AFA-PLN (black), S16E-AFA-
PLN (blue), S16D-AFA-PLN (grey) and pS16-AFA-PLN (red). See materials and 
methods for calculation of ΔpKCa, normalized ∆δ, <[1H,15N]-NOE> and normalized 
solvent exchange. 
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Figure S1. Folding of the PLN1-20 peptide upon titration of DPC. [1H,13C]-HSQC spectra 
of PLN1-20 without DPC (orange), with 8 mM DPC (purple), and 300mM DPC (green).  
(A) Leu, Val, Thr, (B) Ile δ1, and (C) Ile γ2 methyl groups. The spectra of PLN1-20 are 
overlaid onto the spectrum of AFA-PLN (black) chosen as a guide for a state that is 
primarily T state. 
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Figure S2. Gdn HCl-induced unfolding of PLN. [1H,15N]-HSQC spectra of AFA-PLN in the 
absence (A) and in the presence of 2.79 M Gdn HCl (B). 
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Figure S3. Chemical shift trajectories of residues in domain Ia upon chemical unfolding. 
Overlay of [1H,15N]-HSQC spectra of AFA-PLN (black) and pS16-AFA-PLN (red) with 
increasing amounts of Gdn HCl (the direction of the arrow corresponds with increasing 
[Gdn HCl]). Peaks corresponding to S16E-AFA-PLN and S16D-AFA-PLN are shown in 
blue and grey respectively. Note that surrounding and overlapping peaks have been 
removed for clarity. Residues Q5 and R9 were excluded due to spectral overlap and 
residue 16 and 17 due to the large effect of mutation or phosphorylation on peak 
position. 
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Figure S4. Chemical shift trajectories of residues in domain Ib upon chemical unfolding. 
Overlay of [1H,15N]-HSQC spectra of AFA-PLN (black) and pS16-AFA-PLN (red) with 
increasing amounts of Gdn HCl (the direction of the arrow corresponds with increasing 
[Gdn HCl]). Peaks corresponding to S16E-AFA-PLN and S16D-AFA-PLN are shown in 
blue and grey, respectively. Surrounding and overlapping peaks have been removed for 
clarity. 
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Figure S5. Hill coefficients determined from the hyperbolic fitting of the 15N chemical 
shift changes upon Gdn HCl unfolding of AFA-PLN to the Hill equation for domain Ia 
(residues 3-8 and 10-16) and domain Ib (residues 22-28). Error bars indicate the 
standard error of the mean. The averages for domains Ia and Ib are significantly different 
as determined by a student's t-test (p-value of 0.0066). 
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Figure S6. (A.) Unfolding midpoints (k) for residues in domain Ia and Ib of AFA-PLN and 
pS16-AFA-PLN. (B.) Average unfolding midpoint (k) for residues in domains Ia and Ib (3-
17 and 22-28) for AFA-PLN and pS16-AFA-PLN. Error bars indicate the standard error 
of the mean. The averages for AFA-PLN and pS16-AFA-PLN are significantly different 
as determined by a t-test (p-value of 0.0042). 
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Figure S7. (A) [1H,15N]-HSQC spectra for AFA-PLN (black), S16E-AFA-PLN (blue), 
S16D-AFA-PLN (grey), and pS16-AFA-PLN (red). Insets (A): residues showing the 
gradual change in chemical shifts from AFA-PLN  S16E-AFA-PLN  S16D-AFA-PLN 
 pS16-AFA-PLN. (B) 1H and 15N combined chemical shift difference (Δδcombined, defined 
in Eq 6) between AFA-PLN and phosphorylated and pseudo-phosphorylated variants 
(S16E-AFA-PLN, S16D-AFA-PLN and pS16-AFA-PLN). 
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Figure S8. [1H,13C]-HSQC spectra of (A) Leu, Val, Thr, and (B) Ile methyl groups for 
AFA-PLN (black), S16E-AFA-PLN (blue), S16D-AFA-PLN (grey) and pS16-AFA-PLN 
(red). 
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Figure S9. Fast (ps-ns) backbone dynamics of AFA-PLN and variants. (A) Residue-
specific [1H,15N] heteronuclear-NOEs for AFA-PLN (black), S16E-AFA-PLN (blue), 
S16D-AFA-PLN (grey), and pS16-AFA-PLN (red). (B) Average of [1H,15N] heteronuclear-
NOEs for the different dynamic domains.  
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Figure S10. Solvent exchange curves from [1H,15N]-CLEANEX experiments for 
residues in domain Ia of AFA-PLN (black), S16E-AFA-PLN (blue), S16D-AFA-PLN 
(grey), and pS16-AFA-PLN (red). Note for L7, T8, I12, and R13, the black circles are 
overlapped with the blue points. For I12, all circles are overlapped, indicating very slow 
amide hydrogen exchange with H2O. 
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 Table S1. Amide 15N chemical shift changes upon unfolding, and results from fitting the 
chemical shift trajectories to the Hill equation for AFA-PLN. 
Residue START (ppm) END (ppm) k (M) n 
2 121.67 123.86 2.50 0.94 
3 120.14 125.41 2.57 1.38 
4 117.78 122.19 1.31 1.58 
5 120.98 126.48 1.50 1.70 
6 119.04 122.10 1.58 1.68 
7 120.27 124.01 1.69 2.43 
8 112.51 114.51 1.71 3.36 
9     
10 114.51 116.88 1.55 2.55 
11 124.38 126.35 1.59 2.46 
12 116.62 120.05 1.59 2.38 
13 120.02 126.57 1.66 1.94 
14 119.04 123.49 1.49 2.31 
15 121.43 124.07 1.34 2.43 
16 110.15 115.94 1.48 2.21 
17 110.73 116.55 1.28 1.94 
18 122.07 122.40 2.02 5.35 
19 125.17 124.76 0.54 2.62 
20 122.83 122.64 0.17 5.44 
22 122.20 120.88 0.84 1.76 
23 118.06 120.51 1.61 1.78 
24 121.64 125.30 1.28 1.97 
25 117.56 121.76 2.10 1.51 
26 117.82 122.69 1.83 1.47 
27 117.52 121.97 2.13 1.46 
28 120.97 123.95 1.87 1.39 
29 117.84 120.55 4.53 1.31 
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Table S2. Amide 15N chemical shift changes upon unfolding, and results from fitting the 
chemical shift trajectories to the Hill equation pS16-AFA-PLN 
  START (ppm) END (ppm) k (M) n 
2 121.65 122.91 0.41 1.24 
3 120.07 123.13 0.72 1.39 
4 117.64 121.70 0.54 1.31 
5 120.70 124.02 0.56 1.49 
6 118.87 121.85 0.74 1.13 
7 119.37 124.23 0.92 1.31 
8 111.00 115.07 0.85 1.32 
9     
10 114.39 117.01 0.68 1.28 
11 123.91 126.39 0.72 1.31 
12 115.79 120.11 0.67 1.33 
13 121.30 125.55 0.56 1.40 
14 120.28 123.65 0.54 0.97 
15 124.22 125.94 0.44 1.74 
16 113.35 116.40 0.55 1.31 
17 113.10 115.17 0.48 1.40 
18 122.10 122.85 0.80 1.57 
19 124.79 125.30 4.00 1.30 
20 122.58 123.01 0.98 1.75 
22 121.46 120.90 0.25 2.44 
23 118.75 121.78 0.85 1.13 
24 122.30 126.07 1.10 1.16 
25 118.12 120.20 0.93 2.54 
26 118.45 122.41 1.28 0.98 
27     
28 121.23 123.30 0.97 1.24 
29 118.00 119.84 4.32 0.93 
 
  
68 
 
Chapter 3- cAMP-Dependent Protein Kinase A Selects the 
Excited State of the Membrane Substrate Phospholamban 
 
Reprinted with permission from: 
Masterson, L.R., Yu, T., Shi, L., Wang Y., Gustavsson, M., Mueller, M.M., Veglia, G., 
cAMP-Dependent Protein Kinase A Selects the Excited State of the Membrane 
Substrate Phospholamban J. Mol. Biol. 2011, 412, 2, 155-164 
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Phosphorylation of membrane proteins is a central regulatory and signaling mechanism 
across cell compartments. However, the recognition process and phosphorylation 
mechanism of membrane-bound substrates by kinases are virtually unknown. cAMP-
dependent protein kinase A (PKA) is a ubiquitous enzyme that phosphorylates several 
soluble and membrane-bound substrates. In cardiomyocytes, PKA targets 
phospholamban (PLN), a membrane protein that inhibits the sarcoplasmic reticulum 
Ca2+-ATPase (SERCA). In the unphosphorylated state, PLN binds SERCA, reducing the 
calcium uptake and generating muscle contraction. PKA phosphorylation of PLN at S16 
in the cytoplasmic helix relieves SERCA inhibition, initiating muscle relaxation. Using 
steady-state kinetic assays, NMR spectroscopy, and molecular modeling, we show that 
PKA recognizes and phosphorylates the excited, membrane-detached R-state of PLN. 
By promoting PLN from a ground state to an excited state, we obtained a linear 
relationship between rate of phosphorylation and population of the excited state of PLN. 
The conformational equilibrium of PLN is crucial to regulate the extent of PLN 
phosphorylation and SERCA inhibition. 
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3.1 Introduction 
Protein phosphorylation is a central mechanism in cell signaling and regulation. 
Inhibitory proteins are reversibly phosphorylated to cycle between active and inactive 
states. (1) These different states are characterized by conformational and dynamic 
transitions that are essential for stability and function. (2, 3) Muscle proteins are salient 
examples of these structure–dynamics–function correlations. The rhythmic contraction 
and relaxation of the heart muscle, for instance, are orchestrated by protein complexes 
that regulate calcium homeostasis, and phosphorylation is the driving force to control 
these cyclic events.(4) 
In muscle cell membranes, protein kinases target peripheral or integral membrane 
proteins involved in regulatory complexes, initiating signaling events that cross the 
membrane bilayer.(4) This is the case of phospholamban (PLN), a reversible inhibitor of 
the sarcoplasmic reticulum Ca2+-ATPase (SERCA).(5, 6) SERCA is a  110-kDa 
membrane-embedded, adenosine 5′-triphosphate (ATP)-driven calcium pump and is 
regulated by intramembrane interaction with PLN. In its storage form, PLN exists in a 
pinwheel pentameric assembly that de-oligomerizes upon interaction with SERCA.(5, 
7) PLN comprises multiple dynamic domains: the inhibitory domains include the 
transmembrane segment (domain II) and the juxtamembrane domain Ib, (8-12) while the 
regulatory elements include a short dynamic loop and an amphipathic helix (domain Ia) 
that interacts reversibly with the membrane and contains the protein kinase A (PKA) 
recognition sequence. (13, 14) Domain Ia of PLN exists in at least four conformational 
states: T-state (membrane attached and helical), T′-state (membrane attached and 
partially helical), R′-state (membrane attached and unfolded), and R-state (membrane 
detached and unfolded). (6, 11, 15) PLN phosphorylation at Ser16 by PKA in domain Ia 
is sufficient to reverse SERCA inhibition and increases the enzyme affinity for calcium 
that is pumped into the sarcoplasmic reticulum, initiating muscle relaxation. (16) 
Disruptions in this phosphorylation/dephosphorylation cycle lead to pathologies such as 
dilated cardiomyopathy. (17) 
Once unleashed from its tetrameric assembly by cyclic adenosine monophosphate, 
(18) the monomeric catalytic subunit of PKA (PKA-C) recognizes, binds, and 
71 
 
phosphorylates PLN. The molecular mechanisms of PLN recognition by PKA are still 
elusive. Recent NMR and X-ray data on PKA-C in a ternary complex with nucleotide and 
the cytoplasmic domain of PLN suggest that binding by PKA-C may involve an unfolding 
of PLN domain Ia (Figure 1a). (3) This result is striking given that, in several membrane 
mimics, the most populated state for the full-length PLN is folded, with the majority of the 
recognition sequence in close proximity with the lipid membrane. (7-9, 12, 19, 20) 
 
Figure 1. (a) Crystal structure of PKA-C bound to PLN1–20 showing the key contacts 
between substrate (green) and enzyme (gray) within the binding groove. (b) Primary 
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structures and (c) cartoon representations of the different analogs used to mimic the 
T- and R-states of PLN. 
 
To gain insights into the recognition mechanism of PKA-C for PLN, we used a 
combination of steady-state kinetic assays, NMR, and molecular modeling. We show 
that PKA-C preferentially binds and phosphorylates a membrane-detached and unfolded 
conformation of PLN, corresponding to the excited R-state of this protein. (15) Using a 
series of PLN variants in different lipid environments, we tuned the extent that domain Ia 
of PLN interacts with the membrane. We found a linear correlation between the catalytic 
efficiency of phosphorylation and the population of membrane-detached and unfolded 
domain Ia of PLN. Molecular modeling from NMR data shows that the kinase binds an 
extended conformation of PLN in solution. Taken together, these data demonstrate that 
the conformational equilibrium of PLN is an important requirement for efficient 
phosphorylation by PKA and activation of SERCA. 
3.2 Results 
3.2.1 PKA-C selects an extended conformation of PLN 
To understand whether PKA-C has a preference for the different conformational states 
of PLN, we prepared several PLN analogs that mimicked different populations of the 
ground and excited states of the cytoplasmic domain Ia (Figure 1b and c). The first PLN 
analog was obtained by synthetic incorporation of dialkyl 1′,3′-dioctadecyl-N-succinyl-
L-glutamate (Lip) to the N-terminus of full-length PLN. This analog has been shown to 
skew the equilibrium toward the well-folded, membrane-associated T-state, anchoring 
domain Ia to the lipid membrane. (21) On the other hand, to mimic the membrane-
detached, unfolded R-state, we synthesized a peptide corresponding to the cytoplasmic 
domain Ia (PLN1–20) and studied it in the absence of any membrane-mimicking 
environment. Under these conditions, PLN1–20 is an intrinsically disordered polypeptide 
as probed by circular dichroism (CD), NMR chemical shifts, and nuclear spin relaxation 
measurements (3) (Figure S1). To mimic the gradual progression from a full T-state to 
the R-state, we used synthetic and recombinant versions of full-length PLN with no 
lipidation, as well as a lipidated peptide corresponding to domain Ia of PLN (Lip-PLN1–20). 
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Finally, since full-length PLN reconstituted in dodecylphosphocholine (DPC) micelles has 
been well characterized by our laboratory, we also included this form in our studies. 
For each of the PLN analogs, PKA-C-catalyzed steady-state phosphorylation assays 
were performed, and the Michaelis–Menten constants were measured. Although all 
reactions eventually reached completion and displayed similar values for kcat (Table S1), 
the Km values for the reactions differed significantly. Specifically, PLN1–20 in the absence 
of membranes was phosphorylated with a high catalytic efficiency 
(kcat/Km   ∼ 0.6 µM−1 s−1), while full-length PLN in DPC micelles was phosphorylated with 
a low catalytic efficiency (kcat/Km   ∼ 0.05 µM−1 s−1). A variety of intermediate catalytic 
efficiencies were measured for the phosphorylation of PLN analogs under different 
conditions, as reported in Figure 2. The trend in catalytic efficiencies agrees qualitatively 
to an increasing population of R-state in PLN. 
 
Figure 2. Structure–function correlations for PLN analogs. The catalytic efficiency of 
the kinase increases with the increase in the R-state population. The errors were 
propagated from least-squares fitting analysis. Each data point in the Michaelis–
Menten plot represented an average of triplicate measurements. 
 
To provide a more quantitative analysis for the T-state population of the PLN analogs, 
we characterized the degree of folding using NMR. As reported previously, (3) the PLN 
peptide constitutes a good mimic of the cytoplasmic domain of full-length PLN as verified 
by chemical shift indices (CSIs) and secondary structure propensity scores. The 
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cytoplasmic domain of PLN is mainly α-helical (∼ 4% R-state) (22) in DPC micelles. (15) 
CSI and secondary structure propensity scores for PLN1–20 in the presence of DPC 
micelles agreed well with those findings, indicating that the peptide forms a stable α-
helix (Figure S1). In fact, only small differences were detected between the cytoplasmic 
regions of both constructs. The latter demonstrates that PLN1–20 closely mimics the 
cytoplasmic region of the full-length protein. 
Also, the chemical shifts of methyl-bearing side chains of the PLN cytoplasmic domain 
provide excellent probes for the T- and R-states of the protein. (15) Therefore, we 
measured the chemical shift positions of the methyl groups for each of the PLN analogs 
under conditions similar to the steady-state assays. The methyl groups showed a linear 
trend between the PLN1–20 free in solution (100% R-state (15)) and the PLN in DPC 
micelles (∼ 4% R-state (22)) (Figure 3a). The other analogs represented different 
intermediates between these two extremes, illustrating that these species gradually shift 
the population of the R-state toward the T-state (Figure 3a). Also, CD spectroscopy 
measurements on PLN1–20 analogs revealed a gradual increase in α-helical content in 
the presence of bicelles and, in particular, when the analog is lipidated. We therefore 
used the position of the methyl resonances to estimate the extent of unfolding and 
quantify the R-state for these analogs (Figure 3b). As expected, the comparison of PLN 
and Lip-PLN in isotropic bicelles showed a decrease in the R-state for Lip-PLN, 
consistent with the trends observed by CD spectroscopy. 
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Figure 3. Quantitative relationship between the extent of R-state and 
phosphorylation efficiency. (a) Selected regions of the methyl-transverse relaxation 
optimized spectroscopy NMR spectra for the different PLN analogs display a linear 
trend in the chemical shifts from the T- to R-state. (b) Linear relationship between 
the population of R-state of the PLN analogs and their respective phosphorylation 
kinetics. Errors in % R-state reflect the spread of populations estimated from the 
position of 12 chemical shifts. 13C and 1H chemical shifts from residues V4, L7, and 
I12 were used as probes of the R-state population. 
 
A quantitative relationship between the efficiency of phosphorylation and the population 
of the membrane-detached state (full R-state) of PLN was obtained when we 
plotted kcat/Km against the population of R-state (Figure 3b). Notably, the extent of 
unfolded R-state is linearly correlated with increased phosphorylation efficiency. These 
results demonstrate that PKA-C preferentially binds and phosphorylates the membrane-
detached conformation of PLN. 
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3.2.2 Molecular modeling of PLN1–20 bound to PKA-C 
To investigate how PKA-C recognizes and binds PLN and to characterize the protein–
protein interface, we used a combination of NMR, mutagenesis, and sequence 
homology data to model the complex between enzyme and substrate. Chemical shift 
perturbation profiles in both the substrate and the enzyme were analyzed to provide 
harmonic distance restraints for the molecular model of the complex. Perturbations in 
PLN1–20 resonances were almost exclusively localized to the recognition region for PKA-C 
upon titration with the enzyme. These perturbations were used as restraints for modeling 
the molecular complex. As for our previous titrations with kemptide, (23) residues 
perturbed in PKA-C upon titration with PLN1–20 are located in the immediate vicinity of the 
substrate binding groove, as well as residues in remote regions of the enzyme. 
Substantial chemical shift perturbations are observed in the glycine-rich (residues 50–
55), Asp184-Phe185-Gly186 (residues 185–187), activation (residues 190–197), and 
P + 1 (residues 198–205) loops. Distal sites are also affected: residues 30, 31, and 36, 
which lie toward the N-terminus, and residues 145, 146, 148, and 156 of the E helix. 
Perturbations are also apparent for residues 163 and 164 of β6, residue 271 in the loop 
connecting H and I helices, and residue 315 near the C-terminus. 
The membrane-free conformation of the PLN1–20 peptide is mostly unstructured, with 
chemical shifts displaying characteristics of an intrinsically disordered polypeptide. (24-
26) The negative [1H,15N]heteronuclear nuclear Overhauser effect values and the 
uniformity of the R2/R1 ratios indicate that, in solution, PLN1–20 is flexible and monomeric 
and reorients relatively fast. (27) When bound to PKA-C, the substrate does not show a 
defined secondary structure (α-helical or β-sheet conformations), as demonstrated by 
the relatively small changes in the chemical shift perturbation plot, as well as the CSIs 
for the 13Cα/13Cβ resonances (Fig. S2), supporting the previously published 
crystallographic structure. (3) 
To model the complex, we used the coordinates from the crystal structure of PKA-C in 
the closed conformation (1ATP). Since PLN1–20 has sequence similarity with protein 
kinase inhibitor (PKI), the endogenous PKA-C inhibitor, we aligned the PLN recognition 
sequence in the PKA-C binding groove as defined by the crystal structure (
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to PKI5–24 and ATP. (28) We oriented the side chain of the phosphorylation site (Ser16) 
of PLN1–20 toward the γ-phosphate of the ATP molecule. Chemical shift perturbations for 
PKA-C indicated that many areas distal to the binding site were perturbed by allosteric 
effects. Therefore, the crystal structure of PKA-C bound to PKI5–24 was used to filter out 
these long-range effects, considering only those residues in PKA-C with large chemical 
shifts (greater than the median value) and within 10-Å radius in the binding pocket 
defined by PKI5-24 (Figure 4b). The PKA-C crystal structure depleted of PKI5–24 (29) was 
used as the initial structure and held fixed during simulated annealing calculations. The 
NMR data were implemented as harmonic distance restraints. (30) PLN1-20 was modeled 
starting from a helical conformation(8, 12) and was allowed to be fully flexible during the 
docking protocol. The final model of the complex is reported in Figure 4c. The ensemble 
of the PLN1-20 conformers is in an extended conformation within the enzyme binding 
pocket. Taken with the kinetic experiments, this model supports the hypothesis that the 
enzyme selects an extended conformation from the ensemble of states sampled by PLN. 
This extended conformation has its recognition sequence fully accessible and detached 
from the membrane surface. 
 
 
Figure 4. Hybrid X-ray and NMR-based molecular model of the complex between 
PLN1-20 and PKA-C. Active (red) and passive (yellow) residues are indicated for (a) 
PLN1-20 and (b) PKA-C. (c) Twenty lowest conformers generated with HADDOCK. 
(30) (d) Atomic details of the interactions observed between PKA-C and PLN1-
20 based on the molecular model. 
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3.3 Discussion 
Based on phosphorylation kinetic assays, NMR data, and molecular modeling, we 
propose a recognition model for PLN, as reported in Figure 5. Since both PLN and PKA-
C undergo conformational equilibria between ground and excited states, (2, 3, 11, 15, 
31) the recognition model exemplifies the recently theorized extended conformational 
selection model, where the two binding partners affect each other, with a mutual 
adjustment process and changing both energy landscapes. (32) In fact, PLN exists in 
equilibrium between four major conformational states, driven by the reversible binding of 
the cytoplasmic domain Ia to the membrane. The T-state (L-shaped configuration) with 
domain Ia adsorbed on the membrane surface is the most populated and represents the 
ground state of PLN, while the remaining three states (T′, partially unfolded in domain 
Ib; R′, partially unfolded at the N-terminus and in the C-terminal part of domain Ia; and 
an R-state, which has domains Ia and Ib unfolded) are less populated and represent the 
excited states. In the ground state, PLN is less accessible to the protein kinase and is 
poorly phosphorylated, whereas the excited R-state comprises an ensemble of 
conformations from which PKA-C selects the extended conformation that molds into the 
substrate binding site. On the other hand, PLN binding drives the PKA-C conformational 
equilibrium toward the closed state of the enzyme as probed by both X-ray and NMR 
spectroscopy. (2, 3) 
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Figure 5. Extended conformational selection model for PLN recognition by PKA-C. 
Both PKA-C and PLN have been shown to undergo conformational exchanges. 
PKA-C undergoes a global change that opens and closes its active site upon 
interaction with the nucleotide. This likely facilitates efficient binding of PLN, as 
shown previously. (3) PLN also undergoes conformational fluctuations. (11, 
15) Unfolding of the cytoplasmic portion of PLN and detachment from the membrane 
facilitate the recognition and subsequent phosphorylation by PKA-C. 
 
The folding/unfolding transitions of PLN are relatively fast, (11) and the phosphorylation 
efficiency is proportional to the population of the most excited state (R), in which the 
helix of domain Ia is melted. In contrast, for the most helical construct studied (PLN in 
DPC micelles), the conformational equilibrium is skewed toward the full T-state, and the 
phosphorylation efficiency is much lower. 
The overall phosphorylation efficiency trends for both the peptide and the full-length 
protein mirror one another, demonstrating that the cytoplasmic portion of the protein is a 
good model for the full protein. This latter result supports the selection of the peptide to 
model the molecular complex of PKA-C/ATP/PLN1-20. Using chemical shift changes that 
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occurred upon formation of the Michaelis complex for both PKA-C and PLN1-20, 
sequence homology with the high-affinity inhibitor peptide of PKA-C, and results from 
mutagenesis, we modeled the PKA-C/PLN1-20 complex. This complex indicates that 
PKA-C binds an unfolded conformation of PLN. Initial molecular dynamic simulations 
(data not shown) indicate that this complex is stable, with the recognition sequence of 
PLN1–20 confined to the active site of the enzyme and regions outside of this remaining 
relatively mobile. This matches well with our previous nuclear spin relaxation 
measurements of the bound peptide, which indicated high mobility across the substrate 
backbone, with the exception of the recognition sequence, which was more ordered. (3) 
The conformational dynamics of the cytoplasmic domain of PLN are reminiscent of the 
binding-and-folding model proposed for amphipathic helices of membrane proteins. (33, 
34) According to this model, interactions with the membrane bilayer surface (likely driven 
by electrostatic residues) cause the amphipathic peptide to insert and fold onto the 
membrane with the hydrophobic face pointing toward the hydrocarbon region of the 
membrane bilayer and the hydrophilic face pointing toward the lipid headgroup/water 
interface. In addition to regulating the extent of PLN interaction with the membrane 
bilayer, a similar binding-and-folding mechanism is probably present in the PLN/SERCA 
inhibitory complex. (8) As suggested by NMR and electron paramagnetic resonance 
studies, phosphorylation probably shifts the conformational equilibrium toward a non-
inhibitory state of PLN, affecting the stability of domains Ia and Ib. We are currently 
investigating this hypothesis. 
The reversible folding of domain Ia is likely part of a more general class of regulation 
mechanisms that are mediated by amphipathic domains. (35, 36) For instance, a parallel 
can be made with the autoinhibitory process that takes place in Vav, a multidomain 
protein that is negatively regulated by its DH domain. (37) In Vav, autoinhibition is 
reversibly modulated by a folding/unfolding equilibrium of the amphipathic DH helix, 
which fluctuates between protein-free and bound conformations. This equilibrium is 
shifted toward the unfolded state upon phosphorylation at Tyr174. Phosphorylation 
efficiency was correlated with unfolding of this amphipathic domain. Another example is 
LOV2-Jα. (38, 39) As for Vav, LOV2-Jα also contains a region that can switch between 
an amphipathic α-helix and an unfolded conformational state. The conformational 
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equilibrium of this region dictates the inhibitory strength of the protein. These results 
mirror the current study with PLN, where the catalytic efficiency of the kinase is linearly 
correlated with the population of the unfolded excited state, which exposes the 
phosphorylation site to the protein kinase. 
This current study demonstrates that the modulation of the cytoplasmic domain to 
different states affects the ability of PLN to adapt to its binding partner, PKA-C. The 
ability to interact with other proteins through a population shift highlights the scaffolding 
capability PLN has for a number of known binding partners: PKA-C, protein 
phosphatase-1, Ca2+/calmodulin-dependent kinase II, SERCA, HS1-associated protein 
X-1, and A-kinase anchoring protein 18δ. The coupling of conformational plasticity of the 
PLN cytoplasmic domain and its interactions with cytosolic proteins (e.g., PKA-C) also 
demonstrates the importance of dynamics for signaling processes to occur efficiently 
and transiently to facilitate multiple functional interactions. (40-44) This appears to be 
particularly important for the case studied here, where a protein links signaling between 
the cytosolic and the membranous environments of the cell. 
Finally, this work underscores the role of the complex conformational fluctuations that 
PLN undergoes to cater to the phosphorylation process by PKA-C and, ultimately, 
SERCA regulation. Future studies on the localization of PKA (i.e., role of N-terminal 
myristoylation and A-kinase anchoring protein binding) will elucidate how regulatory 
domains, such as domain Ia of PLN, are integrated into macromolecular complexes to 
achieve signal specificity. 
3.4 Materials and Methods 
3.4.1 Materials 
Lactic dehydrogenase (LDH) from bovine heart and pyruvate kinase (PK) from rabbit 
muscle were purchased from Sigma (Solon, OH, USA). ATP, phosphoenolpyruvate 
(PEP), magnesium chloride, and reduced nicotinamide adenine dinucleotide (NADH) 
were purchased from Sigma-Aldrich (St. Louis, MO, USA). 
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3.4.2 Expression and purification of PLN and PLN1–20 
PLN1–20 was expressed in Escherichia coli cells as a fusion system with maltose binding 
protein and a 6-histidine tag to facilitate purification. (45, 46) The cells were grown 
overnight at 30 °C in LB rich media. At OD600 ∼ 1.0, cells were transferred into M9 
minimum media, containing 15N-labeled NH4Cl or 13C-labeled glucose for uniformly 15N- 
or 13C-labeled NMR samples. IPTG (0.5 mM) was added to induce fusion protein 
expression at 37 °C for 5 h . The pelleted cells were lysed in phosphate buffer 
(pH   8.0) in the presence of 6 M guanidine. The cell lysate was separated by 
centrifugation (18,000 rpm at 4 °C for 40 min ). The purification of the fusion protein was 
carried out using Ni2+-NTA resin. The eluted fusion protein was then dialyzed and 
cleaved with tobacco etch virus protease, which separated the PLN1–20 from maltose 
binding protein and the 6-His tag. The final purification was achieved by reversed-phase 
HPLC using a C-18 column (Vydac). After HPLC purification, approximately 2 mg of 
PLN1–20 was obtained from 150 mg of fusion protein. The mass of the purified PLN1–
20 (2472.8 Da) was confirmed by electrospray ionization time-of-flight mass 
spectroscopy. The full-length PLN was expressed and purified as reported previously. 
(46) 
3.4.3 Peptide synthesis 
Peptide synthesis was performed using standard Fmoc chemistry on an Applied 
Biosystems Pioneer or a CEM Liberty/Discover microwave synthesizer, starting with 
Fmoc-Glu(OtBu)-PEG-PS resin (0.4 g, 0.5 mmol/g). The side-chain protecting groups 
were 2,2,5,78-pentamethylchroman-6-sulfonyl (Pmc) for arginine; Nω-triphenylmethyl 
(Trt) for asparagine and glutamine; t-butyl ester (OtBu) for glutamic acid; and t-butyl 
ethers (tBu) for serine, threonine, and tyrosine. Addition of the lipid moiety was 
performed using standard coupling reagents and dialkyl 1′,3′-dioctadecyl-N-succinyl-
L-glutamate to the unprotected N-terminal methionine residue. (47) Cleavage of the 
resin-bound peptide was performed using Reagent K (82.5% trifluoroacetic acid, 5% 
phenol, 5% thioanisole, 2.5% 1,2-ethandiol, and 5% water) for 3 h  at 298 K. The resin 
mixture was washed three times (2 ml each) using the same cocktail, and filtrate was 
collected. The peptide was precipitated overnight at 273 K in 80 ml of diethyl ether and 
then collected by centrifugation and washing the pellet three times with 30 ml of diethyl 
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ether. The crude peptide was then purified by preparative HPLC using a Waters C18 
reversed-phase cartridge (2.5 cm × 10 cm, 15 µm, 300 Å) with 0.1% trifluoroacetic acid 
and CH3CN as eluents and detection at 220 nm. A linear gradient of 100:0 to 70:30 over 
30 min at 5 ml/min was used. The purity of pooled fractions was > 97% as determined by 
analytical HPLC using a Vydac C18 column (0.46 cm × 25 cm) and confirmed by 
electrospray ionization time of flight; for the analog PLN1-20: calculated, 2252.65 m/z; 
found, 2252.73 m/z. Stock solutions were prepared in water/acetonitrile and lyophilized. 
The concentrations of these solutions were verified by amino acid analysis. 
3.4.4 Kinetic assays 
The steady-state enzymatic rates of phosphorylation for PLN analogs were measured 
spectrophotometrically at 299 K following the procedure by Cook et al. (48) Briefly, the 
oxidation of NADH by PK and lactate dehydrogenase is coupled to the production of 
ADP, which occurs during the PKA-C-catalyzed phosphoryl transfer. The reaction rates 
were monitored at 340 nm using a Molecular Devices SpectraMax Plus384 equipped with 
a 96-well microplate reader. The reaction solutions contained 50 mM Mops (pH 7.0), 
20 mM DTT, 10 mM MgCl2, 5.0 mM ATP, 1.0 mM PEP, 0.2 mM NADH, 12 units of LDH, 
and 4 units of PK. For the kinetic assays with lipid bicelles, PEP, NADH, LDH, and PK 
were added after bicelle formation. Stock solutions of 2 mM PLN1-20 were prepared fresh 
and used immediately. For determination of the linear region of PKA-C concentration, 
PLN1-20 was kept at 300 µM, while PKA-C was varied between 2 and 728 nM. The 
reactions were initiated by the addition of PKA-C, which was equilibrated in a solution 
containing 50 mM Mops (pH 7.0), 20 mM DTT, and 10 mM MgCl2. No differences in the 
reaction rates were observed when the substrate was used to initiate these reactions. 
The measurements were performed in triplicate for each peptide concentration. Rates 
reflecting the small decrease in absorbance due to intrinsic NADH oxidation were 
measured and did not exceed ∼ 2% of any reaction studied. 
The values of kcat and Km were determined using nonlinear least-squares fitting of the 
initial velocities versus substrate concentration according to: 
 (1) 
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where v is the initial velocity, [S] is the concentration of the substrate, Vmax is the 
maximum velocity for the reaction, and Km is the Michaelis–Menten constant. The value 
of kcat was taken as Vmax divided by the total PKA-C concentration. Fitting of Eq. (1) to 
the kinetic data was performed using the software Origin 7. 
3.4.5 NMR spectroscopy 
NMR experiments were carried out on a Varian Inova operating at 800 MHz equipped 
with an HCN probe. The temperature of the experiments was held constant at 27 °C. 
Samples were prepared in 20 mM KH2PO4, 180 mM KCl, 1 mM NaN3, 10 mM DTT, and 
5% vol/vol D2O (pH 6.5) at concentrations of ~ 0.3–0.8 mM. Data were processed with 
the software NMRPipe (49) and visualized and analyzed using SPARKY. 
(50) Populations of the R-state (pR-state) were quantified using: 
 (2) 
where Ωx, ΩT-state, and ΩR-state are the chemical shifts of sample x, PLN in DPC, and 
PLN1–20 in aqueous buffer, respectively. The mean of pR-state was determined from six 
methyl groups in the protein (originating from V4, L7, and I12) that were observed in 
[1H/13C]heteronuclear multiple quantum coherence spectra. Due to poor sensitivity for 
the bicelle-bound states, amide spectra could not be used to estimate the population. 
3.4.6 Molecular modeling 
The three-dimensional model of the PKA-C/ATP/PLN1–20 complex was generated using 
HADDOCK 2.0. (30) As an initial configuration, the coordinates from the crystallographic 
ternary complex of PKA-C/ATP/PKI5–24(1ATP) were used and depleted of PKI5–24. 
(28) The coordinates of the enzyme were kept fixed during the docking of PLN1–20 using 
simulated annealing. Restraints based on NMR chemical shift data were implemented as 
ambiguous interaction restraints. Specifically, active residues were categorized as those 
that had solvent accessibility > 50% and chemical shift perturbations greater than the 
median and within 10 Å from the binding pocket of the enzyme. The active residues 
identified were S53, K78, L82, K83, S130, L198, G200, Q245, D328, D329, and Y330. 
Solvent-accessible residues within 3 Å of the active residues were categorized 
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as passive. Active and passive residues were defined for the PLN1–20 using the same 
criteria. An ambiguous interaction restraint was satisfied when any atoms of active 
residues in one molecule were within 4 Å of an active or a passive residue of the docking 
partner. Also, the canonical recognition sequence of PLN1–20 (P − 3 to P + 1 site) was 
aligned to match the corresponding positions of PKI5–24 in the binding groove of 
the 1ATP structure. (28) Based on this alignment, five additional distance restraints were 
used: three hydrogen bonds from the R14 guanidinium group of PLN1–20 to Glu170, 
Tyr204, and Glu230 of PKA-C; one hydrogen bond from Ser16 of PLN1–20 to Ser53 of 
PKA-C; and one hydrogen bond involving the carboxyl group of Thr17 and the backbone 
amide of Gly200 in PKA-C. The hydrogen-bond distances (from N or O heteroatoms to 
hydrogen atoms) were incorporated as nuclear Overhauser enhancement distance 
restraints using a flat well potential with 1.5 (4) Å as lower (upper)-bound distances. 
PLN1-20 was set to be flexible, with the exception of the residues occupying P − 3 to P + 1 
sites of PKA-C, consistent with the results based on NMR dynamic measurements.2 The 
backbone conformation of PKA-C was kept fixed, while full flexibility was allowed for side 
chains. The initial structures of PKA-C and peptide were subjected to rigid-body docking 
and subsequent structure refinement using the docking protocol from HADDOCK with 
adjusted weighting factors.29 A total of 2000 initial structures of the complex were 
generated after rigid-body docking, and the 200 lowest energy structures were optimized 
by simulated annealing, followed by refinement in explicit water using the Tip3 water 
model. (30) These structures were then clustered according to their pairwise RMSDs 
with respect to the conformation of PKI in the 1ATP crystal structure. The 20 lowest-
energy structures were selected for the final analysis. 
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Table S1:  Steady-state kinetic parameters for the phosphorylation of PLN analogues. 
 
 
 
 
 
 
 
 
 
  
            
    kcat (s-1)   Km (µM)   kcat/Km (µM-1 s-1)     
PLN1-19 (Free)   22.3  ±  1.3   36.4  ±  5.5   0.61  ±  0.10   
PLN1-19 (Bicelle)   25.0  ±  1.8   43.0  ±  5.2   0.58  ±  0.8   
AFA-PLN (Bicelle)   20.2  ±  0.6   47.6  ±  4.3   0.42  ±  0.04   
Lip-PLN1-19 (Bicelle)   24.7  ±  1.9   90.1  ±  14.9   0.27  ±  0.05   
Lip-AFA-PLN (Bicelle)   21.9  ±  1.5   114.8  ±  17.9   0.19  ±  0.03   
AFA-PLN (DPC)   13.0  ±  0.8   
238.1  ±  
21.0   0.05  ±  0.01   
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Figure S1:  Structural details of PLN1-20 in the presence and absence of membrane 
mimicking environments.  A) CD spectra of PLN1-20 in aqueous buffer, TFE, isotropic 
bicelles, or DPC indicate higher α-helical content in the presence of membrane 
mimicking environments.  B)  The amide perturbations from interaction with DPC 
was followed by recording an 1H/15N HSQC NMR spectra of PLN1-20 with and without 
DPC micelles.  This supported that drastic changes likely occur in the secondary 
structure.  NMR chemical shifts for 13Cα, 13Cβ, 13C' and 15Nα resonances were used 
to determine the secondary structure propensity scores of PLN1-20 in C) aqueous 
solution or with D) DPC micelles.  Along with proton Hα chemical shift indices (in 
aqueous solution, E, or DPC micelles, F), the peptide exchanges between a 
membrane absorbed α-helix and a membrane detached, disordered conformation.   
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Figure S2:  Structural transitions of PLN1-20 upon interaction with DPC or PKA-C.  A) 
Combined chemical shift indices for Cα and Cβ residues indicate the unstructured 
peptide forms an α-helix upon interaction with DPC micelles, but remains largely 
unstructured when bound to PKA-C.  The changes in secondary structure was also 
evident from full chemical shift perturbations (13Cα, 13Cβ, 13C' and 15Nα, panel B) of 
PLN1-20 upon binding DPC or PKA-C. 
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Chapter 4 - Paramagnetism-Based NMR Restraints Lift Residual 
Dipolar Coupling Degeneracy in Multidomain Detergent-
Solubilized Membrane Proteins 
 
Reprinted with permission from: 
Lei Shi, Nathaniel J. Traaseth, Raffaello Verardi, Martin Gustavsson, Jiali Gao, and 
Gianluigi Veglia. Paramagnetic-Based NMR Restraints Lift Residual Dipolar Coupling 
Degeneracy in Multidomain Detergent-Solublized Membrane Proteins J Am Chem Soc. 
2011; 133(7): 2232–2241. 
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Residual dipolar couplings (RDCs) give orientational dependent NMR restraints that 
improve the resolution of NMR conformational ensembles and define the relative 
orientation of multidomain proteins and protein complexes. The interpretation of RDCs is 
complicated by protein dynamics and the intrinsic degeneracy of solutions that lead to ill-
defined orientations of the structural domains (ghost orientations). Here, we illustrate 
how paramagnetic-based restraints can remove the orientational ambiguity of 
multidomain membrane proteins solubilized in detergent micelles. We tested this 
approach for the monomeric form of phospholamban (PLN), a 52-residue membrane 
protein, which is composed of two helical domains connected by a relatively flexible 
loop. We show that the combination of classical solution NMR restraints (NOEs and 
dihedral angles) with RDCs and PREs resolve topological ambiguities, improving the 
convergence of the PLN structural ensemble and giving the depth of insertion of the 
protein within the micelle. This combined approach will be necessary for membrane 
proteins, whose three-dimensional structure is strongly influenced by interactions with 
the membrane-mimicking environment rather than compact tertiary folds common in 
soluble proteins. 
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4.1 Introduction 
Residual dipolar couplings (RDCs) constitute an excellent source of structural and 
dynamic information (1-4). Their use spans from structural refinement (1, 5, 6) to the 
characterization of unfolded proteins (7-11) and excited states of biomolecules (12, 13). 
RDCs are also an invaluable NMR parameter to orient multidomain proteins and protein 
complexes, where the detection of inter-domain or inter-protein nuclear Overhauser 
effects (NOEs) are very challenging (4, 14, 15). However, the inherent degeneracy of 
RDCs (ghost orientations) complicates the extraction of orientational information (16). It 
was originally thought that the RDC equation resulted in eight-fold degeneracy for 
peptide plane orientations (16), but recently, it was shown that the analytical solution of 
the RDC equation contains a 16-fold degeneracy (17). This degeneracy is reduced to 
four if one considers the regular patterns of the dipolar couplings (i.e. dipolar waves) for 
secondary structure domains (8, 18-22). In favorable cases, this RDC inherent 
degeneracy is resolved using two or more alignments media (23). Nonetheless, local 
geometry can still be ill-defined (17) and further confounded by the presence of 
conformational dynamics (24-27). Therefore, a major issue is to eliminate ghost 
orientations from the true orientations. Bertini and coworkers have proposed the use of 
paramagnetism-based NMR restraints (28). These authors have developed a new 
analysis of the paramagnetic-based restraints to give a comprehensive view of the 
different conformations and dynamics of calmodulin as well as the calmodulin-α-
synuclein complex (28). A similar approach has been utilized for resolving the solution 
conformation of the ternary complex of the E. coli Hsp70 chaperone (29). Membrane 
proteins solubilized in detergent micelles are not immune to these challenges. Polytopic 
(integral and/or peripheral) membrane proteins are often organized in multiple domains 
(independent or partially independent) that facilitate intra- and inter-cellular 
communication (30). Flexibility of protein domains can prevent the formation of compact 
tertiary structures, which results in the structure being defined by domain interactions 
with the lipid membrane, i.e. topology (31). Several small and medium size membrane 
proteins involved in regulatory function of ion pumps fall into this category (31). While 
membrane proteins are amenable to modern solution NMR techniques, it is still a 
challenging task to obtain long-range distance restraints from nuclear Overhauser effect 
(NOEs) data (32), especially for helical membrane proteins. Side chain methyl labeling 
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schemes can help determine the overall fold of membrane proteins, and new protocols 
have been developed to introduce a variety of different probes on proteins (33-35). 
RDCs constitute a viable alternative to obtaining long-range distance restraints, and 
accordingly have been an important source of constraints for membrane proteins. To 
measure RDCs, membrane proteins need to be aligned in an anisotropic media (36-38) 
or bound to a lanthanide ion either through adventitious sites (39) or engineered tags 
(40, 41). In several instances, RDCs were crucial to improving the resolution of the 
conformational ensemble of membrane proteins solubilized in micelles (32, 42, 43).  
In this article, we show that the ghost orientations generated after RDC refinement of the 
detergent solubilized protein phospholamban (PLN) can be eliminated by using 
paramagnetism-based restraints derived from site-directed spin-labeling using MTSSL 
(1-oxyl-2,2,5,5-tetramethyl-D3-pyrroline-3-methyl methanethiosulfonate). 
4.2 Material and methods 
4.4.2 PLN expression, purification, and mutagenesis 
The overexpression and purification of AFA-PLN (i.e. cysteine-null monomer, C36A, 
C41F, C46A) was carried out as described in Buck et al. (44). For the A24C mutant, the 
plasmid containing fully functional cysteine-null PLN was used as a template to introduce 
a single point mutation (A24C) by site directed mutagenesis using Quick-change kit 
(Stratagene, San Diego, CA). PCR was carried out as previously described (44). The 
primers were designed as follows: forward 5’-GCCGCAGCAGTGCCGCCAGAACCTGC-
3′, reverse 5’- GCAGGTCTGGCGGCACTGCTGCGGC-3’ (the mutated codon is 
underlined). The mutated plasmid was amplified in XL1-blue competent cells 
(Stratagene, San Diego, CA) and purified using QIAprep Spin kit (Qiagen, Carlsbad, 
CA). The sequence was confirmed by DNA sequencing (ABI PRISM 3130xl Genetic 
Analyzer. Biomedical Genomic Center, Minneapolis, MN). BL21(DE3) (Stratagene, San 
Diego, CA) E. coli cells were transformed with 100 ng of purified plasmid and selected 
on LB agar plates containing ampicillin (100 mg/mL). The L7C mutant was designed in a 
similar way. Protein expression and purification were carried out using a combination of 
affinity chromatography and HPLC (44). 
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4.2.3 A24C-PLN and L7C-PLN spin-labeling with MTSSL 
MTSSL (1-oxyl-2,2,5,5-tetramethyl-D3-pyrroline-3-methyl methanethiosulfonate, Toronto 
Research Chemicals, North York, ON) spin label reacts with the terminal SH of cysteine 
residue to form a covalent bond. A stock solution of 200 mM MTSSL in DMF was 
prepared. The labeling reaction protocol was derived from Kirby et al. (45). One mg of 
lyophilized A24C-PLN (or L7C-PLN) protein was solubilized in 1 mL of spin labeling 
buffer (60 mM Tris-HCl at pH 7.0 and 0.2% SDS). The final concentration of PLN was 
~0.2 mM. A 10-fold molar excess of MTSSL was added to the reaction mix and 
incubated overnight at 4 °C in the dark. The unreacted spin label was removed by HPLC 
with the PLN peak collected and lyophilized after removal of organic solvent. Lyophilized 
MTSSL spin labeled A24C-PLN (or L7C-PLN) was dissolved in 300 mM DPC, 20 mM 
phosphate buffer (pH = 6.0, 120 mM NaCl, 0.01% NaN3, and 10% D2O). The final 
concentration of A24CPLN was ~0.1 mM. 
4.2.4 Sample preparation for RDC measurements 
AFA-PLN [U-13C, 15N] was reconstituted into 100 mM deuterated DPC (Cambridge 
Isotope Laboratories), 25 mM phosphate buffer (pH 6.0), 125 mM NaCl, 10% D2O, and 
0.1% NaN3 to give a final protein concentration of ~0.8 mM. The stretched gels were 
polymerized from a 5.7 mm diameter cylinder under the following conditions: 100 mM 
Tris-HCl (pH 8.0), 5.1% acrylamide, 1.3% bis-acrylamide, 0.1% ammonium persulfate, 
and 0.33% TEMED. The gels were thoroughly washed twice with 50 mM 
NaH2PO4/Na2HPO4 pH 6.5 (8 hr/wash) and then twice with H2O (8 hr/wash) as 
described previously (46). The protein/detergent mixture was added to the dried 
polymerized gel and incubated at 37 °C for ~24 hr. After stretching in a 5 mm Shigemi 
tube, the length of the gel increased by a factor of ~1.7. The stretching apparatus was 
purchased from New Era Enterprises, Inc. and has been previously described (46). 
4.2.5 NMR Spectroscopy 
RDC measurements: Experiments were carried out at 37 °C using a Varian 
spectrometer operating at a 1H Larmor frequency of 599.54 MHz. 2D TROSY based 
(1H, 15N) pulse sequences described by Permi and Annila (47) were performed to 
measure 13C’-13Cα and 1H-15N one-bond couplings. Each 2D experiment was acquired in 
the presence and absence of the stretched gel where the difference in splitting allowed 
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for the calculation of the residual dipolar couplings. The total acquisition times in t1 and t2 
were 62 and 77 ms with spectral widths of 1300 and 6600 Hz in the 15N and 1H 
dimensions, respectively. In order to measure the 15N-13C’ one-bond couplings, we 
performed a 3D uncoupled HNCO experiment in the presence and absence of stretched 
gel. Experiments utilized 64 scans, spectral widths of 10000 Hz (1H), 1000 Hz (13C) and 
1200 Hz (15N) with total acquisition times of 83.2, 40, and 26.7 ms in the 1H, 13C, and 15N 
dimensions, respectively. Experiments were acquired at 37 °C with a recycle delay of 1.3 
s. All data were processed with NMRPipe (48) and viewed using NMRVIEW (49). The 
1H-15N, 13C′-15N, and 13C′-13Cα RDCs versus residue are shown Figure 1A. 
PRE measurements: [1H, 15N] heteronuclear single quantum coherence (HSQC) spectra 
were acquired in the presence of MTSSL (paramagnetic) and the diamagnetic analog at 
positions 7 and 24 of PLN. The intensity reduction (Iox - diamagnetic, Ired - paramagetic) 
of the amide resonances were converted into R2sp values and then to distance 
restraints using Eq. 1 (50): 
 [1] 
where r is the distance between the nuclear spins and the unpaired electron,τc is the 
correlation time for the electron/nuclear spin interaction, ωh is the proton Larmor 
frequency, K is a constant that depends on the gyromagnetic ratio, electronic g factor 
and the Bohr magneton and is set to 1.23 × 10−32 cm6 s−2. For PLN, we used two 
different correlation times (τc): 8.2 ns for the cytoplasmic domain and 15.4 ns for the 
transmembrane domain (51). For peaks with intensity retention greater than 90%, no 
upper limits were used. For the other peaks, the intensity retentions were converted into 
distances according to equation [1], and implemented with upper and lower bounds of ± 
4 Å (50). The PRE quenching data and the converted distance restraints for PLN are 
shown in Figure 2. 
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Calculation protocol: We used the standard energy target function that has been 
implemented in XPLOR-NIH (52):  
 [2] 
where Eempirical is the sum of the energy terms of the covalent geometry (bond stretching, 
bond bending, improper angle vibration) and short-range repulsion (repulsive VDW 
interaction): 
 [3] 
Esolution includes the penalty functions due to distance restraints from NOEs, dihedral 
angles, RDCs, and PREs: 
 [4] 
All of the NOE-derived distance restraints used in the present study are taken from the 
previously published structure of PLN in DPC micelles (53). A total of 373 distances (142 
intra-residue and 231 inter-residue) are included. In addition, 58 hydrogen-bonds derived 
from H/D exchange measurements are used to constraint the helical amide groups (HN-
CO[i, i+4]) of PLN. Finally, we have obtained 38 dihedral angle restraints using the 
program TALOS (54) based on the chemical shifts of Hα, Cα, Cβ, C′, N, and HN (55). A 
summary of all of the restraints used in the calculations is listed in Table S1. To illustrate 
the significance of RDC and PRE restraints in the structural refinement of the membrane 
protein PLN, we used three protocols in the simulated annealing optimization to 
generate three structural ensembles (56). In the first protocol, we used the restraints 
derived from typical solution NMR experiments, including NOE-derived distances, 
dihedral angle restraints generated from chemical shifts (TALOS), and hydrogen-
bonding interactions from H/D exchange experiments (53). The second protocol includes 
the restraints from the first protocol plus RDCs derived from the partial alignment of PLN 
in stretched gels. Finally, the third protocol was constructed by adding MTSSL distance 
restraints determined from PRE data to all constraints used in the first two protocols. 
Details for the calculation are presented in the supporting material. 
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4.3 Results 
4.3.1 Structural refinement with NOE and dihedral angle restraints (protocol one) 
To test our approach, we used phospholamban (PLN), a 52-residue integral membrane 
protein in the sarcoplasmic reticulum (SR) that regulates the SR Ca2+-ATPase (SERCA) 
(57). PLN exists as an inactive pentamer in the SR and depolymerizes into active 
monomers upon encountering SERCA (58, 59). To mimic the monomeric state, we 
mutated the three transmembrane Cys residues (C36A, C41F, C46A) to obtain a stable 
monomer with activity identical to that of wild type PLN (60). The NMR structure of PLN 
monomer in dodecylphosphocholine micelles has been solved by our group (53). For the 
structure determination, we used distance restraints from 15N-edited NOESY spectra, 
dihedral restraints from chemical shifts (54), and hydrogen bonds derived from exchange 
factors (61). Based on the results of the calculations and subsequent backbone 
dynamics studies, we identified four dynamic domains: α-helical domain Ia (residues 1–
16), α-helical region spanning domains Ib (residues 23–30) and II (residues 31–52), and 
a loop connecting the two helical regions (residues 17–22) (51). Given the limited 
amount of distance and angular restraints found between the loop and its adjacent 
domains, the final structural ensemble resulted in many different conformers with poor 
convergence for the overall backbone conformation and topology. In our previous paper, 
we mapped solvent accessibility using Mn2+ ions and the insertion of PLN in the micelles 
using 5- and 16-DSA, and manually eliminated structures that contradicted the 
paramagnetic mapping. We concluded that PLN adopts a helical L-shaped conformation 
with the cytoplasmic amphipathic domain Ia adsorbed on the surface of the micelle. 
These results were also supported by solid-state NMR experiments carried out in the 
lipid membrane (62). While these studies represent the initial characterization of PLN in 
membrane mimicking environments, they were limited by two factors: (a) the absence of 
topological restraints with respect to the micelle (the selection was carried out manually), 
and (b) the absence of the relative orientation of the two helical domains. 
4.3.2 Structural refinement with RDCs plus NOE (protocol two) 
Since the publication of our first paper on PLN, several groups have obtained 
orientationally dependent information utilizing RDC data for both membrane bound and 
soluble proteins. Therefore, our first step to improve the solution NMR structural 
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ensemble of PLN was to introduce restraints from three sets of RDCs obtained from the 
partial alignment of PLN in a stressed gel system (36, 63). Figure 1 shows three sets of 
RDCs versus the PLN residue number: 1H-15N, 13C′-15N, and 13C′-13Cα. As expected from 
the helical secondary structure of PLN, the values of the RDCs oscillate periodically. 
There is a significant change in the pattern from residues 20 to 30 for the 1H-15N RDCs. 
These residues belong to domain Ib, a helical region that is more dynamic and solvent 
exposed than the transmembrane domain II (51). When fitting these dynamically 
averaged RDCs to an average structure, a pronounced kink is observed between 
domain Ib and domain II. In fact, CPMG relaxation dispersion measurements obtained 
from PLN in DPC indicate the presence of chemical exchange (at least two 
conformations) for domain Ib (51, 64) and for this reason we excluded RDCs from 
domain Ib during our structural calculation. Dynamic model or ensemble simulations are 
needed to explain the discontinuity of RDCs patterns in this domain. One of the 
difficulties during structural refinement with RDCs is to accurately determine the axial 
(Da) and rhombic (R) components of the alignment tensor. Several methods are 
available to estimate these values such as the maximum likelihood method by Moore 
and Warren (65) and the histogram method by Bax and co-workers (66). To use these 
methods, large numbers of RDCs are needed and their reliability is dependent on the 
accuracy of the experimental measurements. Due to the increased size of the 
membrane proteins within the detergent micelle, the experimental RDCs have larger 
errors than their soluble counterparts. Therefore, the errors of heavy atom RDCs such 
as 13C’-15N and 13C’-13Cα are much larger after scaling to the 15N-1H RDCs. To overcome 
this, Da and R were allowed to vary in the simulated annealing procedure (6). This 
introduced two extra parameters into the structural fitting in addition to the tensor 
orientations. The refined 400 structures are clustered based on two groups of Da and R 
values (Figure 3). The solutions with Da = −8 Hz and R = 0.667 resulted when RDCs 
were not properly fitted; these structures were excluded from further analysis. The 
structures generated from the second group (shown red in Figure 3) were used in the 
following calculation where Da = 8.6 (± 0.3) and R = 0.52 (± 0.04). The high rhombicity R 
is consistent with the RDC histogram shown in Figure 1B. Note that all of the RDCs 
were implemented in the simulated annealing protocol using a flat-well potential52. The 
force constants for RDCs during the structure refinement were determined using the R 
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factor method (RRDC) as described by Clore and co-workers (56). In this method, two 
factors are monitored as a function of the RDC force constant: (1) the R factor for 
different sets of RDCs and (2) the energy penalties from energy terms other than RDCs. 
During the force constant ramping, the tensor values Da and R were fixed (determined 
above to be Da = 8.6 and R = 0.52). We found that the best value for the force constant 
was 0.5 kcal mol−1 Hz−2 (see Figure S1), which can give reasonable RDC agreement 
without large penalties from other structural and experimental restraints. After optimizing 
Da, R, and the force constants, we generated ~300 structures and selected the lowest 
100 structures for further analysis. The resulting structures were clustered into four 
distinct families (I–IV) when the transmembrane domain II was overlaid. As expected, 
these structures differ in the relative orientation of the two helical domains giving rise to 
a four-fold degeneracy (Figure 5B). Each structural ensemble shows a backbone RMSD 
less than 1.6 Å, with good correlations between experimental and calculated RDC 
values (Figures S2). When viewed in the alignment tensor frame (Figure 3C), 16 
different solutions for two helical domain structures are resolved when only one 
alignment medium is used. A similar result has been obtained by Bax and co-workers 
(67) for the monomeric subunit of KcsA solubilized in detergent micelles. For PLN, 
however, several of these solutions are degenerate, and the reason the structures could 
be grouped into four unique structural families (I, II, II and IV in Figure 5B). The 
solutions can be distinguished by analyzing the orientation angles (θ,φ) for each helical 
domain in the alignment tensor frame (Figure 3A) as well as the inter-helical angle χ 
(angle between domains Ia and II). For both the transmembrane (blue) and cytoplasmic 
(red) helices, the orientations correspond to the following angles: (θ, ϕ), (θ, π+ϕ), (π–
θ, π –ϕ), and (π –θ, 2π –ϕ) (Figure 3B). The same solutions were found using 
theoretical equations by Wang and co-workers (21). The hydrophobic residues of the 
cytoplasmic domain Ia are approximately oriented toward the transmembrane domain for 
families I and II and away from it for families III and IV. As for the interhelical angle, 
family I has a χ angle of ~90°, while families III and IV display χ angles of ~70°. Family II 
has a nearly anti-parallel orientation between the two helical domains (χ ~140°). This 
orientation is similar to the monomer unit obtained using RDCs for the bellflower model 
of pentameric PLN by Oxenoid and Chou (68). 
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4.3.3 Structural refinement with RDCs and PREs (protocol three) 
To reduce the degeneracy from the RDC solutions and remove the translational degree 
of freedom between the two domains, we measured PRE distance restraints. 
Specifically, we implemented PRE distance restraints from MTSSL-PLN constructs. 
These restraints were included in the calculations using the convention introduced by 
Battiste and Wagner (50) (see Materials and Methods). To restrict the flexibility of the 
spin label, we used a dihedral angle potential (sinusoid potential) to restrict the χ1, χ2 and 
χ3 angles of the spin label, which have been identified to adopt defined values from 
crystal structures (69). Even with these long-range distances, families I, III and IV 
remained in the 100 lowest energy structures. However, these three solutions can easily 
be distinguished based on the PRE energies (EPRE). In protocol two (RDC+NOE 
refinement), the four families are energetically degenerate (ERDC and ENOE) (Figure 4A, 
B), while in protocol three, each of the three families clearly have different values of EPRE 
(Figure 4C,D). The structures within family I display the lowest PRE and NOE energies, 
and thus was selected as the final structure ensemble (Figure 5C), giving a backbone 
RMSD of ~ 1.2 Å and good agreement with experimental RDCs (Figures S4) and PREs 
(Figure S5). The energy differences between families I, III and IV is very small. In fact, 
this explains why structures blindly selected based on total energy (and not EPRE) cannot 
adequately decipher between the three families present. PREs were helpful, because 
the major differences between structural families was in the positioning and facing of the 
cytoplasmic helix. Only family I had the hydrophobic residues facing toward the 
transmembrane helix, i.e., facing the micelle interior (Figure 4C). As an attempt to 
further support our justification of using PRE energies to eliminate families III and IV, we 
tried to label PLN with MTSSL at a different position. When engineered at position 9 
(R9C-PLN), however, the spin label inserts into the hydrophobic core of the micelle 
(Figure S6C), while the backbone amide of R9C points toward the solvent (Figure S6D, 
Gd3+ quenching pattern). When the MTSSL is engineered, the long chain of MTSSL 
cross-linked to Cys 9 inserts in the detergent micelle (see quenching of the resonances 
in the transmembrane domain in Figure S6C), resulting in an incorrect positioning of the 
side chain and faulty interpretation of the structural topology of the protein. Therefore, 
the flexibility and hydrophobic nature of the MTSSL spin label calls for special care when 
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engineering site-specific mutants in membrane proteins when those sites are proximal to 
the membrane (70). 
4.3.4 Application to the PLN Pentamer 
The structure of the PLN pentamer heavily relied on the use of RDCs in the structure 
refinement (68). In fact, monomer structures were built prior to assembly in the 
symmetric pentamer. In the monomer calculation, the alignment tensors (Da=9.00, 
R=0.33) were determined from singular value decomposition (SVD) (71) using 15N-1H, 
13C-15N and 13C’-13Cα RDCs. The alignment tensor was slightly different from the value 
in our monomer case. A comparison of RDC restraints between the pentamer (Oxenoid 
and Chou (68)) and monomer (this paper) showed a good correlation (Figure S7), 
especially with the N-H RDCs. We then performed the similar structural calculation using 
their tensor values and data. Similarly we also obtained four degenerate solutions 
(Figure 6A, B) as in our AFAPLN monomer calculation. Without help from long-range 
distance PRE restraints, only one of the families was selected to build the high-
resolution pentamer. Aside from the degeneracy issue, the choice of the tensor value is 
also debatable for a symmetric pentamer (or another symmetric oligomeric protein). It is 
well-known in the literature 15 that the symmetry axis should coincide with the long axes 
of the alignment tensor, resulting in R=0 (zero rhombicity). It was argued that non-
symmetric tensor values could result from protein dynamics (68), however the dynamic 
averaging of RDCs needs to be interpreted using a dynamic ensemble rather than fitting 
data to an average structure. We performed structural calculations of the monomer using 
RDCs measured by Oxenoid and Chou (68) and implemented a symmetric tensor (R=0), 
as would be expected from a symmetric pentamer. The Da value was determined to be 
6.5 using the methods described earlier (Figure S1). The structure analysis is shown in 
Figure 6C and D. Note that the φ angle does not have defined minima as in Figure 6B. 
This is also in agreement with a theoretical study, which showed that an infinite number 
of solutions existed for cases where R=0 17. 
4.4 Discussion 
To address the challenges of high-resolution structure determination of membrane 
proteins complexes in micelles, the classical NOE-driven approach has been 
supplemented with RDCs. However, internal protein dynamics and intrinsic degeneracy 
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of the RDC solutions complicate the data interpretation, resulting in ghost orientations. 
Here, we show that the degeneracy problem can be addressed by supplementing RDC 
restraints with PREs from covalent attachment of the MTSSL spin label, which provides 
a fast and efficient method both for determination of membrane protein structure and its 
topology. We applied this method to a small multi-domain membrane protein, PLN, 
which regulates the enzymatic activity of the SR Ca2+-ATPase in cardiac muscle. While 
structural biologists agree on the secondary structure content of PLN, there is an active 
debate about the topological arrangement of this protein in the lipid membrane. The 
structure calculations carried out with NOE based distance restraints do not provide for a 
high-resolution picture of PLN due to the lack of restraints between the helical domains. 
The correct orientation of the helical domains of PLN were selected manually based on 
the PRE data from Mn2+ and doxyl stearic acids (53). The introduction of RDCs improves 
the resolution of the ensemble, but exemplifies four different solutions, with ghost 
orientations of the cytoplasmic domain Ia. The combination of paramagnetic-based 
restraints PREs with RDCs and NOEs enabled us to resolve the orientation that agrees 
best with all available data. This solution (family I) is similar to the recently determined 
structural ensemble of monomeric PLN in lipids (55, 72). This is not surprising since 
several recent reports have shown that the structures of membrane proteins in micelles 
are similar to those determined in lipid bilayers (73). The slight discrepancy in the 
average rotation angles between the hybrid ensemble and that determined by combining 
NOEs, RDCs, and PREs (Figure 7) has several possible origins. First, there are several 
approximations used for the determination of the alignment tensor. Second, the 
cytoplasmic domain of PLN is rather dynamic (51, 64) and our data treatment does not 
take this into account. Third, the non-planar surface of the micelle can cause bends and 
curvature to malleable domains of membrane proteins and peptides (46). Last, RDC 
provides information of bond orientations with respect to three alignment tensor axes in 
a nonsymmetric tensor. PISEMA only encodes bond orientations with respect to one of 
the tensor axis (z axis), similar to RDC with a symmetric tensor. Moreover, as with all the 
NMR parameters, the PREs are affected by protein dynamics (74) and our approach 
does not take into account these effects. Since the studies of membrane proteins in 
detergent micelles are likely to continue to offer insightful information, we conclude that 
for multidomain membrane proteins the use of RDCs is not sufficient to define their 
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conformational space and topology. Rather, orientational restraints need to be 
supplemented with long-range paramagnetic restraints from spin labels covalently linked 
to proteins to uniquely define their topology (32, 75). Finally, we would like to point out 
that this paper address only the geometric ambiguities derived from RDCs. In fact, 
intrinsic dynamics complicates the use of both PRE and RDC for structure 
determination. To overcome these problems, molecular dynamics methods are being 
developed to for the variability of alignment tensors (76, 77) as well as for the 
modulations of the PRE effects on long-range interactions (74, 78). A more 
comprehensive approach for flexible domains of membrane proteins would require the 
combined use of PRE and RDCs using ensemble molecular dynamics methods (74). 
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Figure 1. RDC versus residue for PLN weakly oriented in stretched gels. (A) Top: 13C′-
15N RDCs; middle: 13C′-13Cα RDCs; bottom: 1H-15N RDCs. We reported only the RDC 
values for well resolved peaks. (B) RDC histogram with all the data in (A) scaled to the 
1H-15N RDCs.  
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Figure 2. PRE data obtained from A24C-PLN (black) and L7C-PLN (red) cross-linked 
with MTSSL. (A) Intensity retention plot for A24C-PLN and L7C-PLN labeled with 
MTSSL. Unresolved peaks are not reported and are indicated with points. (B) Distances 
derived from PREs (see materials and methods). Note: only peaks with intensity 
retention ratio less than 0.95 were used in the calculations. Also some residues lacking 
R2 values were omitted. (C) Cartoon representation of PLN with MTSSL label at C24 
and C7.  
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Figure 3. (A) Definition of orientation angles (θ, ϕ) of helical rigid body in the alignment 
frame. (B) (θ, ϕ) plot of cytoplasmic (Cyto, red) and transmembrane (TM, blue) domain 
orientations in the alignment frame. (C) Detailed orientation of TM and Cyto with each 
letter corresponding to (θ, ϕ) in (B). Different combinations of orientations result in 
different families (labeled in the bottom). 
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Figure 4. (A) Comparison between representative structures from each family refined 
from protocol II. Sidechains of MTSSL label (yellow) and hydrophobic residues (A12 and 
I13, orange) are shown and labeled. (B) ENOE and ERDC of the four families of structures 
from protocol II. (C). Similar to (A) except for protocol III. (D) EPRE and ERDC of the 
three families of structures from protocol III. 
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Figure 5. Structure overlay of different ensembles AFA-PLN. The overlay is done by 
overlaying backbone atoms from residues 24–50 using MOLMOL. (A) Protocol one: 
solution-only ensemble (20 monomers) with NOEs, torsion angles and hydrogen bonds. 
(B) Protocol two: RDC ensemble (15 monomers) with additional 1H-15N, 13C′-15N and 
13C′-13Cα RDCs. Four families of structures result. (C) Protocol three: PRE ensemble (20 
monomers) that utilize RDCs and PREs from MTSSL.   
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Figure 6. (A) Structure overlay of monomer structures using published RDC data from 
wt-PLN using non-symmetric tensor. (B) Orientation angles (θ, ϕ) of helical rigid body in 
the nonsysmmetric alignment frame. (C) Structure overlay of monomer structures using 
published RDC data from wt-PLN using symmetric tensor. (D) Orientation angles (θ, ϕ) 
of helical rigid body in the sysmmetric alignment frame. 
  
119 
 
4.6 Supporting information 
In the first protocol, we started from a fully extended structure of AFA-PLN and carried 
out simulated annealing calculations starting at 6000 K and cooled to 0 K in Cartesian 
and torsion-angle space. The NOEs were modeled using a soft-square potential with a 
force constant ramping from 2 to 50 kcal Å-2, while torsion angles were restrained by a 
square-well potential with a force constant of 200 kcal rad-2. In addition, the torsion angle 
database potential ‘RAMA’ was used to bias the conformational search in the most 
allowed regions of the Ramachandran plot.  
For the protocol two, residual dipolar coupling data were introduced during the lower 
temperature simulated annealing (3000 K) starting from the folded PLN structures 
obtained from protocol one. The system was cooled down to 0 K with a cooling rate of 5 
K/step using 4000 steps of internal dynamics and 4000 steps of Cartesian dynamics. 
Only RDCs derived from residues in the helical regions with order parameters S2 > 0.6 
were used. The force constants for RDC restraints were ramped from 0.05 to 0.5 kcal 
Hz-2, which was determined by compromising RDC agreement and geometrical 
penalties. After obtaining the tensor magnitude, only tensor orientations were allowed to 
vary during the internal and Cartesian dynamics. For protocol three, additional MTSSL 
derived distance restraints are added to the restrains used in protocol two. The MTSSL 
restraints were imposed by a force constant ramped from 2 to 50 kcal Å-2. The 
parameter and topology files for MTSSL were taken from the library available in XPLOR-
NIH (52). All calculations were performed on a Linux cluster at the Minnesota 
Supercomputing Institute.  
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Figure S1. The (Da, R) clustering (black) of structures refined with NOE and RDCs with 
variable tensor magnitude. Structures with Da > 0 and R > 0.4 are selected for further 
structural calculation and analysis (red).  
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Figure S2. RDC R factors and energy value as functions of force constant used in the 
simulated annealing. The force constant for RDC was ramped from 0.25 kcal mol-1 Hz-2 
to 4.5 kcal mol-1 Hz-2, while the force constants for other energy terms such as NOEs 
and torsion angles were fixed. RDCs were modeled using flat-well potentials with the 
relative weight between 15N-1H, 13C’-15N and 13C’-13Cα was set to be 1:1:1. The energy 
values are summations from different terms in Equation 1 other than RDCs and the 
magnitude indicates penalties from other solution NMR data (NOEs and torsion angles) 
and ideal geometry (bond, angle etc.).  
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Figure S3. Correlation of experimental versus calculated RDCs of RDC ensemble family 
I, II, III and IV (15 monomers). Experimental errors of 3.0 Hz, 4.5 Hz and 0.5 Hz are 
used for 13C’-15N (A), 13C’-13Cα (B) and 15N-1H (C) respectively.  
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Figure S4. Correlation of experimental versus calculated RDCs from protocol three, the 
PRE ensemble (20 monomers). Experimental errors of 3.0 Hz, 4.5 Hz and 0.5 Hz are 
used for 13C’-15N (A), 13C’-13Cα (B) and 15N-1H (C) respectively.  
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Figure S5. Correlation of experimental distances obtained from PREs (A24C MTSSL in 
black and L7C MTSSL in red) with calculated distances measured from the PRE 
ensemble (20 monomers). Experimental errors of 4 Å are plotted from the correlation 
line (dotted lines). The calculated distances (and error bars) reflect the average (and 
standard deviation) from the 20 structures in the PRE ensemble.  
  
125 
 
 
Figure S6. (A) Cartoon representation of R9C-AFA-PLN-MTSSL labeled AFA-PLN in a 
simplified micelle model. The model is supported by PRE data obtained from (B) NMR 
HSQC experiments. (C) Intensity retention from covalent attachment of MTSSL indicates 
that the hydrophobic spin label prefers to insert into the micelle, significantly quenching 
inserted residues around 35. (D) Intensity retention from 1.5 mM Gd3+ to the HSQC 
spectrum of R9C-AFA-PLN indicates that the cytoplasmic domain Ia is inserted into the 
micelle with preferential orientation for hydrophobic (e.g., L7) and hydrophilic residues 
(e.g., R13). 
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Figure S7. Comparison of 13C’-15N, 13C’-13Cα, and 15N-1H RDCs of AFA-PLN 
(monomer, red) and wt-PLN (pentamer, black) by residue number (left column) and as 
correlation plots (right column).  
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Table S1. NMR and Structural Refinement Statistics 
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Phospholamban in Model and Native Lipid Membranes by Magic 
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Excited States of Phospholamban in Model and Native Lipid Membranes by Magic Angle 
Spinning NMR Spectroscopy Biochim Biophys Acta. 2012;1818(2):146-53 
 
 
  
129 
 
Membrane proteins exist in a Boltzmann distribution of conformational states. Classical 
structural biology techniques are biased toward the characterization of the average 
conformations or conformational snapshots along the folding energy landscape. In this 
paper, we analyzed the ground and excited states of phospholamban (PLN), a 
membrane protein that regulates sarcoplasmic reticulum calcium ATPase (SERCA), in 
different membrane mimetic environments. Previously, we proposed that the 
conformational equilibria of PLN are central to SERCA regulation. Here, we show that 
these equilibria detected in micelles and bicelles are also present in native sarcoplasmic 
reticulum lipid membranes as probed by MAS solid-state NMR. Importantly, we found 
that the kinetics of conformational exchange and the extent of ground and excited states 
in detergent micelles and lipid bilayers are different, revealing a possible regulatory role 
of the membrane composition on the allosteric regulation of SERCA. Since the extent of 
excited states is directly correlated to SERCA inhibition, these findings open up the 
exciting possibility that calcium transport in the heart can be controlled by the lipid 
bilayer composition.  
  
130 
 
5.1 Introduction 
Membrane proteins exist as ensembles (Boltzmann distributions) of ground and excited 
states. These states are accessible by small scale atomic fluctuations around the 
average structure or large scale reorganizations of entire domains. In addition to intrinsic 
thermal fluctuations, membrane protein folding energy landscape is shaped by the 
interactions with the lipid membrane, which have been hypothesized to modulate protein 
function through allosteric interactions (1). In the past years, the need to obtain high-
resolution membrane protein structures for structural genomics initiatives drove 
researchers toward high-quality views of average conformations or crystallographic 
snapshots of membrane proteins in non-native detergent micellar environments. This 
effectively relegated the analysis of conformational fluctuations and protein-lipid 
interactions to secondary roles. While the structures have given us a vivid view of static 
membrane proteins, our knowledge on how these biological macromolecules transmit 
the regulatory effects through the membrane at the atomic level is still primordial. It is 
clear that a complete description of membrane protein function must include structure, 
the characterization of their motions (conformational dynamics), and their interactions 
with lipid membranes. Magic angle spinning (MAS) NMR (2-12) and oriented solid-state 
(OSS) NMR (13-18) have evolved as powerful methods to study the structure and 
dynamics of membrane proteins in native-like lipid bilayers. While the development of 
these solid-state NMR techniques will be instrumental to determine the structure of large 
membrane proteins, their major advantage with respect to X-ray crystallography will be 
to describe membrane proteins as ensemble of structures, including ground and excited 
states.   
In the past years, our group has focused attention on the small membrane protein 
phospholamban (PLN, 52-residue) that regulates the function of sarcoplasmic reticulum 
(SR) Ca2+-ATPase (SERCA) in cardiac muscle (19, 20). While apparently simple in its 
secondary structure content, PLN has a complex dynamics when reconstituted both in 
micelles and synthetic lipid membranes (21-23). In its monomeric and pentameric forms, 
PLN consists of a membrane spanning helix connected to an amphipathic helix (domain 
Ia) through a short loop (15, 16, 24) (Figure 1). The membrane-spanning helix can be 
divided into a rigid and hydrophobic domain II and a more dynamic and hydrophilic 
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domain Ib, which is positioned at the lipid head group and unfolds on a µs time scale 
(21, 25). Domain Ia of PLN is in a complex conformational equilibrium that involves at 
least four different states and resembles the folding/unfolding proposed for amphipathic 
helices: detached/unfolded (R), absorbed/unfolded (R’), absorbed/partially folded (T’), 
and absorbed/fully folded (T) (26-28). For monomeric and pentameric PLN, the R state 
has a small population in DPC detergent micelles and mechanically aligned lipid bilayers 
(< 15%) (28). Although most of the information on the high energy (excited) R, T’ and R’ 
states was derived from studies in detergent micelles, we found a direct relationship 
between the extent (population) of these excited states and PLN effects on SERCA, i.e., 
the more populated is the R state, the less inhibitory is PLN (26, 29). This structure-
function correlation can potentially be used to design loss-of-function PLN analogs to be 
used in gene therapy (30, 31).    
To understand how PLN’s conformational equilibria are modulated by lipid membrane 
composition, we utilized Magic Angle Spinning (MAS) solid-state NMR in conjunction 
with solution NMR methods. We show that, although the relative populations of the 
different states can be tuned by the type and charge of lipids, a conformational 
equilibrium of PLN is present in all of the membrane mimicking systems analyzed, 
ranging from dodecylphosphocholine (DPC) micelles and 1,2-dimyristoyl-sn-glycero-3-
phosphocholine/1,2-dihexanoyl-sn-glycero-3-phosphocholine (DMPC/DHPC) bicelles to 
native SR lipid bilayers. These results demonstrate the presence and importance of 
conformational fluctuations in native cellular membranes.    
5.2 Materials and methods 
5.2.1 Sample preparation 
Synthetic lipids and natural egg PC, phosphatidylethanolamine (PE) and 
phosphatidic acid (PA) lipids were purchased from Avanti polar lipids (Alabaster, AL). 
Native SR lipids were extracted from rabbit hind leg skeletal muscle using a 
chloroform:methanol procedure as previously described(32). All experiments utilized a 
monomeric PLN mutant with Cys36, 41, and 46 mutated to Ala, Phe, and Ala, 
respectively (AFA-PLN) (33).  [U-13C,15N] AFA-PLN was recombinantly expressed and 
purified according to Buck et al. (34) [EQN-13C,15N; A-13C] AFA-PLN was produced by a 
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reversed labeling method, where unlabeled analogs of all other amino acids were added 
to the growth medium which also contained 13C-glucose and 15NH4Cl (35). Selectively 
[15N,13C] labeled AFA-PLN was synthesized using [15N,13C] labeled amino acids (Sigma-
Aldrich, Isotec, Miamisburg, OH) on a microwave peptide synthesizer (CEM Corporation, 
Matthews, NC) essentially as previously described (16, 33). The exceptions were that 
1% sodium dodecyl sulfate (SDS) was added during cleavage from the resin and the 
protein was dissolved in 10% SDS prior to HPLC purification, which utilized a 2-
propanol/H2O gradient from 10% to 90% on a C18 column. To avoid oxidation of Met50, 
we made a conservative substitution to norleucine in the synthetic samples. This 
substitution had no effect on the inhibitory effect of AFA-PLN on SERCA. The quality of 
the final synthetic product was assessed by mass spectrometry and solution NMR in 
DPC micelles. SERCA activity assays were performed as described previously (29, 36) 
to confirm that all recombinantly and synthetically produced AFA-PLN proteins inhibited 
SERCA.   
 Isotropic bicelle samples for solution NMR were prepared by dissolving 1 mg of 
[U-13C,15N] AFA-PLN in a 174 mg/mL solution of DHPC containing 20 mM MOPS, 100 
mM NaCl, and 5% D2O. The protein/DHPC solution was added to 21.9 mg of lyophilized 
DMPC lipids, and was followed by several freeze/thaw cycles to form a clear bicellar 
solution. The pH was adjusted to 7.0 and the 250 µL sample containing a DHPC:DMPC 
molar ratio (q) of 0.33 was transferred to a 5 mm Shigemi tube. Negatively charged 
bicelles were prepared identically with the exception that 33% of the DMPC was 
replaced by 1,2-dimyristoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (DMPG).  
 Magic angle spinning samples were prepared by dissolving 15 mg of lyophilized 
lipids in HPLC elution (~70% 2-propanol, ~30% H2O) containing 1.6 mg AFA-PLN. To 
this solution, 20 mM MOPS (pH 7.0) and 100 mM NaCl were added based on a final 
volume of 2 mL. The 2-propanol was then evaporated using nitrogen gas to form AFA-
PLN-containing multi-lamellar lipid vesicles (MLVs). The mixture was lyophilized, re-
suspended in 2 mL of double distilled H2O and centrifuged at 200,000×g to yield a 
hydrated lipid pellet, which was transferred to a 3.2 mm thin wall rotor MAS rotor. The 
final samples contained ~60% H2O and had a lipid:AFA-PLN ratio of 80:1. For 
paramagnetic quenching experiments, gadopentetate dimeglumine (Gd3+) (Magnevist; 
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Bayer Shering Pharma, Berlin, Germany) was added to the MAS sample and several 
freeze/thaw cycles were performed (final Gd3+ concentration was 20 mM).     
5.2.2 NMR experiments 
 All NMR experiments were performed on a Varian (VNMRS) spectrometer 
operating at a proton frequency of 600 MHz. Solution NMR chemical shifts of AFA-PLN 
in isotropic bicelles were assigned using two-dimensional HNCO, HN(CO)Cα, and 
HNCαCβ experiments and were referenced to 2,2-dimethyl-2-silapentane-5-sulfonate 
(DSS). Chemical shifts in MLVs were assigned using single quantum double quantum 
correlation (SQ-DQ), dipolar assisted rotational resonance (DARR) (37), and refocused 
Insensitive Nuclei Enhanced by Polarization Transfer (38) (rINEPT) experiments 
acquired using a 1H/13C 3.2 mm BioMAS Varian probe. Pulse widths corresponding to a 
flip angle of π/2 were typically 5.5 µs (13C, 15N) and 2.5 µs (1H). Proton TPPM decoupling 
(39) was applied at ωRF/(2π) = 100 kHz. SQ-DQ experiments were acquired at a spinning 
rate of 8 kHz, a cross-polarization (CP) time of 1 ms and spectral widths of 100 and 16 
kHz in the single and double quantum dimensions, respectively. A 500 µs SPC5 element 
(40) was used for excitation and reconversion. DARR experiments were acquired with a 
200 ms mixing time at a spinning speed of 13.3 kHz and a 1 ms cross-polarization (CP) 
time. 4000 points with a spectral width of 100 kHz and 30 increments with a spectral 
width of 13.3 kHz were acquired in the direct and indirect 13C dimensions, respectively. 
rINEPT experiments were acquired at the same spinning rate with the same number of 
points and spectral width in the direct 13C dimension and 30 increments with a spectral 
width of 3.33 kHz in the indirect 1H dimension. Chemical shifts were referenced to the 
CH2 signal of adamantane (40.48 ppm). Data were processed by NMRPipe (41) and 
analyzed with Sparky (42).      
5.3 Results 
5.3.1 Residue-Specific Assignments in Lipid Bilayers 
 Due to the lack of residue-specific resolution in [U-13C, 15N] MAS spectra, we 
opted to assign chemical shifts of AFA-PLN from synthetically labeled AFA-PLN 
reconstituted into egg PC/PE/PA 8/1/1 MLVs (labeling is shown in Table 1). Combined 
with a [QNE-13C, 15N, A-13C]-labeled sample, this allowed for unambiguous backbone 
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and side chain chemical shifts for domain Ib and II from single-quantum double-quantum 
(SQ-DQ) correlation spectra (Figure 2A). Isotropic backbone and side chain chemical 
shifts of AFA-PLN were previously reported using solution NMR in DPC micelles (16, 
24), which allows for a direct comparison between membrane mimicking systems on 
AFA-PLN’s structure. Importantly, the hydrophobic domain II chemical shifts were 
markedly similar between micelles and bilayers (Figure 2B,C). Given the sensitivity of 
backbone chemical shifts to secondary structure, this confirms that the structure of 
domain II is helical in both DPC micelles and lipid bilayers. The 13C chemical shift index 
(CSI) (δCα - δCβ) - (δCα,RC - δCβ,RC) (43) of domain Ib in lipid bilayers indicates a greater 
extent of helicity than we observed in DPC micelles. Based on CSI values, we estimated 
that ~50% was helical in micelles, based on a helicity of ~100% in lipid bilayers. This has 
important ramifications for SERCA inhibition, since we have previously shown that the 
hydrophilic domain Ib of AFA-PLN is in equilibrium between folded (helical) and unfolded 
states (25, 26), which plays a role in inhibiting the ATPase. This difference may be due 
to the shorter chain length of the micelles (C12 for DPC) compared to the lipids (~C18 
for egg lipids) or the intrinsic curvature and more dynamic nature of the micelles. 
5.3.2 Domain Ia Conformation in Neutral and Negatively Charged Isotropic 
Bicelles 
 In analogy to the classic model of amphipathic helix folding (44, 45), we recently 
found that domain Ia of AFA-PLN exists in equilibrium between at least four 
conformational states (26). In micelles, these states are in fast exchange on the NMR 
timescale with the most populated state possessing helical structure with the 
hydrophobic face of the helix inserted into the micelle. In contrast, Baldus and co-
workers (46) studied AFA-PLN in DMPC vesicles using MAS solid-state NMR and 
concluded domain Ia was unfolded and membrane detached based on the random coil 
chemical shifts.  
 To probe the structure of domain Ia in lipids we reconstituted [U-13C,15N] labeled 
AFA-PLN into isotropic DMPC/DHPC bicelles with a DMPC:DHPC ratio of 1:3 (q=0.33). 
The [1H,15N] HSQC spectrum (Figure 3A) showed only ~40% of the resonances that 
were observed in DPC micelles. These resonances were assigned using HN(CO)Cα and 
HNCαCβ solution NMR experiments, and were confirmed to be residues from domain Ia 
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and the loop. This suggested that domain Ia was significantly more dynamic than 
domain Ib or II, and did not assume the overall rotational correlation time of the bicelle. 
The failure to observe resonances from transmembrane domains in isotropic bicelles 
has been documented in other membrane protein systems such as those from the small 
multidrug resistance family, which required high temperatures and deuteration to 
observe backbone amide signals (47). 
 In Figure 3B, we plot the 13C CSI (δCα - δCβ) for full-length AFA-PLN obtained in 
isotropic bicelles and DPC micelles and the values obtained from a cytoplasmic domain 
peptide (PLN1-20) (48) . The chemical shifts in isotropic bicelles are intermediate between 
shifts in DPC micelles (AFA-PLNDPC, helical and mostly T state) and the shifts for a 
peptide corresponding to residues 1-20 of PLN (PLN1-20, unfolded and mostly R state). 
Thus, in isotropic bicelles the conformational equilibrium is shifted to a more unfolded 
state than in DPC micelles, but still retains helical character, which is in contrast to the 
previous results in DMPC bilayers. 
 Domain Ia has four Arg and Lys residues (K3, R9, R13, R14), which gives PLN a 
positive charge at physiological pH values. Therefore, the introduction of a negatively 
charged lipid could potentially increase the association of domain Ia with the bilayer. To 
test this hypothesis we replaced 33% of the DMPC with DMPG and measured methyl 
group chemical shifts, since these are the best reporters of the association of domain Ia 
with lipids (26). Figure 4 shows spectra for V4, L7, A11, and A15 methyl groups 
obtained in DPC, DMPC/DHPC, DMPC/DMPG/DHPC, and aqueous PLN1-20. The 
resonances corresponding to PG-containing bicelles shift toward the AFA-PLNDPC peak, 
while all peaks are on a linear trajectory spanning from PLN1-20 to AFA-PLNDPC. This 
shows that a) domain Ia is in a fast, apparent two-site exchange between lipid-
associated and lipid-dissociated conformations, and b) negatively charged bilayers 
perturb the conformational equilibrium to favor the membrane-associated conformation. 
While methyl group chemical shifts are sensitive probes of local environment (i.e., 
membrane attached or detached) they are less sensitive to secondary structure content. 
To determine whether the increased affinity of domain Ia for negatively charged lipids 
was associated with increased helicity, we also measured backbone carbonyl (13C') 
chemical shifts in isotropic bicelles using an HNCO experiment and compared CSI 
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values (43) to AFA-PLNDPC (Figure 4E). The CSI values in the presence of PG clearly 
showed a small but significant increase in the helicity of domain Ia. Thus, the presence 
of negatively charged lipids increased the population of the T state, and also support the 
unfolding/folding conformational model by which domain Ia exchanges between a helical 
and membrane embedded conformation and one that is unfolded and detached from the 
surface. 
5.3.3 MAS in DMPC Lipids 
 To validate our results in detergent micelles and isotropic bicelles, we also used 
MAS experiments with AFA-PLN reconstituted into MLVs. It is well-known that INEPT 
based transfers filter out immobile domains due to short transverse relaxation times (46). 
Using refocused INEPT and CP-based experiments of [U-13C,15N] AFA-PLN we detected 
chemical shifts of AFA-PLN at 30°C in DMPC vesicles that were in excellent agreement 
with previously published results in the same lipid bilayers and temperature (46). 
However, due to the abundance of transmembrane domain residues (~60% of the 
protein), CP-based spectra were significantly overlapped, which necessitated the use of 
selectively labeled samples in domain Ia. We synthesized AFA-PLN with Val4, Leu7, 
Ala11, Ile12, Ala15 and Ile18 [U-13C,15N] labeled (AFA-PLN6cyt) and acquired 2D DARR 
spectra at 30°C. From these experiments we were able to detect intense peaks that 
corresponded to these six labels. Some of the observed chemical shifts were identical to 
the random coil values measured from refocused INEPT experiments (Figure 5). 
However, we also detected several peaks in the DARR spectrum that were absent from 
the rINEPT experiment. Specifically, we detected a second population of peaks that had 
13C chemical shifts consistent with helical structure. Interestingly, in contrast to DPC 
micelles and isotropic bicelles the two states observed in the DARR experiments were in 
slow exchange on the NMR time scale (two peaks are observed in the spectrum). 
5.3.4 Effect of Temperature on the Conformational Equilibria of Domain Ia 
 To determine the effect of temperature on the conformational equilibrium of AFA-
PLN we acquired an additional DARR experiment at -25°C. At this temperature the 
helical chemical shifts dominated the spectrum showing that the conformational 
equilibrium has shifted to favor the T state. With the exception of Ala15 at the C-terminal 
end of the domain Ia helix, there is excellent agreement between the T state chemical 
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shifts and the shifts of AFA-PLNDPC (Figure 6). This shows that the domain Ia helix (T 
state) may be slightly shorter in lipid bilayers than in DPC micelles. Importantly, this also 
implies that AFA-PLN samples similar conformational space regardless of the 
membrane mimicking system (detergent micelle, isotropic bicelle, lipid bilayer, etc), but 
that the populations of the conformational states are very sensitive to the choice of 
membrane mimic.  
It is important to note that solution NMR data in DPC micelles show at least four 
resolved conformational states (T, T', R, and R'). However, it is possible that the T' and 
R' states have chemical shifts very similar to the T and R states and, therefore, are 
indistinguishable in the MAS spectra (i.e., broader lines than the detergent micelle 
spectra). Alternatively, the T’ and R’ states may be scarcely populated in lipids and 
therefore not detectable.  
5.3.5 MAS in Native SR Lipids 
 While DMPC vesicles are a well-characterized model membrane system, they 
lack several characteristics of a native lipid bilayer of the SR. For example, the SR 
membrane, where PLN is embedded, contains a significant portion of PE and PS head 
groups and has an average lipid chain length of 18 carbons compared to the 14 carbons 
of DMPC (32). To support our conclusions in synthetic lipid membranes, we 
reconstituted AFA-PLN6cyt into lipids extracted from the SR of rabbit skeletal muscle. In 
these lipids, DARR spectra acquired at -25°C and 20°C were in good agreement with 
spectra obtained using DMPC lipids (Figure 7). Spectra acquired at -25°C and 20°C 
show multiple peaks with a shift in equilibrium toward the T state component at the lower 
temperature. Taken together, these data confirmed that the conformational equilibrium of 
AFA-PLN is also present in native lipids. 
5.3.6 Solvent accessibility of T and R states 
 To further support our assignment of two populations (T and R states), we used 
paramagnetic relaxation enhancement (PRE) by acquiring DARR experiments in SR 
lipids in the presence and absence of 20 mM water-soluble Gd3+. These experiments 
were performed at 4°C to have approximately equal intensities of R and T state peaks. 
Figure 8 shows that the R state (36% signal retained on average) is quenched more 
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than the T state (63% signal retained on average) for residues Val4, Leu7, Ala11, and 
Ile12. Ala15 and Ile18 were excluded from the analysis since they have similar chemical 
shifts in the T and R states. These results confirmed that the T state is membrane-
associated and solvent-protected while the R state is exposed to solvent, and are thus in 
strong agreement with our conformational model of AFA-PLN(26).   
5.4 Discussion 
 The secondary structure content of the transmembrane domain II of PLN is 
preserved in all membrane mimicking systems, spanning from organic solvents (49) and 
detergent micelles (24) to lipid bilayers of different compositions(15, 16). In particular, 
the chemical shifts obtained in DPC micelles and lipid bilayers are in remarkable 
agreement (Figure 2). This suggests that while detergent micelles have limitations, they 
can still offer structural insights on rigid, membrane-spanning portions of membrane 
proteins. On the other hand, DPC micelles altered the conformational equilibria for 
domains Ia and Ib of AFA-PLN that were more malleable and solvent exposed (21, 50). 
For instance, the chemical shifts for domain Ib in lipids have a greater extent of helicity 
than those obtained in DPC micelles, although in both membrane mimics the 
predominant conformation was helical. In contrast, the amphipathic domain Ia is 
significantly more helical in DPC micelles that in lipids, revealing an almost complete 
shift towards the T state in this detergent. The latter is in agreement with the topology of 
AFA-PLN determined in mechanically aligned DOPC/DOPE bilayers (16). Interestingly, 
in lipid vesicles and native SR lipids, the R and T states exchange on a slow time scale. 
Thus, the dynamic nature of the detergent and the isotropic bicelle may act to lower the 
activation energy barrier between the states, which would alter the exchange rates. The 
multiple populations observed in lipids allowed us to analyze the chemical shifts and 
exposure to water separately. Our PRE measurements show that the R state is unfolded 
and solvent-exposed, as proposed previously (26). Also, the excellent overlay between 
spectra acquired in SR lipids and DMPC suggests that the conformations of AFA-PLN 
are conserved between the different lipid systems.  
It is important to stress that neither the unfolded R state nor the folded T state is 
analogous to the architecture of the pentameric PLN solved in DPC micelles with domain 
Ia in a helical, membrane-dissociated conformation (51). However, our data help explain 
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the results reported by Baldus and co-workers (46) from MAS experiments in DMPC lipid 
vesicles. Using INEPT-based transfer experiments, the flexible R state of AFA-PLN was 
detected, filtering out the resonances of the T state. We showed that by using both CP- 
and INEPT-based transfers it is possible to detect both conformational states of AFA-
PLN (T and R states). One possibility why Baldus and co-workers did not observe the T 
state of domain Ia could be the low lipid/protein ratio, which would promote the R state, 
since a smaller amount of lipid surface area would be present. In addition to observing 
both T and R states, we also found the AFA-PLN conformational equilibrium to have 
strong temperature dependence, with the T state favored at lower temperature and the R 
state at higher temperature. This behavior is similar to that observed for the membrane-
active peptide Tat, which is in a random coil conformation at high temperature but forms 
a β-sheet at lower temperatures (52). The dependence of AFA-PLN domain Ia on 
temperature as well as the choice of membrane mimic shows that caution must be taken 
when comparing experiments acquired at different temperatures and in different 
membrane-environments.  
At temperatures above 20°C the R state dominates over the T state (Figure 6). 
In this regard domain Ia of PLN resembles an intrinsically disordered protein, which folds 
into a helix upon interaction with the lipid bilayer (53, 54). In addition to the bilayer 
interactions, PLN binds a number of different proteins. We have recently shown that 
protein kinase A (PKA) preferentially binds an extended conformation of domain Ia (48, 
55). Thus, the malleability of PLN allows for recognition by different binding partners. 
Further research is needed to determine what conformation(s) of PLN is recognized by 
other proteins. Nevertheless, since promotion of the R state relieves the inhibitory effect 
of SERCA by PLN, perturbations that alter the T/R equilibrium directly affect the 
regulation of SERCA. One example of this is the introduction of negatively charged PG 
lipids, which promotes the T state conformation (Figure 4). This observation suggests 
that lipid-PLN interactions may regulate SERCA function.  
In our first characterization of the calcium regulatory cycle, we defined PLN as an 
allosteric modulator of SERCA, without specifying its role in the allosteric phenomenon 
(19, 28, 29, 56). In the light of our recent results, we propose that the allosteric 
regulation of SERCA by PLN has two aspects: a) a more classical aspect  (57-60), 
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where PLN controls SERCA function via intramembrane, long-range interactions, i.e., 
without direct interference with the chemistry of the enzyme (hydrolysis of ATP) or 
calcium translocation, and b) a more modern aspect (59-63), with PLN interconverting 
between ground and excited states, with the latter representing the inactive 
conformational state. These phenomena are interconnected and constitute part of the 
complex mechanism for allosteric signal transduction in the heart muscle. Based on the 
data presented here, it is becoming clear that by fine-tuning PLN conformational 
equilibria, lipid membranes represent a third element for allosteric control of SERCA. 
Through the alteration of the lipid composition from diet or pathophysiology (64-66), it is 
possible that lipid membranes shape both the conformation and function of the 
SERCA/PLN complex, affecting muscle contractility.  
From a more biophysical point of view, these studies revive an old concept of the 
allosteric regulation of lipid membranes (1). Furthermore, the possibility of using solid-
state NMR to study membrane proteins under native lipid compositions allows for the 
characterization of lipid-protein interactions at the atomic level to reveal the role of lipids 
in activation and deactivation of protein function. 
  
5.5 References 
1. Farias, R. N., B. Bloj, R.D. Morero, F. Sineriz and R.E. Trucco 1975. Regulation of 
allosteric membrane-bound enzymes through changes in membrane lipid 
compostition. Biochim. Biophys. Acta. 415, 231-251. 
2. McDermott, A. and T. Polenova 2007. Solid state NMR: New tools for insight into 
enzyme function. Curr. Opin. Struct. Biol. 17, 617-622. 
3. Lange, V., J. Becker-Baldus, B. Kunert, B.J. van Rossum, F. Casagrande, A. Engel, 
Y. Roske, F.M. Scheffel, E. Schneider and H. Oschkinat 2010. A MAS NMR study of 
the bacterial ABC transporter ArtMP. Chembiochem. 11, 547-555. 
4. Tang, M., L.J. Sperling, D.A. Berthold, A.E. Nesbitt, R.B. Gennis and C.M. Rienstra 
2011. Solid-state NMR study of the charge-transfer complex between ubiquinone-8 
and disulfide bond generating membrane protein DsbB. J. Am. Chem. Soc. 133, 
4359-4366. 
5. Cady, S. D., K. Schmidt-Rohr, J. Wang, C.S. Soto, W.F. Degrado and M. Hong 2010. 
Structure of the amantadine binding site of influenza M2 proton channels in lipid 
bilayers. Nature. 463, 689-692. 
141 
 
6. Shi, L., I. Kawamura, K.H. Jung, L.S. Brown and V. Ladizhansky 2011. Conformation 
of a seven-helical transmembrane photosensor in the lipid environment. Angew. 
Chem. Int. Ed Engl. 50, 1302-1305. 
7. Mills, F. D., V.C. Antharam, O.K. Ganesh, D.W. Elliott, S.A. McNeill and J.R. Long 
2008. The helical structure of surfactant peptide KL4 when bound to POPC: POPG 
lipid vesicles. Biochemistry. 47, 8292-8300. 
8. Linser, R., M. Dasari, M. Hiller, V. Higman, U. Fink, J.M. Lopez Del Amo, S. Markovic, 
L. Handel, B. Kessler, P. Schmieder, D. Oesterhelt, H. Oschkinat and B. Reif 2011. 
Proton-detected solid-state NMR spectroscopy of fibrillar and membrane proteins. 
Angew. Chem. Int. Ed Engl. 50, 4508-4512. 
9. Qiang, W., Y. Sun and D.P. Weliky 2009. A strong correlation between fusogenicity 
and membrane insertion depth of the HIV fusion peptide. Proc. Natl. Acad. Sci. U. S. 
A. 106, 15314-15319. 
10. Saito, H. and A. Naito 2007. NMR studies on fully hydrated membrane proteins, with 
emphasis on bacteriorhodopsin as a typical and prototype membrane protein. 
Biochim. Biophys. Acta. 1768, 3145-3161. 
11. Bajaj, V. S., M.L. Mak-Jurkauskas, M. Belenky, J. Herzfeld and R.G. Griffin 2009. 
Functional and shunt states of bacteriorhodopsin resolved by 250 GHz dynamic 
nuclear polarization-enhanced solid-state NMR. Proc. Natl. Acad. Sci. U. S. A. 106, 
9244-9249. 
12. de Planque, M. R., D.T. Rijkers, J.I. Fletcher, R.M. Liskamp and F. Separovic 2004. 
The alphaM1 segment of the nicotinic acetylcholine receptor exhibits conformational 
flexibility in a membrane environment. Biochim. Biophys. Acta. 1665, 40-47. 
13. De Angelis, A. A., D.H. Jones, C.V. Grant, S.H. Park, M.F. Mesleh and S.J. Opella 
2005. NMR experiments on aligned samples of membrane proteins. Methods 
Enzymol. 394, 350-82. 
14. Sharma, M., M. Yi, H. Dong, H. Qin, E. Peterson, D.D. Busath, H.X. Zhou and T.A. 
Cross 2010. Insight into the mechanism of the influenza A proton channel from a 
structure in a lipid bilayer. Science. 330, 509-512. 
15. Verardi, R., L. Shi, N.J. Traaseth, N. Walsh and G. Veglia 2011. Structural topology 
of phospholamban pentamer in lipid bilayers by a hybrid solution and solid-state 
NMR method. Proc Natl Acad Sci U S A. 108, 9101-9106. 
16. Traaseth, N. J., L. Shi, R. Verardi, D.G. Mullen, G. Barany and G. Veglia 2009. 
Structure and topology of monomeric phospholamban in lipid membranes 
determined by a hybrid solution and solid-state NMR approach. Proc. Natl. Acad. 
Sci. U. S. A. 106, 10165-10170. 
17. Buffy, J. J., N.J. Traaseth, A. Mascioni, P.L. Gor'kov, E.Y. Chekmenev, W.W. Brey 
and G. Veglia 2006. Two-dimensional solid-state NMR reveals two topologies of 
sarcolipin in oriented lipid bilayers. Biochemistry. 45, 10939-10946. 
18. Traaseth, N. J., J.J. Buffy, J. Zamoon and G. Veglia 2006. Structural dynamics and 
topology of phospholamban in oriented lipid bilayers using multidimensional solid-
state NMR. Biochemistry. 45, 13827-13834. 
142 
 
19. Traaseth, N. J., K.N. Ha, R. Verardi, L. Shi, J.J. Buffy, L.R. Masterson and G. Veglia 
2008. Structural and dynamic basis of phospholamban and sarcolipin inhibition of 
ca(2+)-ATPase. Biochemistry. 47, 3-13. 
20. MacLennan, D. H. and E.G. Kranias 2003. Phospholamban: A crucial regulator of 
cardiac contractility. Nat Rev Mol Cell Biol. 4, 566-77. 
21. Metcalfe, E. E., J. Zamoon, D.D. Thomas and G. Veglia 2004. (1)H/(15)N 
heteronuclear NMR spectroscopy shows four dynamic domains for phospholamban 
reconstituted in dodecylphosphocholine micelles. Biophys. J. 87, 1205-1214. 
22. Karim, C. B., T.L. Kirby, Z. Zhang, Y. Nesmelov and D.D. Thomas 2004. 
Phospholamban structural dynamics in lipid bilayers probed by a spin label rigidly 
coupled to the peptide backbone. Proc Natl Acad Sci U S A. 101, 14437-42. 
23. Abu-Baker, S., J.X. Lu, S. Chu, C.C. Brinn, C.A. Makaroff and G.A. Lorigan 2007. 
Side chain and backbone dynamics of phospholamban in phospholipid bilayers 
utilizing (2)h and (15)n solid-state NMR spectroscopy. Biochemistry. 46, 11695-
11706. 
24. Zamoon, J., A. Mascioni, D.D. Thomas and G. Veglia 2003. NMR solution structure 
and topological orientation of monomeric phospholamban in dodecylphosphocholine 
micelles. Biophys. J. 85, 2589-2598. 
25. Traaseth, N. J. and G. Veglia 2010. Probing excited states and activation energy for 
the integral membrane protein phospholamban by NMR CPMG relaxation dispersion 
experiments. Biochim. Biophys. Acta. 1798, 77-81. 
26. Gustavsson, M., N.J. Traaseth, C.B. Karim, E.L. Lockamy, D.D. Thomas and G. 
Veglia 2011. Lipid-mediated Folding/Unfolding of phospholamban as a regulatory 
mechanism for the sarcoplasmic reticulum ca(2+)-ATPase. J. Mol. Biol. 408, 755-
765. 
27. Karim, C. B., Z. Zhang, E.C. Howard, K.D. Torgersen and D.D. Thomas 2006. 
Phosphorylation-dependent conformational switch in spin-labeled phospholamban 
bound to SERCA. J. Mol. Biol. 358, 1032-1040. 
28. Zamoon, J., F. Nitu, C. Karim, D.D. Thomas and G. Veglia 2005. Mapping the 
interaction surface of a membrane protein: Unveiling the conformational switch of 
phospholamban in calcium pump regulation. Proc. Natl. Acad. Sci. U. S. A. 102, 
4747-4752. 
29. Ha, K. N., N.J. Traaseth, R. Verardi, J. Zamoon, A. Cembran, C.B. Karim, D.D. 
Thomas and G. Veglia 2007. Controlling the inhibition of the sarcoplasmic Ca2+-
ATPase by tuning phospholamban structural dynamics. J. Biol. Chem. 282, 37205-
37214. 
30. Kaye, D. M., M. Hoshijima and K.R. Chien 2008. Reversing advanced heart failure 
by targeting Ca2+ cycling. Annu. Rev. Med. 59, 13-28. 
31. del Monte, F., S.E. Harding, G.W. Dec, J.K. Gwathmey and R.J. Hajjar 2002. 
Targeting phospholamban by gene transfer in human heart failure. Circulation. 105, 
904-907. 
143 
 
32. Bick, R. J., L.M. Buja, W.B. Van Winkle and G.E. Taffet 1998. Membrane asymmetry 
in isolated canine cardiac sarcoplasmic reticulum: Comparison with skeletal muscle 
sarcoplasmic reticulum. J. Membr. Biol. 164, 169-175. 
33. Karim, C. B., C.G. Marquardt, J.D. Stamm, G. Barany and D.D. Thomas 2000. 
Synthetic null-cysteine phospholamban analogue and the corresponding 
transmembrane domain inhibit the ca-ATPase. Biochemistry. 39, 10892-7. 
34. Buck, B., J. Zamoon, T.L. Kirby, T.M. DeSilva, C. Karim, D. Thomas and G. Veglia 
2003. Overexpression, purification, and characterization of recombinant ca-ATPase 
regulators for high-resolution solution and solid-state NMR studies. Protein Expr 
Purif. 30, 253-61. 
35. Tong, K. I., M. Yamamoto and T. Tanaka 2008. A simple method for amino acid 
selective isotope labeling of recombinant proteins in E. coli. J Biomol NMR. 42, 59-
67. 
36. Reddy, L. G., R.L. Cornea, D.L. Winters, E. McKenna and D.D. Thomas 2003. 
Defining the molecular components of calcium transport regulation in a reconstituted 
membrane system. Biochemistry. 42, 4585-92. 
37. Takegoshi, K., S. Nakamura and T. Terao 2001. 13C–1H dipolar-assisted rotational 
resonance in magic-angle spinning NMR. Chem. Phys. Lett. 344, 631. 
38. Morris, G. A. and R.J. Freeman 1979. Enhancement of nuclear magnetic resonance 
signals by polarization transfer. J. Am. Chem. Soc. 101, 760-762. 
39. Bennett, A. E., C.M. Rienstra, M. Auger, K.V. Lakshmi and R.G. Griffin 1995. 
Heteronuclear decoupling in rotating solids. J Chem Phys. 103, 6951-8. 
40. Hohwy, M., C.M. Rienstra, C.P. Jaroniec and R.G. Griffin 1999. Fivefold symmetric 
homonuclear dipolar recoupling in rotating solids: Application to double quantum 
spectroscopy. J Chem Phys. 110, 7983-7992. 
41. Delaglio, F., S. Grzesiek, G.W. Vuister, G. Zhu, J. Pfeifer and A. Bax 1995. 
NMRPipe: A multidimensional spectral processing system based on UNIX pipes. J. 
Biomol. NMR. 6, 277-293. 
42. Goddard, T. D. and D.G. Kneller SPARKY 3. University of California, San Francisco. 
43. Zhang, H., S. Neal and D.S. Wishart 2003. RefDB: A database of uniformly 
referenced protein chemical shifts. J. Biomol. NMR. 25, 173-195. 
44. White, S. H. and W.C. Wimley 1999. Membrane protein folding and stability : 
Physical principles. Annual Review Biophysics Biomolecular Structures. 28, 319-365. 
45. Engelman, D. M., Y. Chen, C.N. Chin, A.R. Curran, A.M. Dixon, A.D. Dupuy, A.S. 
Lee, U. Lehnert, E.E. Matthews, Y.K. Reshetnyak, A. Senes and J.L. Popot 2003. 
Membrane protein folding: Beyond the two stage model. FEBS Lett. 555, 122-125. 
46. Andronesi, O. C., S. Becker, K. Seidel, H. Heise, H.S. Young and M. Baldus 2005. 
Determination of membrane protein structure and dynamics by magic-angle-spinning 
solid-state NMR spectroscopy. J. Am. Chem. Soc. 127, 12965-12974. 
144 
 
47. Poget, S. F., S.M. Cahill and M.E. Girvin 2007. Isotropic bicelles stabilize the 
functional form of a small multidrug-resistance pump for NMR structural studies. J. 
Am. Chem. Soc. 129, 2432-2433. 
48. Masterson, L. R., T. Yu, L. Shi, Y. Wang, M. Gustavsson, M.M. Mueller and G. 
Veglia 2011. cAMP-dependent protein kinase A selects the excited state of the 
membrane substrate phospholamban. J. Mol. Biol. 412, 155-164. 
49. Lamberth, S., H. Schmid, M. Muenchbach, T. Vorherr, J. Krebs, E. Carafoli and C. 
Griesinger 2000. NMR solution structure of phospholamban. Helvetica Chimica Acta. 
83, 2141-2151. 
50. Traaseth, N. J. and G. Veglia 2009. Probing excited states and activation energy for 
the integral membrane protein phospholamban by NMR CPMG relaxation dispersion 
experiments. Biochim. Biophys. Acta. 
51. Oxenoid, K. and J.J. Chou 2005. The structure of phospholamban pentamer reveals 
a channel-like architecture in membranes. Proc. Natl. Acad. Sci. U. S. A. 102, 10870-
10875. 
52. Su, Y., A.J. Waring, P. Ruchala and M. Hong 2010. Membrane-bound dynamic 
structure of an arginine-rich cell-penetrating peptide, the protein transduction domain 
of HIV TAT, from solid-state NMR. Biochemistry. 49, 6009-6020. 
53. Mittag, T., L.E. Kay and J.D. Forman-Kay 2010. Protein dynamics and 
conformational disorder in molecular recognition. J. Mol. Recognit. 23, 105-116. 
54. Wright, P. E. and H.J. Dyson 2009. Linking folding and binding. Curr. Opin. Struct. 
Biol. 19, 31-38. 
55. Masterson, L. R., C. Cheng, T. Yu, M. Tonelli, A.P. Kornev, S.S. Taylor and G. 
Veglia 2010. Dynamics connect substrate recognition to catalysis in protein kinase A. 
Nat Chem Biol. 6, 821-828. 
56. Traaseth, N. J., D.D. Thomas and G. Veglia 2006. Effects of Ser16 phosphorylation 
on the allosteric transitions of phospholamban/Ca(2+)-ATPase complex. J. Mol. Biol. 
358, 1041-1050. 
57. Monod, J., J. Wyman and J.P. Changeux 1965. On the nature of allosteric 
transitions: A plausible model. J Mol Biol. 12, 88-118. 
58. Koshland, D. E.,Jr, G. Nemethy and D. Filmer 1966. Comparison of experimental 
binding data and theoretical models in proteins containing subunits. Biochemistry. 5, 
365-385. 
59. Tsai, C. J., A. Del Sol and R. Nussinov 2009. Protein allostery, signal transmission 
and dynamics: A classification scheme of allosteric mechanisms. Mol. Biosyst. 5, 
207-216. 
60. Cui, Q. and M. Karplus 2008. Allostery and cooperativity revisited. Protein Sci. 17, 
1295-1307. 
61. Smock, R. G. and L.M. Gierasch 2009. Sending signals dynamically. Science. 324, 
198-203. 
145 
 
62. Ma, B. and R. Nussinov 2010. Enzyme dynamics point to stepwise conformational 
selection in catalysis. Curr. Opin. Chem. Biol. 14, 652-659. 
63. Tzeng, S. R. and C.G. Kalodimos 2009. Dynamic activation of an allosteric 
regulatory protein. Nature. 462, 368-372. 
64. Taffet, G. E., T.T. Pham, D.L. Bick, M.L. Entman, H.J. Pownall and R.J. Bick 1993. 
The calcium uptake of the rat heart sarcoplasmic reticulum is altered by dietary lipid. 
J. Membr. Biol. 131, 35-42. 
65. Mrak, R. E. and S. Fleischer 1982. Lipid composition of sarcoplasmic reticulum from 
mice with muscular dystrophy. Muscle Nerve. 5, 439-446. 
66. Krainev, A. G., D.A. Ferrington, T.D. Williams, T.C. Squier and D.J. Bigelow 1995. 
Adaptive changes in lipid composition of skeletal sarcoplasmic reticulum membranes 
associated with aging. Biochim. Biophys. Acta. 1235, 406-418. 
 
146 
 
Table 1. Synthetically labeled AFA-PLN samples 
 
Sample 
[13C,15N] Residues  
1 
2 
3 
4 
5 
6 
V4, L7, A11, I12, A15, I18 
N30, L31, F32, I33 
N34, F35, A36, L37, I38 
L39, I40, F41, L42 
L44, I45, A46, I47 
A24, I48, V49, L51 
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Figure 1. Conformational equilibria and primary sequence. A.) Conformational equilibria 
of monomeric PLN. The T state is represented by its high resolution structure (PDB ID: 
1N7L) (16). B.) Primary sequence of AFA-PLN. 
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Figure 2. Assignment of domain Ib and II in lipids and comparison with DPC micelles. A.) 
SQ-DQ correlation experiments of AFA-PLN reconstituted into egg PC/PE/PA 8/1/1. B.) 
13Cα-13Cβ CSI for residues in domain Ib and II of AFA-PLN in DPC micelles and EY 
lipids. CSI was calculated as δ13Cα – δ13Cβ – (δ13Cα,RC – δ13Cβ,RC), where RC stands for 
the random coil chemical shifts (43). C.) Correlation between CSI values in DPC 
micelles and egg lipids. Residues in domain Ib are shown as open circles and residues 
in domain II as filled circles. 
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Figure 3. PLN in isotropic bicelles. A.) [15N]-HSQC of AFA-PLN in DMPC/DHPC isotropic 
bicelles with q=0.33. Peak corresponding to residues S10, S16 and T17 (marked with x) 
were detected at a lower noise level as shown in the inset. B.) Helicity of domain Ia in 
different membrane mimics. 13Cα – 13Cβ CSI for domain Ia of AFA-PLN in DPC micelles 
(black), DMPC/DHPC isotropic bicelles (red) and a peptide corresponding to residues 1-
20 of PLN(48) (PLN1-20, orange). 
150 
 
 
Figure 4. Negatively charged lipids shifts the equilibrium towards the T state. A-D.) 13C 
HSQC experiments of AFA-PLN in DPC micelles (black, T state), DMPC/DHPC, q=0.33, 
isotropic bicelles (grey) DMPC/DMPG/DHPC (4:1 DMPC:DMPG) isotropic bicelles 
(green) and PLN1-20 (orange, R state). E.) CO CSI for AFA-PLN in different membrane 
mimics. 
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Figure 5. CP-transfers detect chemical shifts that are absent from INEPT-based 
experiments. Comparison of rINEPT (top) and DARR (bottom, 200ms mixing time) 
experiments of AFA-PLN6cyt reconstituted into d54-DMPC MLVs at 30°C. Dashed lines 
highlight examples of peaks that are detected in both experiments.  
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Figure 6. Conformational equilibrium of AFA-PLN in DMPC at different temperatures. A.) 
Cross-peaks from DARR spectra corresponding to a Cα-Cγ correlation for Val4 (left) and 
Cα-Cδ2 correlation for Leu7 (right) at 30°C (top) and -25°C (bottom). Blue and red dashed 
lines highlight the chemical shift regions of the folded T state and unfolded R state 
respectively. B) Cα-Cβ CSI of the folded T state (measured from experiments at -25°C, 
blue bars) and unfolded R state (measured from experiments at 30°C, red bars) 
compared to DPC micelles (black dotted lines, predominantly T state) and PLN1-20 
(orange dotted line, predominantly R state). 
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Figure 7. The conformational equilibrium of AFA-PLN is conserved in native SR lipids. 
A.) Overlay of DARR experiments of AFA-PLN6cyt reconstituted into DMPC (black) or 
extracted SR lipids (purple). Experiments in SR lipids were acquired at -25°C and 20°C 
and experiments DMPC were acquired at -25°C and 30°C. All experiments utilized a 
200ms mixing time. B.) 13Cα – 13Cβ CSI of the R and T state components in DMPC 
(black) and SR lipids (purple). 
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Figure 8. The T state is inserted into the lipid bilayer. A.) Region from DARR spectra of 
AFA-PLN6cyt in SR lipids acquired in the presence (turquoise) and absence (black) of 20 
mM Gd3+. B.) Signal retention of peaks corresponding to the T and R states quantified 
from DARR spectra acquired in the presence and absence of 20 mM Gd3+. Signal 
retention was calculated as IGd3+/I0. in DARR spectra quenching of T and R states of 
AFA-PLN. For Ala15 and Ile18 the T and R state peaks are overlapped and therefore the 
signal retention reports on a combination of T and R states. 
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Chapter 6 - Activating and Deactivating roles of lipid bilayers on 
the Ca2+-ATPase/Phospholamban Complex 
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Martin Gustavsson, Nathaniel J. Traaseth, and Gianluigi Veglia. Activating and 
Deactivating roles of lipid bilayers on The Ca2+-ATPase/Phospholamban Complex 
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The physicochemical properties of the lipid bilayer shape the structure and topology of 
membrane proteins and regulate their biological function. Here, we investigated the 
functional effects of various lipid bilayer compositions on the sarcoplasmic reticulum 
(SR) Ca2+-ATPase (SERCA) in the presence and absence of its endogenous regulator, 
phospholamban (PLN). In the cardiac muscle, SERCA hydrolyzes one ATP molecule to 
translocate two Ca2+ ions into the SR membrane per enzymatic cycle. Unphosphorylated 
PLN reduces SERCA’s affinity for Ca2+ and affects the enzymatic turnover. We varied 
bilayer thickness, head group, fluidity, and found that both the maximal velocity (Vmax) of 
the enzyme and its apparent affinity for Ca2+ (KCa) are strongly affected. Our results 
show that a) SERCA Vmax has a biphasic dependence on bilayer thickness, reaching its 
maximum with 22-carbon lipid chain length, b) phosphatidylethanolamine (PE) and 
phosphatidylserine (PS) decrease KCa, and c) monounsaturated lipids afford higher 
SERCA Vmax and Ca2+-affinity than diunsaturated lipids. The presence of PLN 
removes the activating effect of PE and shifts SERCA’s activity profile, with a maximal 
activity reached in bilayers with 20-carbon lipid chain length. Our results in synthetic lipid 
systems compare well with those carried out in native SR lipids. Importantly, we found 
that specific membrane compositions closely reproduce PLN effects (Vmax and KCa) 
found in living cells, reconciling an ongoing controversy regarding the regulatory role of 
PLN on SERCA function. Taken with the physiological changes occurring in the SR 
membrane composition, these studies underscore a possible allosteric role of the lipid 
bilayers on the SERCA/PLN complex.   
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6.1 Introduction 
 Sarcoplasmic reticulum (SR) Ca2+-ATPase (SERCA) is a multi-domain 
membrane-spanning enzyme that regulates muscle relaxation by Ca2+ translocation from 
the cytosol into the SR lumen (1, 2). SERCA is a P-type ATPase and transports two Ca2+ 
ions per hydrolyzed ATP (3). Phospholamban (PLN) is the main endogenous inhibitor of 
SERCA activity in cardiomyocytes and its inhibition is relieved upon phosphorylation at 
Ser 16 or Thr 17 of PLN (4-7). Since SERCA and PLN are the main regulators of the 
cardiac output, they are targets for treatment of cardiac disease (8, 9).  
 SERCA function has been measured in several different systems including 
mammalian cell lines (10), insect cell microsomes (11), and reconstituted lipid vesicles 
(12). In a reconstituted system, the bilayer lipid composition can be tightly controlled, 
making it ideal for studying the effects of lipids on SERCA function. Specifically, the 
effects of bilayer thickness, head group, and membrane fluidity have all been previously 
investigated. SERCA activity directly depends on bilayer thickness, with a maximum 
activity found for a lipid chain length of 18 carbons and a gradual decrease in activity for 
either thicker or thinner bilayers (13, 14). Later data from Cornea and Thomas support 
these results and, more importantly, showed that the effect of bilayer thickness is 
correlated to the degree of SERCA oligomerization (15). The biochemical results were 
supported by molecular dynamics simulations, which show that SERCA can adapt to the 
thickness of the bilayer through small conformational changes but that this adaptation is 
not efficient in thin (14-carbon) bilayers (16). Moreover, Squier and co-workers showed 
that the zwitterionic phosphatidylethanolamine (PE), which represents 16% and 27% of 
the skeletal and cardiac SR membrane lipid, respectively (17), increases SERCA’s 
maximal activity (Vmax) (18). A similar activating effect was seen for the anionic lipids 
phosphatidylserine (PS) and phosphatidylinositol (PI) phosphate which are present at 
lower concentrations in the SR membrane (19). In addition, SERCA requires fluid, liquid 
crystalline bilayers to function properly (i.e., more active in 18:1 phosphocholine (PC) 
than 18:0 PC) (20). All of these SERCA activity studies based their conclusions on the 
maximum ATPase activity or the activity at a single Ca2+ concentration. Also, the 
functional effects of lipids on the SERCA/PLN complex are currently unknown.  
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 Here, we analyzed the effects of bilayer thickness, head group composition and 
fluidity for SERCA and the SERCA/PLN complex in reconstituted lipid vesicles, 
monitoring the ATPase activity using enzyme-coupled assays. We show how apparent 
Ca2+ affinity (KCa) and Vmax are strongly dependent on the nature of the lipid bilayer. 
Importantly, our data reveal how the lipid bilayer composition influences the regulation of 
SERCA by PLN. Our conclusions on model membranes are supported by activity 
measurements in lipid membranes extracted from rabbit skeletal muscle. 
 
6.2 Experimental procedures 
 All synthetic lipids (Table 1) were purchased form Avanti Polar Lipids (Alabaster, 
AL). Skeletal SR lipids were extracted using an acidified solution of 2:1 
chloroform:methanol (17).  
 SERCA1a was purified from rabbit skeletal muscle using a reactive red affinity 
column (21) and was reconstituted for functional assays according to a well established 
protocol (12, 22-28). Briefly, the lipids solubilized in chloroform were dried under N2(g), 
desiccated for several hours, and resuspended in a buffer containing 20 mM Imidazole, 
0.1 M KCl, 5 mM MgCl2, 10% (v/v) Glycerol and octaethylene glycol monododecyl ether 
(C12E8) at 4:1 (w/w) C12E8:lipid ratio. SERCA (~1 mg/mL in 0.1% w/v C12E8) was added 
to the suspension to a final lipid:SERCA (mol/mol) ratio of 700:1. To remove the 
detergent, the samples were incubated with Biobeads SM2 (75:1 (w/w) Biobeads:C12E8) 
for three hours at 30°C (for experiments where the bilayer thickness or lipid chain 
saturation was varied) or 20°C (for all other experiments). A temperature of 30°C was 
chosen to ensure that lipids with relatively high gel-liquid crystal transition temperature 
(Tm) (i.e. 24:1 PC) were in the liquid crystalline phase during the incubation period. A 
coupled enzyme assay was used to monitor SERCA activity (hydrolysis of ATP) at 37 ºC 
as a function of calcium concentration (12). The rate of enzyme activity was measured 
as a decrease of NADH absorption at 340 nm using a Spectramax plate reader 
(Molecular Devices). Data were fit using the Hill equation: 
𝑉 = 𝑉𝑚𝑎𝑥 [𝐶𝑎2+]𝑛[𝐶𝑎2+]𝑛 +  𝐾𝐶𝑎𝑛 
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 to extract the maximum activity (Vmax), Hill coefficient (n), and calcium concentration 
needed to achieve half maximal activity (KCa). 
 To monitor the inhibition of SERCA by PLN, we chose a monomeric mutant of 
PLN (AFA-PLNN27A) that induces a larger shift in SERCA’s apparent Ca2+ affinity than 
wild-type PLN (PLNwt). Recombinant AFA-PLNN27A and PLNwt were expressed and 
purified as described previously (29). The co-reconstitution of SERCA and PLN was 
identical to the free SERCA samples with the exception that PLN (AFA-PLNN27A or 
PLNwt) dissolved in a 4:1 (v/v) mixture of trifluoroethanol/cholorform was dried together 
with the lipids at a molar ratio of  10:1 or 5:1 PLN:SERCA. 
 
6.3 Results 
6.3.1 Effects of lipid chain structure on SERCA activity  
 The lipid chain structure is the main determinant of the fluidity as well as the 
thickness of the lipid bilayer. To evaluate the effects of bilayer thickness on SERCA 
activity, we conducted ATPase assays in cis-mono unsaturated PC bilayers of varied 
lipid chain length. PC lipids were utilized since they constitute the major lipid of the SR 
membrane (17). In our experience, SERCA Vmax varies between different rabbits and 
preparations (2.9 ± 1.4 I.U, average ± standard deviation for four preparations in 4:1 
(w/w) 18:1∆9-Cis PC (DOPC)/18:1∆9-Cis PE (DOPE) bilayers), while KCa is highly 
reproducible (0.47 ± 0.01 µM). Thus, we express SERCA Vmax as a relative value to our 
standard bilayers (DOPC or 4:1 (w/w) DOPC/DOPE) while KCa is reported as raw values. 
In Figure 1A and B, we show that SERCA activity is highest in bilayers with a chain 
length of 22 carbons (22:1 bilayers) with a Vmax value ~40-fold higher than in 14:1 
bilayers, which had the lowest Vmax. Previous studies, however, found that 18:1 bilayers 
support the highest SERCA activity. (13, 15). The discrepancy with our results might be 
due to the higher Ca2+-concentration used in the previous studies (10-fold excess 
relative to this study), which relied on measuring SERCA activity at only one Ca2+ 
concentration. Since our activity assays were measured for several Ca2+ concentrations 
(complete Ca2+ dependence curves), their fits provide an accurate estimate of Vmax. 
From the fitting of the activity curves, we also measured the SERCA KCa for each lipid 
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length. Figure 1C and D show that SERCA affinity for Ca2+ is biphasic, with the 
minimum KCa (highest apparent Ca2+ affinity) in 20:1 bilayers. Taken together, these data 
indicate that SERCA has the highest Vmax in relatively thick bilayers (22:1), while bilayers 
with a thickness similar to the native SR membrane (average chain length of 18.1 
carbons in cardiac SR and 17.8 carbons in skeletal SR) (17) give the highest affinity for 
Ca2+. Therefore, the native SR lipid composition seems tuned to maximize the apparent 
Ca2+ affinity of SERCA. 
Bilayer fluidity is another important physical property of the lipid bilayer and SERCA 
requires a fluid bilayer to function (20). To test the dependence of SERCA on bilayer 
fluidity, we reconstituted SERCA into 18:1∆9-Trans PC (similar bilayer thickness but less 
fluid than DOPC as determined by fluorescence polarization of 1,6-diphenyl-1,3,5-
hexatriene (DPH)) (14, 30) and 18:2∆9,∆12-Cis PC (similar bilayer thickness but more fluid 
than DOPC) (14, 30). In 18:1∆9-Trans PC, SERCA Vmax is slightly higher than in DOPC, 
while in 18:2∆9,∆12-Cis PC Vmax is significantly lower (Figure 2A). However, in both 
18:2∆9,∆12-Cis PC and 18:1∆9-Trans PC bilayers KCa is significantly higher than in DOPC 
(Figure 2B). In the cardiac SR, the average number of unsaturated (cis) bonds per lipid 
chain is 1.6 (17), which is intermediate between that of DOPC and 18:2∆9,∆12-Cis PC. 
Thus, both the thickness and fluidity of the SR bilayer are probably optimized for KCa 
rather than Vmax.   
An inherent shortcoming of our studies is that bilayer thickness and fluidity cannot be 
varied independently (i.e 18:1∆9-Trans PC bilayers are thicker than DOPC bilayers). 
Therefore it is important to emphasize that a change in SERCA activity cannot be 
explained by one single characteristic of the lipid bilayer. Nevertheless, the difference in 
bilayer thickness between DOPC and 18:1∆9-Trans PC is only ~1 Å (14) compared to the 
difference between for example 20:1 PC and 18:1 PC (~3Å) ( (14). Thus, the difference 
in SERCA Vmax and KCa between 18:1∆9-Trans PC and DOPC can be mainly attributed to 
the difference in fluidity between the two bilayers.      
161 
 
6.3.2 Effects of phosphoethanolamine (PE) on the activity of the SERCA/PLN 
complex  
 Since the two major components of the native SR membrane are PC and PE 
lipids (17), 4:1 (w/w) DOPC/DOPE lipid bilayers preparations have been used to study 
SERCA activity (12, 31). To determine the effects of PE on SERCA function, we carried 
out functional assays at different molar ratios of DOPC:DOPE. Since pure PE 
membranes form hexagonal phases and inhibit SERCA activity (32), we limited the PE 
content to 60% (w/w) of the total lipid bilayer composition to retain the liquid crystalline 
phase.  
When SERCA was reconstituted in the absence of PLN, we found that increased PE 
content steadily increases Vmax at PE ratios greater than 20% (w/w), with no significant 
effects observed at PE content <20% (w/w) (Figure 3A and B), in agreement with 
previous studies (18, 32). Also, we found that the DOPC:DOPE bilayers have a 
significantly lower KCa compared to pure DOPC bilayers (Figure 3D, E). Thus, PE has 
an activating role on SERCA function, increasing both the apparent Ca2+ affinity and 
Vmax.  
 PE is a curvature-forming non-bilayer lipid (33), which can affect membrane 
protein function by inducing curvature and changing the lateral pressure in the 
membrane (34, 35). To test if this change in bilayer property could explain the effects of 
PE on SERCA function we measured SERCA activity in the presence of phosphoserine 
(PS) lipids, which make up ~10% of the total SR membrane lipid content (17) and does 
not induce membrane curvature. In this case, we found that the 4:1 (w/w) PC:PS 
bilayers decreased SERCA Vmax relative to both PC and 4:1 (w/w) PC:PE bilayers 
(Figure 3C). However, KCa values were slightly lower than those obtained in PC:PE 
(Figure 3F). The effects on KCa and Vmax are present also at a physiological 9:1 (w/w) 
PC:PS ratio. These data show that PS increases the apparent Ca2+ affinity of SERCA 
and reveal a possible activating role of PS similar to PE lipids. This also suggests that 
the activation of SERCA by PE is not due to increased bilayer curvature.  
 In situ and in vitro experiments have shown that SERCA’s apparent Ca2+ affinity 
is lowered in the presence of PLN (11, 12, 23). To determine the effects of bilayer 
composition on SERCA inhibition by PLN, we co-reconstituted a monomeric, 
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superinhibitory mutant of PLN (AFA-PLNN27A) (12, 36) with SERCA into lipid vesicles 
composed of DOPC or DOPC/DOPE mixtures. We found that AFA-PLNN27A’s effects on 
SERCA are the same either in the absence or presence of 20% PE (w/w). In both cases 
AFA-PLNN27A increases both Vmax and KCa (Figure 4). Note that in the presence of AFA-
PLNN27A, SERCA activity is insensitive to a change in PE content. Therefore, the 
presence of PLN removes the activating effects of PE on SERCA Ca2+ affinity. 
6.3.3 PLN regulation of SERCA and bilayer thickness 
 To analyze how PLN regulation of SERCA depends on the bilayer thickness, we 
co-reconstituted SERCA and AFA-PLNN27A into bilayers of varied chain length and with 
20% (w/w) DOPE to maximize the effects on SERCA activity. From the data in Figure 5 
it is clear that the effects of AFA-PLNN27A on SERCA function are dependent on the 
bilayer composition. In 18:1 bilayers, AFA-PLNN27A binding increases SERCA Vmax and 
decreases its Ca2+ affinity, as previously noted (12, 23). However, in 22:1 bilayers AFA-
PLNN27A  does not alter the enzyme’s Vmax but lowers its Ca2+ affinity in a manner that is 
strikingly similar to the behavior of the SERCA/PLN complex in co-expression systems 
(11). These results imply that differences in bilayer composition may account for some of 
the discrepancies seen between in vitro and in vivo studies. In addition, AFA-PLNN27A 
shifts the highest Vmax of SERCA to thinner bilayers (from 24:1 to 20:1). The slight 
difference in maximum Vmax in the absence of SERCA from that measured in pure PC 
bilayers (Figure 1) is probably attributable to the DOPE (18:1) lipids, which may reduce 
the thickness of 20:1, 22:1 and 24:1 bilayers. As shown in Figure 4, AFA-PLNN27A 
removes the activating effects of PE on SERCA. Also, AFA-PLNN27A attenuates the 
differences in KCa found for bilayers of different chain length (i.e., 5-fold vs 1.5-fold 
difference between 20:1 and 24:1 in the absence and presence of AFA-PLNN27A, 
respectively). Thus, PLN binding alters the effects of head group composition and chain 
length on SERCA activity. 
6.3.4 Lipid effects on the SERCA/PLN complex at physiological protein to lipid 
ratios 
A lipid-to-protein ratio of 700:1 is typically used in the current literature for the ATPase 
assays (12, 31). To determine if the effects of lipids is preserved under more 
physiological lipid-to-protein ratios, we measured SERCA activity using 150:1 
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lipid:SERCA molar ratio. We found that under these conditions both Vmax (35% increase) 
and KCa (0.63 ± 0.02 µM vs 0.47 ± 0.01 µM) are slightly higher than in 700:1 bilayers. 
Figure 6A shows that incorporation of 20% (w/w) PE leads to an increase of Vmax, which 
is also seen in 700:1 bilayers but at slightly higher PE concentrations. Also, 20% (w/w) 
PE leads to lower KCa (Figure 6B) and thus a higher apparent Ca2+ affinity in agreement 
with the data obtained with 700:1 lipid-to-protein ratio (Figure 3). Therefore, the 
conclusions obtained in bilayers with a 700:1 lipid:SERCA molar ratio are also valid for 
150:1 bilayers, which mimic the SR composition. 
In the cardiac SR membrane, SERCA is surrounded by a ~5-fold molar excess of PLN 
(37). Wild type PLN (PLNwt) forms a pentamer (38, 39), but de-oligomerizes into 
monomers to form a 1:1 complex with SERCA (40, 41). To supplement the results with 
the superinhibitory, monomeric AFA-PLNN27A mutant we co-reconstituted PLNwt with 
SERCA at a 5:1 PLNwt:SERCA molar ratio into bilayers containing 150 lipid molecules 
per SERCA, mimicking the conditions of the native SR membrane. As for the 
superinhibitory monomeric PLN, addition of PLNwt increases KCa and raises Vmax of 
SERCA (Figure 6). Importantly, in the presence of PLNwt, PE head groups do not have 
an effect on the KCa or Vmax of SERCA in analogy to the results with AFA-PLNN27A at a 
700:1 lipid:SERCA molar ratio (Figure 4). Thus, we conclude that the effects of lipids are 
similar for pentameric and monomeric PLN and that our results with AFA-PLNN27A are 
representative also for other PLN variants. 
6.3.5 SERCA function and regulation by PLN in native lipids 
 Previous studies have shown discrepancies in SERCA function and PLN 
regulation (Vmax) between different membrane mimicking systems (11, 12, 23). To 
confirm that our conclusions in model membranes apply to native SR lipids, we 
reconstituted SERCA and AFA-PLNN27A into lipids extracted from rabbit hind-leg skeletal 
muscle. While these extracted lipids cannot fully mimic all properties of the SR 
membrane (i.e., asymmetric distribution of lipids between bilayer leaflets or presence of 
lipid rafts) they allowed us to test SERCA activity and PLN regulation in a fully 
physiological bilayer composition. In SR lipids, SERCA Vmax (Vmax,SR/VmaxDOPC = 1.3) and 
KCa (0.81 µM) are slightly higher than in the 4:1 (w/w) DOPC:DOPE bilayers used to 
mimic the SR composition (Figure 7). Addition of AFA-PLNN27A leads to an increase in 
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Vmax (Vmax,+PLN/Vmax-PLN = 2.6) and a shift in KCa (to 2.0 µM). These effects are similar to 
those obtained in synthetic lipid preparations (Figure 4). Interestingly, addition of AFA-
PLNN27A increases the degree of Ca2+ binding cooperativity (Hill coefficient). This effect 
has been seen in SR vesicles (42) and reconstituted lipid bilayers consisting of a mixture 
of natural egg yolk PC and PA (phosphatidic acid) lipids(23) but was not detected in 
synthetic model membranes (Figure 4). Nevertheless, the differences between the 
native lipids and the DOPC:DOPE bilayers are relatively minor considering the sensitivity 
of SERCA to the bilayer thickness and the nature of the lipid head group.  
 
6.4 Discussion 
The importance of lipid bilayer composition for protein function is well established for 
SERCA (43, 44) as well as for other membrane bound enzymes (45). In the present 
study, we show that SERCA Vmax and KCa are significantly affected by the lipid bilayer 
composition. Thus, lipids with different chain length and head groups have activating or 
inhibitory effects on the enzyme. Since PE and PS lipids increase the apparent Ca2+ 
affinity of SERCA (Figure 3), we believe these to be activating with respect to PC lipids. 
This activation could be a result either of specific protein-lipid interactions (46) or non-
specific effects on bilayer properties (47). Previously, it has been shown that addition of 
PE to PC bilayers does not alter lipid chain dynamics or the overall SERCA rotational 
correlation time (18), and that change in lipid head group composition has marginal 
effect on bilayer thickness (48). Thus, the SERCA activation by PE head groups is likely 
due to specific protein-lipid interactions rather than macroscopic changes of the lipid 
bilayer properties. A possible explanation for such interactions is that in contrast to PC, 
PE and PS can function as hydrogen bond donors and potentially form hydrogen bonds 
with sites on SERCA in agreement with other membrane proteins (46). In fact, lipid 
molecules have been detected in SERCA crystal structures (3) with the bound lipids 
modeled as PE and located in the groove between helices M2, M4 and M6. These lipids 
could possibly be responsible for the activating effects of PE on SERCA.  Interestingly, 
this lipid binding site overlaps with the proposed binding site for PLN (49). Here, we 
showed that in the presence of PLN, SERCA activity is independent of PE (Figure 4). 
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Therefore, the inhibitory PLN and the activating PE lipids might compete for the same 
binding site, which could explain part of the inhibitory effect that PLN has on SERCA. 
 It is widely accepted that PLN inhibits SERCA by lowering its apparent Ca2+ 
affinity. However, contrasting studies have reported that PLN increases (12, 23) or does 
not affect Vmax (11). The increase of Vmax has mainly been observed in reconstituted 
systems, but vanishes at high lipid:SERCA ratios (12). Based on our results in model 
membranes, PLN increases (16:1, 18:1, 20:1), does not change (22:1), or decreases 
(24:1) the enzyme’s Vmax in bilayers of different thickness (Figure 5). In 22:1 bilayers 
AFA-PLNN27A lowers the Ca2+ affinity of SERCA without affecting Vmax. The similarity of 
these data with those from co-expression systems (11) raises the question whether 
SERCA and PLN preferentially localize to thicker regions of the bilayer in vivo. Another 
possibility is that PLN changes the thickness of the lipid bilayers, affecting Vmax. In the 
absence of PLN (and in the presence of 20% (w/w) DOPE), SERCA reaches its 
maximum activity in 24:1 lipid bilayers (Figure 5A). In contrast, when co-reconstituted 
with AFA-PLNN27A, SERCA reaches its maximum activity in 20:1 lipid bilayers (Figure 
5A). This result may be rationalized by a thickening of the bilayer caused by PLN. Under 
diluted conditions (high lipid:AFA-PLNN27A molar ratios), the effects of AFA-PLNN27A on 
Vmax vanishes (12). It is possible that under these conditions AFA-PLNN27A concentration 
is too low to affect the thickness of the bilayer, thus losing its ability to increase Vmax. In 
fact, depleting membrane proteins from bilayers can change the thickness by ~5 Å (50), 
which corresponds to a difference in chain length of ~3 carbons. In the native SR 
membrane, the lipid:SERCA molar ratio is ~100:1 (51), and thus significantly lower than 
the 700:1 ratio used in our measurements. Even if additional proteins, lipids, and other 
biomolecules are present in vivo, PLN-induced changes to the lipid bilayer could be 
important for regulation of SERCA in the muscle cell. Previous studies have shown that 
the effect of bilayer thickness on SERCA Vmax is correlated to reversible aggregation 
(15). In light of those results, SERCA aggregation is another possible mechanism for 
regulation of the enzyme by PLN. Also, PLN is in conformational equilibria between 
different conformational states (31, 52, 53), which are sensitive to the composition of the 
lipid bilayer (54, 55). Furthermore, negatively charged lipids influence the ability of a 
soluble peptide corresponding to residues 1-23 of PLN to regulate SERCA activity (56). 
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Further studies are needed to determine if a shift in the conformational equilibrium of 
PLN is responsible for the effects of lipid composition on the SERCA/PLN complex. 
 Cardiac and skeletal SR membranes have an average lipid chain length of ~18, 
and an average of 1.6 unsaturated bonds per lipid chain. They are mainly composed of 
lipids with PC head groups (~53% (cardiac), ~68% (skeletal)) with smaller amounts of 
PE (~27%, ~16%), PS (~10%, 10%), and PI (~1%, ~2%) lipids (17). Our data show that 
in bilayers with this chain length (Figure 1), fluidity (Figure 2) and head group content 
(Figure 3) SERCA’s apparent apparent Ca2+ affinity is optimal in while Vmax, is higher in 
thicker, less fluid bilayers. Thus, the SR membrane appears to be tuned to maximize the 
apparent Ca2+ affinity of SERCA. Our data also show that a PE concentration ≥ 20% 
(w/w) raises SERCA Vmax and KCa is significantly lowered at PE concentrations of less 
than 20% (Figure 3). Therefore, at physiological PE concentrations, small changes in 
the PE head group content of the SR could significantly alter intracellular calcium 
cycling. The same is true for changes in bilayer thickness or lipid saturation.  
Changes to the bilayer composition in mice have been shown to occur with muscular 
dystrophy (57) and aging (58). In addition, diet can also alter the distribution of lipids, as 
shown in another mouse study where increased levels of unsaturated lipids occurred 
from exclusive fish intake. These mice had lower Ca2+ uptake into the SR (59). In 
agreement with this finding, our activity assays using model membranes show that 
SERCA Vmax is significantly lower in polyunsaturated 18:2∆9,∆12-Cis PC than in 
monounsaturated DOPC (Figure 2). This implies that differences in SERCA function 
between bilayers with different lipid chain structure could be explained by differences in 
lipid bilayer thickness. Also, a recent study showed that obesity-induced ER stress can 
significantly raise the PC:PE ratio of the ER (60). Interestingly, this change in head 
group composition was correlated to a decreased SERCA activity which is in excellent 
agreement with our in vitro studies.  
 In the cardiac SR, PLN is present at a five-fold excess molar concentration with 
respect to SERCA (37). Our data show that SERCA activity is significantly less sensitive 
to alterations of the lipid thickness of the PC:PE bilayer in the presence of AFA-PLNN27A. 
167 
 
Thus, PLN may have a buffering effect for SERCA in response to any changes in 
membrane structure due to pathology or diet.  
 In summary, we have shown that SERCA activity and its regulation by PLN are 
sensitive to bilayer thickness, fluidity and head group content with maximum activity in 
bilayers that are slightly thicker than the native SR membrane. SERCA’s apparent Ca2+ 
affinity, however, is optimized in bilayers mimicking the native SR membrane. The 
presence of PLN decreases the calcium affinity, removes the activating effects of PE 
and attenuates the effects on SERCA activity in lipids of varying chain length. These 
new findings for Ca2+ translocation underline the importance of lipids for SERCA function 
and its regulation by PLN and could reconcile discrepancies between reconstituted and 
co-expression systems.  
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Lipid Chemical name 
14:1Δ9-Cis PC 1,2-di-(9Z-tetradecenoyl)-sn-glycero-3-phosphocholine 
16:1Δ9-Cis PC 1,2-di-(9Z-hexadecenoyl)-sn-glycero-3-phosphocholine 
18:1Δ9-Cis PC (DOPC) 1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphocholine 
18:1Δ9-Trans PC 1,2-di-(9E-octadecenoyl)-sn-glycero-3-phosphocholine 
18:2Δ9,Δ12-Cis PC 1,2-di-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine 
20:1Δ11-Cis PC 1,2-di-(11Z-eicosenoyl)-sn-glycero-3-phosphocholine 
22:1Δ13-Cis PC 1,2-di-(13Z-docosenoyl)-sn-glycero-3-phosphocholine 
24:1Δ15-Cis PC 1,2-di-(15Z-tetracosenoyl)-sn-glycero-3-phosphocholine 
18:1Δ9-Cis PE (DOPE) 1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine 
18:1Δ9-Cis PS (DOPS) 1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phospho-L-serine 
 
Table 1. Synthetic lipids used for reconstitutions.  
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Figure 1. SERCA activity in bilayers of varying thickness. A, C.) Representative curves 
of raw and normalized ATPase activity as a function of calcium concentration in 14:1∆9-
Cis, 16:1∆9-Cis, DOPC, 20:1∆11-Cis, 22:1∆13-Cis and 24:1∆15-Cis PC bilayers. Each point 
represents the average and standard error from three measurements. B.) Vmax of 
SERCA relative to DOPC (Vmax/Vmax,DOPC) as a function of bilayer chain length. Error bars 
represent the standard error from at least three separate reconstitutions D.) KCa in 
bilayers of varying thickness. Each bar was determined from the average of ≥ 3 
reconstitutions and error bars show the standard error of the mean. 
   
  
174 
 
 
Figure 2. SERCA activity in C18 bilayers with different fluidity. A, C.) Raw and 
normalized ATPase activity in PC bilayers with differences in geometry around the 
unsaturated bond (18:1∆9-trans PC vs DOPC (18:1∆9-cis PC)) but identical length of the 
aliphatic chains. B, D.) ATPase activity in PC bilayers with differences in chain saturation 
(DOPC vs 18:2∆9, ∆12-cis PC) but identical length of the aliphatic chains. Error bars 
correspond to the standard error of three measurements. Averaged KCa and relative Vmax 
are shown as insets, with the error bars representing the standard error of three or more 
separate reconstitutions. 
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Figure 3. Effects of PE and PS head groups on SERCA activity. A,D.) Representative 
curves of raw and normalized SERCA activity in bilayers composed of DOPC and 
different mole fractions of 18:1 DOPE as indicated in figure. Error bars represent an 
average of triplicate measurements and are for some points smaller than the symbol. B.) 
Vmax of SERCA in bilayer with varied amount of PE head group. Vmax values are shown 
relative to the Vmax in 0% PE (DOPC). C.) Vmax relative to Vmax,DOPC in 4:1 (w/w) 
DOPC:DOPE and 4:1 or 9:1 (w/w) DOPC:DOPS. E.) KCa of SERCA in different amounts 
of PE. ∆KCa corresponds to KCa,X% PE - KCa,0% PE where X is the mole fraction of PE in the 
bilayer. F.) KCa in DOPC, 4:1 (w/w) DOPC:DOPE and 4:1 or 9:1 (w/w) DOPC:DOPS. 
Error bars in B,C,E and F represent the standard error of three or more separate 
reconstitutions. For points where error bars are not visible they are smaller than the 
symbol. 
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Figure 4. Inhibition of SERCA by AFA-PLNN27A in bilayers with different head group 
composition. A,C.) Representative curves of raw and normalized SERCA activity in 
DOPC and 4:1 (w/w) DOPC:DOPE in the absence and presence of a 10-fold molar 
excess of AFA-PLNN27A. Each point shows the average and standard error of three 
measurements, for some points the error bar is smaller than the symbol. B.) Average 
Vmax in DOPC and 4:1 (w/w) DOPC:DOPE in the presence and absence of AFA-PLNN27A 
Values are reported relative to the value in DOPC. D.) Averaged KCa values. Error bars 
in B.) and D.) represent the standard error of three or more separate reconstitutions.   
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Figure 5. Effects of AFA-PLNN27A on SERCA Vmax and KCa in bilayers of varying 
thickness composed of 4:1 (w/w) 14:1 - 20:1∆9-Cis PC:DOPE. A, B.) Vmax values relative to 
4:1 (w/w) DOPC:DOPE in the absence and presence of AFA-PLNN27A. C.) SERCA Vmax 
change caused by AFA-PLNN27A measured as Vmax,+AFA-PLNN27A / Vmax,-AFA-PLNN27A, D, E.) 
KCa values in the absence and presence of AFA-PLNN27A. F.) KCa change due caused by 
AFA-PLNN27A and measured as ∆KCa = KCa,+AFA-PLNN27A - KCa,-AFA-PLNN27A. The error bars 
represent standard error for ≥3 separate reconstitutions.  
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Figure 6. Lipid effects on SERCA and PLNwt at a physiological lipid concentration. 
SERCA activity in samples reconstituted with a lipid:PLNwt:SERCA molar ratio of 
150:5:1. A.) Average Vmax in the presence and absence of PLNwt in DOPC and 4:1 (w/w) 
DOPC:DOPE. Vmax is relative to the value in DOPC. B.) Averaged KCa values. All error 
bars represent the standard error of three separate reconstitutions. 
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Figure 7. SERCA and PLN in native lipids. SERCA ATPase activity and AFA-PLNN27A 
regulation with proteins reconstituted into lipids extracted from rabbit skeletal muscle SR. 
A.) Raw activity. B.) Normalized values. Error bars display the standard error of three 
measurements and are smaller than the symbol for several of the data points. 
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Chapter 7- Phospholamban Excited State Control of SERCA 
Revealed by Paramagnetic Relaxation Enhancements and Solid-
State NMR 
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The membrane protein complex between the sarcoplasmic reticulum (SR) Ca2+-ATPase 
(SERCA) and phospholamban (PLN) regulates Ca2+ transport in the SR, thereby 
controlling cardiac contractility. Using a combination of asymmetric isotopic and spin 
labeling techniques in concert with magic angle spinning NMR spectroscopy, we 
mapped the physical interactions between PLN and SERCA in membrane bilayers and 
revealed the molecular mechanisms of the regulatory cycle. When bound to SERCA, the 
PLN transmembrane domain remains anchored to the ATPase, while the cytoplasmic 
domain populates a helical T state and an unfolded R state. The T state remains 
embedded onto the bilayer surface, whereas the R state interacts transiently with the 
enzyme’s nucleotide binding and phosphorylation domains, forming a fuzzy complex. 
We conclude that conformational equilibrium of PLN is central to SERCA regulation and 
maintains Ca2+ concentration within a physiological range. These results reveal that 
SERCA function is controlled by conformationally excited state of PLN and explain why 
biasing the population of the excited state generates loss-of-function mutants of PLN. 
The methodological advances described here further open the landscape to conducting 
structural studies of membrane protein complexes of molecular weights beyond 100 
kDa.  
 
 
7.1 Introduction 
The SERCA/PLN complex regulates Ca2+ translocation into the sarcoplasmic reticulum 
(SR) of cardiomyocytes and constitutes the main mechanism of cardiac relaxation 
(diastole). (1-4) SERCA is a P-type ATPase that translocates 2 Ca2+ ions per ATP 
molecule hydrolyzed in exchange of 3 H+.(5) The enzyme is organized into a multi-span 
transmembrane (TM) ion channel, comprising ten helical segments and a large 
cytoplasmic region with three structural domains: nucleotide binding domain (N), 
actuator domain (A), and phosphorylation domain (P). (5, 6) PLN is the endogenous 
inhibitor of the ATPase, with a helical TM region (divided into a hydrophilic domain Ib 
and hydrophobic domain II) anchored to SERCA’s TM domain, and an amphipathic 
region (domain Ia), harboring the recognition sequence for cAMP-dependent protein 
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kinase A (PKA). (3, 7, 8) Upon β-adrenergic stimulation, PKA phosphorylates PLN at Ser 
16, reversing its inhibitory action and augmenting Ca2+ transport into the SR. 
Phosphorylation is reversed by protein phosphatase 1, which reinitiates the cycle (8). 
Disruptions in SERCA regulation by PLN degenerate into Ca2+ mishandling and lead to 
heart failure. (3) 
Although several X-ray structures of SERCA have been determined along the enzymatic 
coordinates (5, 6, 9, 10), the high-resolution structure of the SERCA/PLN complex is still 
missing, and more importantly, the atomic details of the regulatory process remain 
unknown. Although informative, cryo-EM studies have offered low-resolution images of 
PLN within the complex (11, 12). Mutagenesis and cross-linking data suggest that PLN 
inhibitory region is positioned into a binding groove located between the TM helices M2, 
M4, M6 and M9 of SERCA. (13-16) These studies also suggested that PLN domain Ia 
binds SERCA’s N-domain in a α-helical conformation, supporting a ‘folding upon binding’ 
mechanism. (13)   
In the absence of SERCA, PLN undergoes a conformational equilibrium. The α−helical 
domain II of PLN is relatively rigid and membrane-embedded, while the cytoplasmic 
domains Ia, Ib, and the intervening loop are dynamic and more solvent exposed. (17, 18) 
Importantly, the amphipathic domain Ia is metamorphic, adopting a helical structure 
when in contact with membrane (T or ground state) and becoming unfolded when 
detached (R or excited state). (19-24) These ground and excited states have been 
detected both in synthetic and natural SR lipid membranes. (21, 23) On average, the L-
shaped T state is the most populated in either monomeric or pentameric PLN. (25, 26), 
with the R state accounting for 16-20% of the overall population. (27) To date, however, 
the significance of PLN conformational equilibrium and the role of the excited state in the 
context of enzymatic regulation have remained elusive.  
Here, we used a combination of asymmetric isotopic and spin-labeling schemes to 
characterize the conformational equilibrium for the SERCA/PLN complex and elucidate 
the role of the R state in the regulatory mechanism. We found that upon complex 
formation, the T state of PLN remains embedded on the surface of the lipid membrane, 
while the R state transiently interacts with the cytoplasmic domain of the enzyme, 
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reversing the inhibition. PLN domain Ia binds SERCA in an unfolded and dynamic 
conformation, which reverses the inhibitory action. Taken with our biological assays, 
these results show that PLN conformational equilibrium plays a central role in SERCA 
regulation and Ca2+ homeostasis, and at the same time, explain why shifting PLN 
conformational equilibrium (i.e., promoting the excited R state) via site specific 
mutagenesis reverses SERCA inhibition. (21, 28) Biasing the conformational equilibrium 
of PLN toward the excited state represents a new paradigm for rational design of 
inotropic gene therapies with PLN loss-of-function mutants to ameliorate heart muscle 
disease (29). 
 
7.2 Results and discussion 
7.2.1 SERCA selects the R state conformation of PLN domain Ia 
Unfolding studies show that the cytoplasmic domain of PLN can occupy at least four 
different conformational states: a T state, membrane-associated and helical; a T’ state, 
membrane-associated and partially helical, an R’ state, membrane-associated and 
unfolded; and an R state, solvent exposed and completely unfolded. While the T’ and R’ 
states are detectable for PLN reconstituted in dodecylphosphocholine micelles, the T 
and R are the most populated states both in synthetic and SR lipid membranes (23). 
Importantly, the conformational equilibrium of PLN persists in the presence of SERCA 
(19, 22), which upon binding modulates the relative populations of the T and R states. 
To map the conformational equilibrium in lipid membranes at the atomic level and 
understand the role of the excited R state, we used magic angle spinning (MAS) NMR 
spectroscopy. We co-reconstituted SERCA with isotopically labeled, monomeric PLN 
(PLNAFA carrying C36A, F41F, and C46A mutations) into egg yolk 
phosphatidylcholine/phosphatidylethanolamine/phosphatidic acid (PC/PE/PA) lipid 
vesicles (8:1:1 molar ratio) at a 150:1:1 lipid:SERCA:PLNAFA molar ratio. This lipid 
composition closely mimics the head group and lipid chain composition of the SR (30) 
and fully preserves SERCA’s function as well as its native interactions with PLN as 
confirmed by enzyme coupled assays and fluorescence resonance energy transfer 
(FRET) (Figure S1). Using MAS dipolar assisted rotational resonance (DARR) 
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experiments (31), we found that, with the exception of Asn 34, which consistently 
showed a > 1 ppm perturbation in both synthetic and recombinant samples, the Cα 
resonances corresponding to the TM domain II and domain Ib remain mostly 
unperturbed when bound to the enzyme (Figure S2,S3). In contrast, the methyl 
resonances of the TM domains show significant chemical shift perturbations. In 
particular, Ile 38 and Leu 42, which were predicted to be cofacial to the TM residues of 
the ATPase, change chemical shift in the presence of the ATPase (Figure 1). (13) For 
several residues belonging to PLN cytoplasmic domain Ia, we observed two distinct 
populations, corresponding to chemical shifts for helical and unfolded conformations, 
which we assigned to the T and R states, respectively (Figure 2). The relative intensity 
(population) of the resonances corresponding to the two states changes as a function of 
the temperature, demonstrating the presence of a conformational exchange in the slow 
regime of the NMR time scale (Figure S4). The chemical shifts of PLN’s T state are 
similar both in the free and SERCA-bound forms (Figure S3). In contrast, the presence 
of the ATPase causes large chemical shift perturbations for residues in the R state 
(Figure S3). In particular, SERCA binding shifts the resonance corresponding to the 
Cα chemical shift of Leu 7 by approximately 1 ppm (Figure 2B). Remarkably, the 
chemical shifts of the bound R state are indicative of a random coil conformation, 
showing that the interaction with SERCA does not induce the previously proposed 
helical conformation of domain Ia  (13, 24). The latter excludes the previously proposed 
mechanism of ‘folding upon binding’ suggested on the basis of molecular modeling and 
NMR spectroscopy (13, 24) Based on these results, we conclude that a) SERCA binds 
PLN with the inhibitory TM domain II and domain Ib in a helical conformation, b) the T 
state of the cytoplasmic domain does not interact with the enzyme, and c) the R state of 
domain Ia binds SERCA in an unfolded and dynamic conformation. 
 
7.2.2 Mapping of SERCA/PLN interactions by PREs 
To map the physical interactions between PLNAFA and SERCA, we utilized paramagnetic 
relaxation enhancements (PREs) measured by MAS NMR spectroscopy. For our 
studies, we used a combination of asymmetric isotopic and spin-labeling schemes which 
are summarized in Figure S5. First, we engineered a TEMPO spin label on SERCA at 
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Cys 674 (SERCAC674SL). This residue is situated in the P-domain of the enzyme and is 
an ideal reporter for SERCA/PLN interactions.(32). Next, we reconstituted SERCAC674-sl 
with uniformly or selectively 13C-labeled PLNAFA (33). Using 13C-13C DARR experiments, 
we mapped the PRE effects on PLN by monitoring the intensities of the 13C resonances 
of PLNAFA. Since the T to R conformational equilibrium is slow, we monitored the PRE 
effects on the two peak populations, simultaneously. The spin-label positioned in the 
cytoplasmic P-domain of SERCA did not affect the PLNAFA residues in the TM domains 
Ib and II (Figure S6). In contrast, several resonances of domain Ia in the R state were 
selectively quenched relative to the T state (Figure 3). Since the R state is more 
dynamic, it can be detected using refocused INEPT (Insensitive Nuclei Enhanced by 
Polarization Transfer, rINEPT) experiments (34). The rINEPT experiment filters out the 
resonances associated with the rigid T state as well as residues in domain Ib and II, and 
detects only the most mobile residues of PLN (23, 35). Remarkably, the intensities of 
several resonances in domain Ia are significantly reduced upon formation of the 
SERCAC674sl/PLNAFA complex (Figures 4 and S7). The most affected residues are 
located in the middle of domain Ia, with Tyr 6 and Leu 7 almost completely quenched. 
The latter demonstrates that these residues in the complex are near SERCA’s P domain. 
In contrast, residues located at both the C- and N-terminal regions of domain Ia (Ala 0, 
Met 1, Met 20, and Pro 21) remain largely unperturbed (Figure 4C). A different 
quenching pattern is observed when PLNAFA is bound to SERCA labeled with 4-
maleimido-TEMPO at both Cys 344 (P domain) and Cys 364 (N domain) 
(SERCAC344C364-sl) (36) (Figure 4). Upon SERCAC344C364-sl/PLNAFA complex formation, 
several resonances spanning the central region of domain Ia are quenched, with the 
exception of residues located at both N- and C-terminal ends of domain Ia. The most 
prominent PRE effect was registered for the Cγ resonance of Lys 3 (I/I0 ~ 0.45). This 
PRE pattern is consistent with the effects observed for SERCAC674-sl, supporting that the 
R state is located near the P and N domains of SERCA. Interestingly, the proximity of 
Cys 364 to Lys 397 and the strong reduction of Lys 3 peak intensity agrees with previous 
reports of a crosslink formation between Lys 397/400 of SERCA and Lys 3 of PLNAFA 
.(37) 
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7.2.3 PRE effects of PLN-sl on methyl-labeled SERCA 
To monitor the PRE effects of PLN on SERCA, we engineered an MTSSL spin label at 
residue 7 of PLNAFA (PLNAFA-sl) and labeled SERCA extracted from mammalian tissues 
with 13C- methyl methanethiosulfonate (MMTS) (38). This reagent reacts with SERCA 
native cysteines, forming methyl thiocysteines (MTC). MTC-labeled SERCA (MTC-
SERCA) retains ~80% ATPase activity as determined by coupled enzyme activity 
assays (Figure S8) (39). To assess the MTC labeling of the SERCA cysteines, we 
reconstituted MTC-SERCA in DPC detergent micelles and acquired a [1H,13C]-HSQC 
spectrum. The spectrum shows six resolved resonances, corresponding to six of the 
most accessible cysteines of SERCA (Figure 5A,B). We co-reconstituted the MTC-
SERCA with PLNAFA-sl in 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) lipid 
vesicles. The methyl group signals from MTC-SERCA, were detected using conventional 
and water-edited cross-polarization (CP) experiments (40) in the presence of reduced 
and oxidized PLNAFA-sl. A single unresolved peak for all of the 6 labeled sites is observed 
at approximately 25 ppm (Figure 5C). The water-edited CP eliminates most of the lipid 
background and enhances the peak envelope corresponding to the MTC groups. Upon 
binding, PLNAFA-sl significantly reduces the intensity of the methyl peaks of MTC-SERCA 
in both types of experiments and reduction of the spin label reverses this effect, 
demonstrating that upon interaction with SERCA, the cytoplasmic region of PLN reaches 
up to the N- and P domains of SERCA. Although at this stage we cannot resolve the 
methyl group resonances of MTC-SERCA in the NMR spectra, these data confirm and 
complement the mapping of PRE on the PLN backbone.  
 
7.2.4 Mapping Lipid Association of the SERCA/PLN complex 
Since no PRE effects were detected for the T state resonances, we deduced that the 
amphipathic T state helix is bilayer associated in the SERCA/PLN complex. To 
substantiate this conclusion, we used rINEPT experiments to measure PRE effects from 
the SERCA/PLNAFA-sl complex to the 13C resonances of the lipid bilayer. The plot of the 
13C resonance intensities show a bimodal distribution, with a significant reduction of the 
13C resonances for the lipid chain and head groups, with the glycerol region of the lipids 
virtually unaffected by PLNAFA-sl (Figure 6A). These data show that the nitroxide spin 
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label in the T state must be deeply embedded into the membrane to quench the 
hydrocarbon resonances of the lipids. On the other hand, the reduction of the peak 
intensities corresponding to the head groups can be explained by transient interactions 
of the nitroxide in the R state with the surface of the lipid bilayer. To further support lipid 
association of the T state of PLN, we engineered a PE head group with a nitroxide spin-
label (PEsl, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-amido-TEMPO, Figure 
S9) and measured PRE from PEsl to selectively 13C-labeled PLNAFA in complex with 
SERCA. The nitroxide spin label of PEsl is localized in the glycerol region of the lipid 
bilayer, as shown in Figure S10. We found that PEsl quenches the T state resonances of 
domain Ia (Figure 6B), further validating that these residues must be embedded on the 
surface of the lipid membrane.  
 
7.2.5 SERCA/PLN complex and conformational equilibrium 
Trapping the SERCA/PLN complex in a defined, crystallizable state has been 
challenging. Although cryo-EM data provided critical information on the SERCA/PLN 
complex (11, 12) they offer low resolution images and do not make it possible to 
distinguish secondary structure and membrane architecture within the complex. A more 
defined model was provided by mutagenesis, biochemical, computational, as well as 
solid-state NMR data (24). The resulting overall architecture of the complex is very 
similar to previous molecular modeling studies carried out by Toyoshima and co-workers 
(13). The helical domains Ib and II were docked to the putative PLN binding groove 
defined by mutagenesis. The loop bridging the TM and cytoplasmic domain were 
modeled in an unfolded configuration, stretching toward the N-domain of SERCA to 
satisfy the cross-linking data from Lys 3 of PLN to Lys 397 of SERCA.(37). PLN domain 
Ia was modeled in a α-helical conformation docked into SERCA’s N domain.  For both 
models, SERCA/PLN contacts were based only on co-immunoprecipitation and cross-
linking assays. In contrast, the combination of PRE effects and MAS NMR spectroscopy 
on asymmetrically labeled proteins presented here enable us to map the transient 
interactions between these two membrane proteins. Importantly, all the spectroscopic 
measurements were carried out in lipid membranes that accurately mimic the natural 
bilayer. We found that PLN conformational equilibrium persists in the presence of 
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SERCA, which upon binding shifts the pre-existing conformational equilibrium towards 
the excited state of PLN. The positioning of domain Ia differs from the predicted models 
(13, 24), with the unfolded domain Ia reaching out and binding the cytoplasmic region of 
SERCA close to Cys 674 and Cys 344 as well as Cys 364 (Figure 4). In the Toyoshima 
model, Tyr6 and Leu7 residues are approximately 31 and 29 Å away from Cys 674.(13) 
In contrast, the PRE data show that the Tyr6ε1 and Leu7 δ2 resonances are almost 
completely quenched by the spin-label at Cys 674 of SERCA (Figure 4B), probing 
significantly shorter distances. Importantly, domain Ia does not ‘fold upon binding’, as 
previously reported; rather, it remains in an unfolded and dynamic conformation in the 
bound form, as demonstrated by the 13C chemical shift index probed by rINEPT 
experiments. In contrast, the T state of domain Ia remains largely unperturbed by 
SERCA, but interacts strongly with the membrane bilayer (Figure 6). The SERCA/PLN 
complex exemplifies transient, low-affinity encounter complexes (‘fuzzy complexes’) (41, 
42) that been found in several signaling membrane protein complexes. (43) For the 
SERCA/PLN complex, we can speculate that the presence of the conformational 
equilibrium explain the reversibility of the inhibitory action to enable cyclic translocation 
of Ca2+ ions, contributing to the coupled cardiac contraction and relaxation processes. 
The presence of PLN conformational equilibrium within the SERCA/PLN complex was 
not apparent in the previous solid-state NMR studies, which were performed in a 
temperature range of 235-270K.(24) Under these conditions, PLN populates 
predominantly the helical T state and the R state is virtually invisible. (23) In this study, 
we covered a range of temperatures close to the physiological conditions for SERCA 
function (277-293K), where NMR and EPR spectroscopy detect both the T and R states 
(22, 23).  
 
7.2.6 Excited state control and physiological window of SERCA regulation 
Based on our findings and previous studies, we propose that the equilibrium between 
the T and R state corresponds to the inhibitory and non-inhibitory states of PLN that 
determine SERCA’s physiological window of inhibition (Figure 7A) (44). In the T state, 
PLN interacts with SERCA only via the TM domain with domain Ia laying on the surface 
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of the lipid bilayer. In the R state, the TM domain of PLN is still bound to SERCA (as 
supported by methyl chemical shifts (Figure 1) and fluorescence studies (45)), and 
domain Ia interacts with the P and N domains of SERCA. According to this model, the 
cytoplasmic domain Ia would reduce the inhibitory potency of PLN, which is further 
reduced upon phosphorylation. To support our conclusions, we co-reconstituted SERCA 
with a truncated version of PLNAFA, corresponding to domains Ib and II ( AFAPLN 5223− ) and 
analyzed its function using coupled enzyme assays. As predicted by our model, the 
deletion of the regulatory domain Ia resulted in a more inhibitory species than full length 
PLNAFA. (Figure 7B,C). Furthermore, phosphorylation of PLNAFA at Ser 16 (PLNpS16AFA) 
completely reverses inhibition of SERCA (22, 23, 28).  
From the physiological window model, it emerges that PLN does not work as a simple 
on/off switch for Ca2+ translocation; rather its conformational equilibrium exerts a gradual 
control (‘physiological rheostat’) on SERCA activity. If SERCA’s apparent Ca2+ affinity 
exceeds the physiological window, the heart muscle enters a pathological state, leading 
to cardiomyopathy. (46) An analogous situation occurs if SERCA’s apparent Ca2+ affinity 
is drastically reduced. In this scenario, the correct balance between T and R state 
ensures that SERCA inhibition occurs within the physiological window. PLN 
phosphorylation at Ser16 by protein kinase A skews the conformational ensemble 
toward the excited state, increasing SERCA’s apparent Ca2+ affinity, and augmenting the 
contractility within the physiological window. In contrast, aberrant or lack of PLN 
phosphorylation causes SERCA’s activity to be outside the physiological window, 
degenerating Ca2+ handling (47, 48). The conformational ensemble model of SERCA 
regulation by PLN fully explains our recent structural-dynamic-function correlations. In 
fact, we found that by promoting PLN R state, it is possible to augment SERCA function. 
(21, 28). Specifically, we reported that PLN point mutations inducing membrane 
detachment or unfolding of domain Ia decrease SERCA inhibition, with an effect similar 
to phosphorylation. Controlling Ca2+ trafficking in cardiomyocytes is emerging as a new 
possible avenue to treat heart failure (3, 49-52). In addition to SERCA overexpression 
(51), Ca2+ transport can be augmented by engineering loss-of-function (i.e., dominant-
negative) mutants of PLN (49). The rational design of dominant-negative mutants of PLN 
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will be possible by engineering mutations that bias PLN conformational equilibrium 
toward the excited state.  
In conclusion, we used MAS NMR and PRE effects to map the interactions between 
SERCA and PLN in a dynamic complex. We found that the ensemble of conformations 
(ground and excited states), rather than one unique state of PLN, contributes to SERCA 
regulation. Unlike previously proposed models, we found that PLN cytoplasmic domain 
binds SERCA in an unfolded conformation, which forms transient interactions with both 
P and N domains of the ATPase. The presence of PLN conformational equilibrium 
between a fully inhibitory T state and a non-inhibitory R state underscores an excited 
state control of PLN over SERCA function. At the same time, these results explain why 
the promotion of the R state via point mutations generates loss-of-function variants of 
PLN. These mutants are ideal candidates for modulating SERCA function and represent 
a possible new avenue for protein therapy to reverse heart failure by fine tuning Ca2+ 
transport. Finally, we point out that the analysis of membrane protein-protein complexes 
is particularly challenging for the current approaches of structural biology (53, 54). Our 
approach involving multiple PRE mapping (enzyme-inhibitor, inhibitor-enzyme, inhibitor-
lipid, lipid-inhibitor) used for SERCA/PLNAFA complex is a powerful method to define the 
topology and map the interactions and conformational equilibrium of membrane protein 
complexes in their native lipid environment.  
 
7.3 Experimental details 
All unlabeled lipids were purchased from Avanti Polar Lipids (Alabaster, AL). Spin 
labeled sl-PE lipid was synthesized by attaching a TEMPO spin label to the head groups 
of PE lipids (see Supplementary Information). SERCA Ia was purified from hind-leg 
rabbit skeletal muscle as previously described, eluting the protein either in C12E8 (55) or 
DPC (19). Recombinant PLNAFA was expressed and purified according to Buck et al. (33) 
with uniform 13C,15N labeling or with amino acid specific labeling achieved by utilizing 
reverse labeling schemes (23, 56).  Synthesis of PLNAFA and AFAPLN 5223−  was done using a 
microwave synthesizer (CEM) as described elsewhere (22, 23, 25). sl-PLNAFA was 
produced as previously described (57). All PLNAFA preparations were tested for inhibitory 
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activity on SERCA using a coupled-enzyme assay as described previously (28, 39). 
MAS samples were prepared by reconsitituting SERCA and PLNAFA in lipid vesicles (see 
Supplementary Information for details). The final sample contained >60% bulk water with 
a lipid:SERCA:PLN molar ratio of 150:1:1. MAS NMR experiments were performed on 
Varian (VNMRS) spectrometers operating at proton frequencies of 600 and 700 MHz 
and equipped with 1H/13C 3.2 mm BioMAS Varian probes. 
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Figure 1. Intramembrane interactions between PLN and SERCA. A) Methyl group 
chemical shift perturbations in the PLN TM domain measured as ∆δ13C =δ13C+SERCA - δ13C-
SERCA. The inset shows the methyl region of a single quantum double quantum 
correlation spectrum of 13C N34,F35,A36,L37,I38 PLNAFA free (black) and in complex 
with SERCA (pink). B) Transmembrane region of the previously proposed model for the 
SERCA/PLN interaction. (13)  PLN residues with large chemical shift perturbations are 
indicated in the figure.  Coordinates of the complex were generously provided by D. H. 
Maclennan and C. Toyoshima. 
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Figure 2. T and R states of PLN in the presence of SERCA. A.) Structures of T and R 
states of PLNAFA, respectively. B.) Portion of the [13C,13C]-DARR spectrum showing Leu7 
Cα-Cδ correlations in the absence (top) and presence (bottom) of SERCA. Blue and red 
shaded regions indicate helical and coil regions of Leu Cα. C.) Histograms showing Cα-
Cβ chemical shift index (CSI) for R and T states of PLN in complex with SERCA. The 
CSI was calculated as δ13Cα−δ13Cβ−(δ13Cα,RC−δ13Cβ,RC), where RC refers to the random coil 
chemical shifts. (58) For residues in domain Ib and II and residues E2, S16, T17, I18 and 
E19 in domain Ia the peaks corresponding to R and T states are not resolved.  
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Figure 3. PREs effects from SERCAC674-sl to PLNAFA A.) [13C,13C]-DARR spectra of 13C 
and 15N selectively labeled PLNAFA at Val4, Leu7, Ala11, Ile12, Ala15, Ile18, (PLNAFA6cyt) 
in complex with SERCA in the absence and presence of TEMPO spin label at Cys 674. 
B) Zoom-in of the [13C,13C]-DARR spectra showing Cα-Cβ and Cα-Cδ correlations for Ala 
11 and Leu 7 corresponding to the T and R states. C) Plot of the relative peak intensities 
(IR/IT) for T and R state resonances for selected residues obtained in the presence and 
absence of the spin label on SERCA. 
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Figure 4. PRE effects on domain Ia of PLN. A) Methyl region of 13C-1H rINEPT spectra in 
the presence and absence of TEMPO at Cys674 of SERCA. Lipid peaks are marked 
with asterisks. B) Intensity retention plot for residues in domain Ia probed by rINEPT 
experiments. I and Io are the peak intensities in the presence and absence of the spin 
label, respectively. Error bars reflect the signal-to-noise in the spectra. Resonances 
broadened beyond detection are marked with asterisks. C) Mapping of the PRE onto 
PLN structure in the R state. PREs from C674SL and C344/364SL are colored in red 
and blue, respectively; while resonances unaffected are colored in yellow.  The dashed 
box highlights resonances that are broadened out beyond detection. 
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Figure 5. PRE effects from spin labeled PLN on methyl-labeled SERCA. A) [1H,13C]-
HSQC spectrum of 13C-MTC-SERCA in DPC micelles. B) Location of the cysteine 
residues in the cytoplasmic domain of SERCA (PDB ID: 1IWO). C) CP spectra (top) and 
water-edited CP spectra (bottom) of 13C-MTC-SERCA in the presence of PLNAFA-sl 
acquired before and after addition of ascorbate. The additional peaks in the spectra 
correspond to the natural abundance 13C resonances of lipids and proteins.  
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Figure 6. Lipid association of PLN domain Ia determined by PRE effect. A) Top: 
chemical structure and nomenclature of DOPC; bottom: PRE effects on PC/PE/PA lipid 
resonances from PLNAFA-sl in complex with SERCA. The bar labeled “Glycerol” 
corresponds to the PRE effect of PLNAFA-sl on the free glycerol present in the buffer 
(NMR buffer contains 2.5% glycerol to prevent loss of SERCA activity) I and I0 
correspond to the peak intensities before and after addition of 10 mM ascorbate, 
respectively. B) Chemical structure of the synthesized PEsl. C.) Representative regions 
of [13C, 13C]-DARR spectra of 13C,15N Val4, Leu7, Ile12 labeled PLNAFA in complex with 
SERCA before and after addition of 10 mM DTT. E.) Average PRE values for V4, L7 and 
I12 in domain Ia. Error bars show the standard error of three resonances from each 
indicated residue.    
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Figure 7. Functional effect of domain Ia interaction with SERCA. A.) Correlation between 
the conformational equilibrium of PLN and the inhibitory state of SERCA B.) 
Representative SERCA activity curves in the absence of regulator (ctrl) and in the 
presence of a 5-fold molar excess of PLNAFA, PLNpS16AFA and AFAPLN 5223− . C.) Averaged 
inhibitory activity for PLN variants. ∆pKCa was calculated as pKCa,SERCA- pKCa,PLN, error 
bars represent the standard errors of four independent reconstitutions. 
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7.5 Supporting information 
7.5.1 Synthesis of spin-labeled lipid (PEsl) 
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) (8.2 mL, of a 2 % w/v solution 
in CHCl3) (0.22 mmol, 164 mg) was placed in a 25 mL round bottom flask and the CHCl3 
was removed under a stream of N2. Dichloromethane (10 mL) was added and removed 
in vacuo to remove possible traces of ethanol. A solution of EDC (0.22 mmol, 38.4 mg) 
with 4-carboxy-TEMPO (0.22 mmol, 40.0 mg) in dichloromethane (1.0 mL) was added to 
DOPE lipids dissolved in dichloromethane (9 mL). DIEA (0.22 mmol, 39.0 uL) was added 
to the mixture and the reaction was stirred for ~48 h. The dichloromethane was removed 
in vacuo and the residue was taken up in ethyl acetate (25 mL) and transferred to a 
separatory funnel. The solution was washed with 1N HCl (3 x 15 mL). An emulsion 
formed that was partially broken by addition of small amounts of MeOH and saturated 
NaCl solution. The emulsion was mainly found in the aqueous phase and could be 
extracted without loss of product. The organic phase was dried over MgSO4 and 
concentrated using a vacuum pump. The crude product was analyzed by TLC (Rf = 0.71, 
CHCl3/MeOH/H2O, 65:31:4). The final yield was 118 mg, 58 %.  Deconvoluted ESI-MS, 
calc.: 925.7, found: 925.7. 
7.5.2 FRET experiments  
SERCA was incubated for 30 min by a 20-fold excess of 5-((((1-
iodoacetyl)amino)ethyl)amino)naphthalene-1-sulfonic acid (IAEDANS) (Invitrogen) to 
attach the fluorescent AEDANS group to Cys 674 (32). The label-ing extent was 
determined by absorbance at 334 nm (εAEDANS= 6100 M-1 cm-1) (59). To introduce an 
acceptor for energy transfer, AFA-PLN was incubated in 1% SDS, 100 mM NaHCO3 at 
pH 9 for 16 h with a 20-fold excess of 4-((4-(dimethylamino)phenyl)azo)benzoic acid, 
succinimidyl ester (dabcyl-SE), and free label was removed using reverse-phase HPLC. 
Labeling efficiency was determined by electrospray ionization mass spectrometry (ESI-
MS). SERCAAEDANS was co-reconstituted with PLNDab at molar ratios of 1:0, 1:1 and 1:2 
at a 700:1 lipid:SERCAAEDANS ratio. Steady-state fluorescence was measured with a 
Varian Eclipse Fluorimeter, using an excitation wavelength of 351 nm (20 nm bandwidth) 
and emission wavelengths between 400 and 600 nm.  
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Figure S1. A.) Ca2+-dependent ATPase activity of SERCA/PLN complex in Egg 
PC/PE/PA lipid vesicles measured using a coupled enzyme assay. B.) FRET between 
SERCAAEDANS and PLNDab-AFA. FRET was measured as a decreased in SERCAAEDANS 
(donor) steady state fluoresence due to the presence of PLNDab-AFA (acceptor).    
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Figure S2. Representative spectra for assignment of PLNAFA in complex with SERCA 
from synthetically and recombinantly labeled samples. 13C-labeled residues are 
indicated in the spectra. 
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Figure S3. Effects of SERCA binding on PLN resonances for domain Ia and the loop. 
The Cα chemical shifts were obtained from  [13C,13C]-DARR experiments in egg 
PC/PE/PA bilayers in a 8:1:1 molar ratio. The chemical shift perturbations (CSP) are 
differences between the chemical shifts in the presence and absence of SERCA (δ+SERCA 
- δ-SERCA).  
  
207 
 
 
 
Figure S4. Regions of the [13C,13C]-DARR spectra of the SERCA/PLNAFA complex at 20 
and -20 oC. Dotted circles highlight the position of Ile and Ala T state peaks, which are 
not detectable or significantly attenuated at 20°C.   
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Figure S5. Schematic of the spin labeling schemes used to probe the topology and the 
conformational equilibrium of the SERCA/PLN complex. PREs measured by NMR 
experiments included SERCAC674-sl and SERCAC344/364-sl to 13C labeled PLN (orange 
arrows), PLNL7-sl to 13C MTC-SERCA (purple arrow), PLNL7-sl to lipid (13C natural 
abundance) (blue arrow), and PEsl to 15N, 13C labeled PLN (cyan arrow). 
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Figure S6. [13C,13C]-DARR spectra of u13C-PLN in complex with SERCAC344C364-sl before 
(top) and after (bottom) addition of 10 mM DTT. Experiments were acquired with a 6 ms 
DARR mixing time. 
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Figure S7. [1H,13C]-rINEPT spectra of PLN in complex with SERCAC344C364-sl before 
(bottom) and after (top) addition of 10 mM DTT.  
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Figure S8. Comparison of SERCA activity before and after methylation at the cysteine 
residues. The activity was normalized to an unlabeled control. Error bars represent the 
standard deviation of three independent measurements.  
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Figure S9. Spin labeled PE-sl lipid.   
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Figure S10. Intensity retention of the 13C resonances of PC/PE/PA lipid bilayers (8:1:1 
molar ratio) doped with PEsl (2% w/w) obtained from [13C,13C]-rINEPT experiments at 
20°C before (I) and after (I0) addition of 10 mM DTT. 
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Chapter 8 - Tuning the structural coupling between the 
transmembrane and cytoplasmic domains of phospholamban to 
control sarcoplasmic reticulum Ca(2+)-ATPase (SERCA) 
function 
 
Reprinted with permission from: 
Ha KN, Gustavsson M, Veglia G Tuning the structural coupling between the 
transmembrane and cytoplasmic domains of phospholamban to control sarcoplasmic 
reticulum Ca(2+)-ATPase (SERCA) function J Muscle Res Cell Motil. 2012 In press  
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Ca2+ ions signal muscle contraction and relaxation, coupling the membrane action 
potential and the mechanical contraction of muscle (1, 2). The interplay between the 
sarcoplasmic reticulum ATPase (SERCA) and phospholamban (PLN) is crucial to 
intracellular Ca2+ cycling and proper cardiac muscle contraction and relaxation, and 
dysfunction in their protein–protein interactions have been implicated in cardiac disease 
(3). SERCA is a 110 kDa integral membrane P-type ATPase which utilizes ATP 
hydrolysis to transport Ca2+ into the SR (4). SERCA is responsible for 70 % of the 
calcium reuptake during diastole in human cardiomyocytes (4). SERCA comprises a 
large cytoplasmic domain that includes the actuator domain, the phosphorylation 
domain, and a nucleotide binding domain, along with ten transmembrane helices 
constituting the Ca2+ transport pathway (5). The cardiac isoform of SERCA (SERCA2a) 
is regulated by PLN, a single-pass membrane protein that binds the enzyme via 
intramembrane interactions, reducing its apparent Ca2+ affinity (6-8). β-Adrenergic 
stimulation unleashes protein kinase A (PKA) that phosphorylates PLN at Ser16, 
reversing its inhibition of SERCA and augmenting the diastolic phase (9). 
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8.1 Introduction 
PLN is a 52-amino acid integral membrane protein which is comprised of three structural 
domains (10-12) that are further subdivided into four dynamic domains (cytoplasm: 
domain Ia (residues 1–16), loop (residues 17–22), domain Ib (residues 23–30); 
transmembrane: domain II (residues 31–52)) (10, 11, 13) (Figure 1). The 
transmembrane helix of PLN is the principle structural domain that inhibits SERCA (14, 
15), while the regulatory phosphorylation Ser16 site, which determines the inhibitory or 
non-inhibitory state, lies in the cytoplasmic helix (16). PLN can populate several 
conformational states, and domain Ia and Ib participate in folding/unfolding equilibria, 
which are important for SERCA inhibition as well as recognition by PKA (17-20). The 
loop connecting these two domains also has functional relevance, in particular the Pro21 
residue that lies in the center of the loop. Squier and co-workers reported that mutation 
of Pro21 to Ala in a monomeric cysteine-null background led to partial inhibition of 
SERCA, increase in overall helicity, decreased dynamics at the C-terminus, and local 
structural changes at the loop leading to diminished solvent accessibility (21). 
Additionally, our group found that the SERCA inhibition and binding could be tuned 
modulating the conformational dynamics of the loop through mutation in the Pro21 site, 
via a so-called dynamic rheostat (22). Our studies identified the mutant species AFA-
PLNP21G to be a possible candidate for treatment of heart failure by delivery via rAAV 
gene therapy. AFA-PLNP21G was found to have the same structural dynamics and 
functional characteristics as PLNS16E, a PLN pseudo-phosphorylated mutant already 
proven to be successful in reversing heart failure in large and small animal models by 
Chien and coworkers ((23, 24). 
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Figure. 1 Hybrid solution and solid state NMR structures for pentameric wt-PLN (PDB 
2KYV, left) and monomeric AFA-PLN (PDB 2KB7, center) and structure of the R state of 
PLN determined from solution NMR and molecular dynamics simulations. The four 
dynamic domains of PLN are color-coded: green domain Ia, orange loop, red domain 
Ib, blue domain II. Sites of loop mutations are rendered in the space-filling motif. 
Naturally occurring mutations in PLN have also been linked to familial forms of 
cardiomyopathy: R9C (25), R9L and R9H (26), R14del (27), and L39stop (28). PLN has 
also become a target for gene therapy (23, 24, 29), namely by delivering PLN mutants 
which decrease SERCA inhibition. The challenge remains in how to rationally design 
PLN mutants with tunable effects on SERCA to account for the diversity of patient 
population and the various manifestations of heart failure (30). 
Numerous mutagenesis studies of PLN have been carried out by the MacLennan, 
Jones, and Young groups, offering invaluable insight by identifying residues crucial to 
PLN’s inhibitory ability (31-33). Although these studies served as a crucial starting point 
to understanding the effect of point mutations in PLN have on SERCA activity, they often 
did not identify the reasons for observed functional effects, i.e., whether the mutation 
induced a change to structural dynamics, altered the binding surface, decreased SERCA 
binding, etc. The data clearly demonstrate that the transmembrane domain is Janus-
faced, with one side of the helix primarily involved in oligomerization and the other side 
binding to SERCA. Mutagenesis studies show that domain Ia and the loop are the 
optimum targets for designing loss-of-function (LOF) mutants. In contrast, mutations in 
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domain Ib and domain II yield varying results, but all known gain-of-function (GOF) and 
super-inhibitors are concentrated in those two domains. 
The rationale of this study is to build on our previous success tuning the structural 
dynamics of PLN to control SERCA function by introducing a series of glycine residues 
to the loop domain. Our original hypothesis was that an increase in conformational 
dynamics in the loop would interrupt the structural coupling between the transmembrane 
helix, which is primarily responsible for SERCA inhibition, and the cytoplasmic helix, 
which contains the phosphorylation sites that dictate the inhibition state. To test this 
hypothesis, we sought to introduce single Gly mutations at the M20 site and Q22 site to 
investigate whether the LOF rendered by the P21G mutation was site-specific (Figure 
2). Secondly, we determined the SERCA inhibition of the phosphorylated species to see 
if post-translational control of these single Gly-mutants of PLN still remains intact, a 
property which has been suggested to be crucial for therapeutic success (22). Thirdly, 
we expanded the Gly mutations into double and triple mutations: AFA-PLNM20G P21G and 
AFA-PLNM20G P21G Q22G. To characterize the conformational dynamics of the various 
mutants and correlate with their functional state, we used nuclear magnetic resonance 
(NMR) spectroscopy that enables one to probe molecular motions of proteins at the 
atomic level (34). 
 
Figure 2. Primary structures of glycine mutants in this study. The secondary structure 
motifs of PLN (helix, loop, helix) and dynamics domains are displayed above. Mutations 
are highlighted in the loop region 
Our results suggest that the structural dynamics of the glycine mutants can be tuned, 
resulting in varying degrees of fast timescale dynamics and degrees of SERCA 
inhibition. However, species where the mutation increased the conformational dynamics 
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past the threshold set by the phosphorylated species behave as the transmembrane 
helix alone. The mutants represent new templates for rational design of protein therapies 
using gene transfer approaches, modifying the effects of an inhibitor to control enzyme 
function. 
8.2 Materials and methods 
8.2.1 Cloning of PLN mutants 
Primary sequences of the mutants cloned in this study are described in Figure 2. 
Cloning was performed using the Stratagene QuikChange protocol as previously 
described (22). For the AFA-PLNM20G, AFA-PLNP21G, and AFA-PLNQ22G constructs, the 
pMal-c2E-TEV-AFA-PLN plasmid was used as a parental template, which expresses a 
maltose binding protein (MBP) PLN fusion protein with a tobacco etch virus (TEV) 
protease cleavage site encoded in-between. The forward primer for the AFA-PLNM20G is 
as follows: 5′-ACC ATT GAA GGC CCG CAG CAG GCG CGC CAG AAC-3″. The 
forward primer for the AFA-PLNQ22G is as follows: 5′-ACC ATT GAA ATG CCG GGC 
CAG GCG CGC CAG AAC-3″. The forward primer for the AFA-PLNM20G P21G is as 
follows: 5′-GGC AGC ACC ATT GAA GGC GGC CAG CAG GCG CGC CAG AAC CTG-
3″. The cloning of GGG-PLN required two PCR reactions on the P21G PLN AFA 
background, first converting M20 to G and then Q22 to G. Pentameric mutants were 
cloned using the pMal-c2E-TEV-wtPLN plasmid as the parental template. PLNM20G 
P21G was cloned stepwise, using PLNP21G as the initial template. Stepwise mutagenesis 
was necessitated due to the high Tm values of primers containing codons encoding for 
glycine, because of their high GC content. After mutagenesis was confirmed from EtBr 
stained agarose gels, the PCR reaction was transformed into DH5α cells and grown on 
ampicillin-agarose plates. Subsequent colonies were grown overnight in 5 mL Luria–
Bertani media with 0.1 % ampicillin, and then spun down on a tabletop centrifuge at 
13,000 rpm. The remaining pellet was resuspended and the plasmid was extracted from 
the pellet using the Qiagen Quick-Spin Miniprep kit. Constructs were confirmed through 
sequencing at the University of Minnesota Biomedical Genomics Center. Correct target 
constructs were then transformed into BL21 (DE3) Escherichia coli cells. 
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8.2.2 Protein preparations and ATPase activity assays 
Protein expression and purification of all constructs were performed as previously 
described (8, 35). Phosphorylation of PLN samples at Ser16 was performed as 
previously described (17, 22, 36) using recombinantly expressed protein kinase A 
purified by an established protocol (37). Phosphorylation was confirmed by a band shift 
in the SDS-PAGE, and by MALDI-TOF mass spectrometry. The degree of SERCA 
inhibition by PLN analogs was determined using a coupled enzyme assay correlating the 
depletion in NADH absorbance to ATPase activity as previously described (22, 38). 
SERCA inhibition was measured in reconstituted lipid samples according to Reddy et al. 
(39). PLN variants were co-reconstituted with purified SERCA in lipid bilayer membranes 
(DOPC:DOPE, 4:1) at molar ratios of 10:1 PLN:SERCA and 700:1 lipids:SERCA. The 
calcium dependence of the ATPase activity was measured at 37 °C using a coupled 
enzyme assay, monitoring the consumption of NADH by the decrease in absorbance at 
340 nm using a Spectromax microplate reader (Molecular Devices). Initial rate of 
SERCA (V) was measured as a function of calcium concentration (pCa), and data was fit 
to the Hill equation (39). 
8.2.3 NMR studies 
Unless otherwise noted, NMR samples were prepared with a buffer containing 20 mM 
Na2HPO4 (J.T. Baker), 120 mM NaCl (Malinkrodt), 0.1 % NaN3, and 300 mM 
dodecylphosphocholine (DPC) (Avertec). Lyophilized PLN was weighed and added in 
increments to 300 μL buffer until the sample reached an approximate concentration of 
1–1.5 mM protein. After addition of HPLC purified protein, all samples were adjusted to 
pH 6.0 with dilute NaOH to neutralize residual trifluoroacetic acid remaining in the 
protein powder. All [1H, 15N] heteronuclear single quantum coherence (HSQC) spectra 
were collected on a Varian spectrometer operating at a 1H Larmor frequency of 
600 MHz. Sample quality was assessed by signal-to-noise and resolution in the 2D 
spectrum with between 32 and 64 increments in the indirect dimension. Heteronuclear 
steady-state NOE spectra were collected as previously described (13, 22). Briefly, two 
spectra were collected using the established pulse sequence based on Farrow et al. (40) 
with a spectral width of 6,000 Hz in the indirect proton dimension and 1500 Hz in the 
indirect nitrogen dimension. 128 scans were done with 64 points in the indirect 
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dimension. The saturation spectrum was collected with a 3 s presaturation period on the 
proton frequency. Peak intensities were analyzed using NMRView5 software (41). 
8.3 Results 
Single Gly mutations were successfully cloned on a monomeric AFA-PLN background, 
yielding AFA-PLNM20G, AFA-PLNP21G, and AFA-PLNQ22G. The species were expressed 
in E. coli, and subsequently isolated by affinity and HPLC chromatography. SERCA 
activity measurements served as the initial screen to assess the effects of the mutations. 
Functional assays were performed with SERCA reconstituted in lipids alone as the 
negative control, and also in the presence of AFA-PLN or the super-inhibitor mutant 
AFA-PLNN27A as a positive control, giving a consistent ΔpKCa shift of 0.3 and 0.5 pCa 
units, respectively. Figure 3a displays a representative normalized ATPase activity 
curve which yields the pKCa shifts. Figure 3b shows the average ΔpKCa values for the 
three mutants as compared to the control AFA-PLN (filled bars). Compared to the AFA-
PLN species, the AFA-PLNM20G, AFA-PLNP21G, and AFA-PLNQ22G analogs reduced the 
PLN inhibition by approximately 0.1 pCa units. Therefore, irrespective of their positioning 
in the dynamic loop, the single site mutations manifested an LOF character. The extent 
of this effect is variable, with a gradient of SERCA inhibition ranging from ΔpKCa of 
0.23 ± 0.01 for M20G to ΔpKCa of 0.16 ± 0.02 for Q22G. Remarkably, previous studies 
showed that Ala mutations of M20 or Q22 do not render LOF characteristics (4, 31). 
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Figure 3. Functional measurements of SERCA in reconstituted lipids in the presence of 
PLN Gly loop mutants. a. Coupled enzyme activity assay measurement of SERCA in 
absence (black circles) and presence of PLN species.Left panel unphosphorylated 
(closed green triangles) and phosphorylated (open green triangles) monomeric M20G 
P21G AFA-PLN. Specific activity of reconstituted SERCA averages 2.9 ± 1.4 IU as 
reported in Gustavsson et al. (2011b). Right panel wt-PLN (blue circles) and M20G 
P21G mutant on pentamer background (PLNM20GP21G, green triangles). As in the 
monomeric conditions, the M20G P21G mutation in pentameric conditions is still severe 
LOF. b. Histogram of ΔpKCa measurements of all PLN species. Error bars are indicative 
of standard deviation from averaged values of ΔpKCa. 
To test their propensity to be phosphorylated by protein kinase A (PKA-C) and thereby 
reverse SERCA inhibition, the Gly mutants of PLN were incubated with catalytic 
amounts of the kinase and analyzed by gel shift assays. We found that all of the single 
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Gly PLN mutants were quantitatively phosphorylated in vitro by recombinant protein 
kinase A. Importantly, SERCA functional assays revealed that phosphorylation at Ser16 
for each single Gly mutant was sufficient to reverse inhibition (Figure 3b, open bars). 
To investigate whether the combination of two or more Gly mutations would increase the 
LOF effect, we cloned a double mutant, AFA-PLNM20G P21G, and a triple Gly mutant, AFA-
PLNM20G P21G Q22G. We found that (1) the AFA-PLNM20G P21G species was a complete LOF 
mutant, and (2) AFA-PLNM20G P21G Q22G completely recovers the inhibitory function 
(Figure 3b). Based on these results, we speculate that combining the Gly at position 
M20 and P21 conferred even stronger LOF behavior, creating an additive effect in the 
double mutant. In contrast, a triple mutation eliminated the structural coupling between 
the cytoplasmic and transmembrane helix, resulting in a species that is similar to the 
transmembrane helix alone (14). Electrophoretic gel shift assays show that incubation of 
PKA with these double and triple mutants does result in a gel shift typically observed for 
the phosphorylated species, consistent with quantitative phosphorylation. These results 
were confirmed by mass spectrometry. The cytoplasmic helix contains the 
phosphorylation site, while the transmembrane helix is the principle domain responsible 
for inhibition. We sought to test the hypothesis that phosphorylation of the Gly mutants 
would not reverse the effects of inhibition, due to the possible breaking of the 
conformational coupling between these domains. Our results indicate that 
phosphorylation does reverse the effects of inhibition for PLNM20G P21G and also PLNM20G 
P21G Q22G. Figure 3b shows the averaged SERCA activity measurements of several 
different samples of unphosphorylated (closed bars) and phosphorylated (open bars) of 
the double and triple glycine AFA-PLN loop mutations. Values of ΔpKCa are reported in 
Table 1. 
Table 1. ΔpKCa values for all PLN species averaged over six measurements 
 ΔpKCa ΔKCa, μM 
AFA-PLN 0.31 ± 0.02 0.46 ± 0.02 
pSer16-AFA-PLN 0.025 ± 0.012 0.064 ± 0.037 
AFA-PLNM20G 0.23 ± 0.01 0.11 ± 0.09 
pSer16-AFA-PLNM20G 0.031 ± 0.018 0.012 ± 0.037 
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ΔpKCa values are calculated from as the difference in pKCa values from the fits of the SERCA 
activity curves in the absence and presence of PLN 
 
A critical issue in the design of possible therapeutic mutations for delivery through gene 
therapy is the effect the species will have in vitro versus in vivo, particularly when 
dealing with possible functional effects that are the result of unknown protein–protein 
interactions and also interactions with the endogenous species. Hence, we studied the 
function of mutant with the most LOF character, AFA-PLNM20G P21G by comparison to the 
endogenous wild-type background sequence in order to determine whether the 
functional results may be due to altered oligomeric states. Functional results with 
SERCA in the presence of the PLNM20G P21G mutant show that this is a strong LOF 
mutant, with a ΔpKCa of 0.095 ± 0.021 (Figure 3a, right), confirming that the M20G P21G 
mutation results in a LOF species regardless of its monomeric or pentameric state. 
To characterize the structural features of the mutations, AFA-PLNM20G, AFA-PLNM20G 
P21G, and AFA-PLNM20G P21G Q22G were expressed in 15N isotopically labeled media, 
purified, and reconstituted in DPC micelles. The 1H–15N HSQC spectra of all three 
mutants were well resolved (Figure S1a) and assigned using 15N edited NOESY-HSQC 
experiments at short (70 ms) mixing times to identify short-range NOEs. Amide 
resonance assignments were correlated to the 1H–15N HSQC assignment for AFA-PLN 
AFA-PLNP21G 0.18 ± 0.01 0.18 ± 0.03 
pSer16-AFA-PLNP21G 0.042 ± 0.013 0.036 ± 0.038 
AFA-PLNQ22G 0.16 ± 0.02 0.053 ± 0.078 
pSer16-AFA-PLNQ22G 0.068 ± 0.014 0.020 ± 0.055 
AFA-PLNM20G P21G 0.047 ± 0.009 0.048 ± 0.024 
pSer16-AFA-PLNM20G P21G 0.015 ± 0.010 0.019 ± 0.022 
AFA-PLNM20G P21G Q22G 0.33 ± 0.01 0.29 ± 0.02 
pSer16-AFA-PLNM20G P21G Q22G 0.090 ± 0.017 0.047 ± 0.019 
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(Figure S1b). Most changes are localized near the mutation site. However, some distal 
changes, especially in domain Ib, are detected, specifically residues Arg25 and Asn27. 
The structural dynamics of these mutations were characterized using nuclear spin 
relaxation measurements (34). R1, R2, and NOE values were measured for AFA-
PLNM20G, AFA-PLNM20G P21G, and AFA-PLNM20G P21G Q22G (Figure S2) in DPC micelles. 
While the structure is largely intact, as evidenced by only minor perturbations in the 1H–
15N HSQC spectrum compared to AFA-PLN, we do observe an increase in the fast (ps–
ns) conformational dynamics of the backbone for all of the mutants examined. Increased 
motions are detected in the intervening loop and domains Ia and Ib. While domain Ib and 
the loop of the Gly mutants have conformational dynamics similar to that of pSer16 AFA-
PLN, the phosphorylated species is significantly more mobile in domain Ia. Thus, 
introduction of the single or multiple Gly mutants change only the local motion and does 
not mimic the conformational dynamics found in the phosphorylated species (pSer16-
AFA-PLN). A possible explanation is that the negatively charged phosphoserine 
interacts with the positively charged side chains of Arg13 and 14, forming transient salt 
bridges that affect the folding and dynamics of the entire cytoplasmic regions including 
domain Ia. In fact, the presence of the phosphoryl group shifts the conformational 
equilibrium of domain Ia of PLN from a folded (T state) to an unfolded (R state) (17, 19). 
The 15N relaxation data do not support a significant T to R state transition upon Gly 
mutations. The latter was confirmed by 1H–13C HSQC experiments that image the side 
chains bearing methyl groups. Indeed, we found that the Gly mutations in the loop do not 
affect the T to R state equilibrium substantially, i.e. we observed only minor chemical 
shift changes for the domain Ia methyl groups (Figure S3). These findings indicate that 
the LOF character of the Gly mutants is not directly related to the T/R equilibrium of 
domain Ia, and that the Gly mutations in the intervening loop cause a local increase in 
backbone flexibility. 
8.4 Discussion 
We sought to expand on previously published results on tuning the function of SERCA 
by altering the conformational dynamics of the loop domain in PLN (22). Our previous 
results showed that AFA-PLNP21G displayed similar structural dynamics to the pseudo-
phosphorylated species PLNS16E, which has shown promise in reversing heart failure in 
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animal models upon delivery via rAAV-mediated gene therapy (29). In addition to 
mimicking the structural dynamics of the pseudo-phosphorylated form, AFA-
PLNP21G also has the additional characteristic of being able to be post-translationally 
modified by phosphorylation at Ser16 by PKA, a regulatory feature which is crucial for 
maintaining Ca2+ homeostasis (42). 
The functional results of AFA-PLNM20G, AFA-PLNP21G, and AFA-PLNQ22G (Figure 3, 
Table 1) show that introduction of the Gly residue did not need to be specifically 
positioned at Pro 21 in order to have a LOF effect. Additionally, the in vitro 
phosphorylation results of the three species suggest that these mutants may still also be 
post-translationally modified in vivo. Remarkably, similar alanine mutations at M20 and 
Q22 did not show appreciable differences in SERCA inhibition (31, 43), demonstrating 
the sensitivity of SERCA activity on the PLN sequence. While all of the mutants resulted 
in LOF characteristics, they inhibited SERCA to different degrees, resulting in a gradient 
of function. This is an important factor when designing mutations to alter contractility. 
While introducing PLN mutants which are completely LOF would increase SERCA 
activity and activate diastole in the short term, constitutive activation of SERCA is known 
to promote hypertrophy (44) and a PLN null genotype is found in humans to result in 
heart failure (26, 28). Hence, development of mutations of PLN for use in gene therapy 
would necessitate mutants which sampled a wide array of levels in SERCA inhibition. 
The results of AFA-PLN M20G P21G show that the LOF effects for the M20 and P21 site 
were additive, resulting in the least inhibitory mutant of this study. Phosphorylation of this 
species resulted in a ΔpKCa similar to that of pSer16 AFA-PLN. The NMR results show 
minimal differences in the average structures of the various mutants. In fact, comparison 
of the protein fingerprints ([1H,15N] HSQC spectra) of the AFA-PLNM20G P21G mutant and 
AFA-PLN show only some slight differences, especially in residues near the mutation 
site in the primary sequence. A few differences are also evident for residues located in 
the juxta membrane domain Ib (Figure 1). A map of the chemical shift changes upon 
increasing glycines in the loop did not follow the same trajectory that was seen for 
pseudo-phosphorylated mutants and the Ser16 phosphorylated species (17). Also, the 
NMR dynamic parameters (R1, R2 and heteronuclear NOE values) in domain Ia indicate 
that AFA PLNM20G P21G is significantly less dynamic than pSer16 AFA-PLN in this domain 
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(Figure S2). Still, AFA-PLNM20G P21G mimics pSer16-PLN functionally, which suggests 
that mutations in the loop leads to the reversal of SERCA inhibition by a different 
mechanism that an order-to-disorder transition of domain Ia, a mechanism that has been 
proposed for phosphorylated and pseudo-phosphorylated mutants of PLN (17). In 
contrast to domain Ia, the conformational dynamics of the loop and domain Ib of the Gly 
mutants are similar to that of pSer16 PLN and thus more mobile than AFA-PLN. Taken 
together with the chemical shift changes in domain Ib, this alteration of domain Ib 
conformational dynamics may be responsible for the functional effects associated with 
the Gly mutations. 
Based on the data collected on these single, double, and triple Gly mutants, we 
hypothesize that the functional effects of the Gly mutations are related to a gradual 
structural uncoupling of the two helical domains of PLN: the inhibitory transmembrane 
domain and the regulatory cytoplasmic regions. A single Gly mutation increases the local 
dynamics and induces LOF character. Also, a double mutation augments the LOF 
character with concomitant increase of local dynamics. However, three sequential 
mutations cause a complete loss of the structural coupling between the regulatory 
cytoplasmic domain and the inhibitory transmembrane domain, rendering the mutant 
similar to the isolated transmembrane domain, which has an inhibitory potency similar to 
that of PLN (14). To support this hypothesis, we showed that single and double Gly 
mutants have increasing LOF character, while the inhibitory potency of the triple Gly 
mutant is virtually identical to that of AFA-PLN. 
Interestingly, AFA-PLNM20G P21G Q22G can still be phosphorylated, reversing SERCA 
inhibition. The substitution of the three Gly residues in the loop does not prevent the 
signal of phosphorylation to be relayed from PLN to SERCA to reverse its inhibition. This 
suggests that phosphorylation is a more complex event that involves both structural and 
electrostatic changes in both binding partners, with a possible allosteric mechanism 
where interactions of the phosphorylated domain Ia lead to changes within SERCA that 
are relayed to domain II. The latter will be resolved when atomic resolution structural 
information on the SERCA/PLN will be available. 
Although the original Ala-scanning experiments performed by (31) show Ala mutations in 
the loop region to be non-effectual on SERCA function (with the exception of P21A), Gly 
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mutations in the same region reveal that fairly conservative alterations in the loop region 
can have a significant impact on SERCA function. Figure 4 shows a structural dynamics 
and function correlation between different species of PLN, and the blue triangle 
highlights the optimum area to target when designing LOF mutants to improve cardiac 
contractility by improving SERCA function. The results of this study are promising in 
revealing the loop region as an area to target for development of therapeutic PLN 
mutants, since the phosphorylation site remains intact. The results of studying PLN 
mutations have established that for a mutant to maintain proper function: (a) it must be 
able to be phosphorylated in order to relieve inhibition, and (b) the dynamic changes 
throughout domain Ia, the loop, and domain Ib can mimic the order-to-disorder transition 
induced by phosphorylation, but they should not exceed the dynamics of pSer16 PLN. 
 
Figure 4. Stuctural dynamics-function correlation plot of PLN Gly mutants. Left axis is 
degree of SERCA inhibition, with a larger ΔpKCa indicating more SERCA inhibition. 
ΔNOE is difference in average NOE values for each PLN species in the loop and domain 
Ib (residues 17–30) from AFA-PLN. Higher values in ΔNOE indicates more fast 
dynamics for that mutant. Blue triangle highlights optimum region for designing PLN 
mutants to improve cardiac contractility. 
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Figure S1. 1H-15N HSQC spectra of AFA-PLNM20G (top left), AFA-PLNM20G P21G (top 
middle), AFAPLNM20G P21G Q22G (top right) and combined chemical shift perturbations 
between AFA-PLN and the M20Gmutant (bottom left, dark blue), M20G P21G mutant 
(bottom middle, evergreen), and M20G P21G Q22Gmutant (bottom right, lime). 
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Figure S2. Fast amide backbone dynamics measurements by solution state NMR of Gly 
PLN mutants. R1 (left), R2 (middle), and {1H-15N} steady state NOE measurements were 
done in 300 mM DPC micelles. AFAPLN (black) and pSer16-AFA-PLN (red) are plotted 
for comparison. Data for AFA-PLN and pSer16-AFAPLN are taken from Metcalfe, et. al. 
2004 and 2005 (13, 36). 
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Figure S3. Overlay of [1H-13C] HSQC spectra of AFA-PLN (black), AFA-PLNM20G (navy), 
and AFAPLNM20GP21G (dark green) in 300 mM DPC at 37 °C. 
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Chapter 9 – Conclusions and future directions 
In the last few years the field of membrane protein NMR has evolved to study larger 
systems under more native-like conditions. This has meant progressing from studies of 
single TM helices in detergent micelles or organic solvent to studies of large membrane-
bound enzymes, channels, and receptors in bicelles, lipid vesicles or nanodiscs. In my 
initial studies I characterized the single-spanning membrane protein PLN in DPC 
micelles while my later studies have focused on the complex between PLN and the 110 
kDa membrane-bound SERCA in native-like lipid bilayers. In this regard, the progression 
of my thesis has reflected the exciting development of the field.  
Chapter 2 describes the characterization of the conformational equilibrium of PLN by 
NMR and concludes that the protein populates at least four different conformational 
states (T, T’, R, and R’). Phosphorylation and pseudo-phosphorylation of PLN perturb 
the equilibrium by increasing the population of the partially unfolded R and R’ states, 
which is correlated with less efficient inhibition of SERCA. The importance of the T and 
R states is further underscored in chapter 3, where we show that the R state but not the 
T state gets phosphorylated by PKA. A limitation with the two initial studies, as well as 
the study in chapter 4 where the high resolution structure of the T state in detergent 
micelles was determined, is that all NMR experiments were conducted in detergent 
micelles or isotropic bicelles. However, SERCA activity and inhibition of PLN is 
measured in lipid bilayers so to fully understand PLN function it was crucial to acquire 
NMR experiments at the same conditions. Chapter 5 describes the characterization of 
the conformational equilibrium of PLN by NMR in lipid vesicles. Importantly, this study 
showed that the structures of T and R states are conserved in lipids even if the relative 
populations of the two states are strongly lipid-dependent. In a parallel study, described 
in chapter 6, we also found that the function of SERCA and its inhibition by PLN can be 
modulated by the lipid composition of the bilayer. Chapter 7 describes how we utilized 
the foundation of sample preparation and NMR experiments that was built through 
chapters 2-6 to determine molecular details of the SERCA/PLN and the role of the R/T 
equilibrium in SERCA regulation. Through asymmetric spin labeling of SERCA, PLN and 
the lipid bilayer, we show that the R state has transient interactions with the cytoplasmic 
P and N domains of SERCA and that the T state remains bilayer-associated. This study 
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marks an unprecedented mapping of a membrane protein complex by solid state NMR 
spectropscopy. For example, this is the first time that PREs were used to probe the 
interaction between two membrane proteins in lipid bilayers. Another important aspect of 
our SERCA/PLN studies is the prospective of translating our in vitro results into in vivo 
studies to develop potential therapies against heart failure. In chapter 8 we find that by 
targeted mutagenesis in the loop region of PLN we can control SERCA function. Since 
mutations in the loop region do not interfere with PKA phosphorylation or SERCA 
binding, these mutants could be future candidates in the therapeutic efforts to treat heart 
failure.     
From a SERCA/PLN perspective, the main conclusions from this thesis are  
• The T and R states of PLN exist in all membrane-mimicking systems but the 
populations of the two states are very sensitive to lipid composition.  
• The T/R state equilibrium of PLN is crucial to control SERCA function and for 
PKA phosphorylation and can be modulated by bilayer lipids.  
• SERCA function is strongly dependent on lipid bilayer composition and SERCA is 
activated by PE and PS lipids. 
• The cytoplasmic of PLN populates mutiple states in the SERCA/PLN complex: 
the T state is helical and bilayer associated, the R state is unfolded and 
membrane-dissociated and interacts transiently with the P and N domains of 
SERCA to form a “bound” state. 
• In the bound state, interactions with the cytoplasmic domains of SERCA relieve 
PLN’s inhibition, forming a non-inhibitory complex.  
Furthermore, our findings solidify the roles of the TM and cytoplasmic domains of PLN 
as inhibitory and regulatory modules, respectively. The regulatory cytoplasmic domain is 
transiently folded and interacts with a number of binding partners in different 
configurations. In fact, based on our data, this domain should be viewed as an 
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intrinsically disordered protein that can adapt its structure to its target of regulation. We 
have showed that this domain is unfolded in complex with both SERCA and PKA and 
helical when associated with the membrane bilayer. The cytoplasmic domain of PLN 
also interacts with HS-1–associated protein X-1 (HAX-1) (1) and A kinase anchoring 
protein 7 (AKAP7) (2). Even if the confirmation of PLN that interacts with these proteins 
remains to be determined it further underscores the versatile role of the cytoplasmic 
domain in PLN function. 
The data presented here will provide a crucial foundation for the determination of 
high resolution structures of the complex between SERCA and the different PLN 
conformations. The structures could answer important questions of the molecular details 
of SERCA regulation. For example, even if we concluded that the cytoplasmic 
interactions between PLN and SERCA are non-inhibitory, we don’t know if they are 
affecting ATP hydrolysis, Ca2+ transport or both. Also, because of the current inability to 
isotopically label SERCA, our NMR experiments have been limited to acquisitions of 
PLN signals and thus we are unable to directly detect the structural changes SERCA 
undergoes upon PLN interaction. By expression of SERCA in yeast or mammalian 
systems or by post-translational labeling, our solid state NMR methods could probe also 
the structure of SERCA. With detection of SERCA signals and extension of our 
asymmetric spin labeling approach to additional sites on both SERCA and PLN, solid-
state NMR is in an excellent position to answer many of the longstanding questions 
about SERCA regulation by PLN. This knowledge could be of paramount importance in 
the development of heart failure novel therapies that target the SERCA/PLN complex.        
In a broader perspective the results presented here have shown that:  
• Membrane proteins, and particularly amphipathic helices, exist in multiple states 
and to understand protein function it is crucial to characterize all these 
conformations.  
• Amphipathic helices are very sensitive to the membrane-mimicking environment 
(i.e detergent micelle, lipid bilayer). 
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• PREs are a powerful approach to map membrane protein interactions by solid-
state NMR and can be applied to large membrane protein systems.    
The conclusions are based on our results with PLN reconstituted into lipid bilayers, 
detergent micelles and bicelles, which were used to stabilize different states of PLN. 
Among these systems, lipid bilayers are undeniably the most native-like environment for 
a membrane protein, and a crucial development in the field of membrane protein 
structural biology will be to acquire experiments in native-like lipid bilayers or even 
complete cell membranes. To this end, solid-state NMR has found a niche in the study of 
biological systems such as membrane proteins and amyloid fibrils that are not amenable 
to solution NMR and X-ray crystallography in their native environment. With the current 
advancements in hardware design and sample preparation as well as novel techniques 
such as the application of dynamic nuclear polarization (DNP) (3) to biomolecules, solid-
state NMR promises to be an even more powerful technique for studies of membrane 
proteins in the future.      
 
9.1 References 
1. Vafiadaki, E., D. Sanoudou, D.A. Arvanitis, D.H. Catino, E.G. Kranias and A. 
Kontrogianni-Konstantopoulos 2007. Phospholamban interacts with HAX-1, a 
mitochondrial protein with anti-apoptotic function. J. Mol. Biol. 367, 65-79. 
2. Lygren, B., C.R. Carlson, K. Santamaria, V. Lissandron, T. McSorley, J. Litzenberg, D. 
Lorenz, B. Wiesner, W. Rosenthal, M. Zaccolo, K. Tasken and E. Klussmann 2007. 
AKAP complex regulates Ca2+ re-uptake into heart sarcoplasmic reticulum. EMBO 
Rep. 8, 1061-1067. 
3. Maly, T., G.T. Debelouchina, V.S. Bajaj, K.N. Hu, C.G. Joo, M.L. Mak-Jurkauskas, 
J.R. Sirigiri, P.C. van der Wel, J. Herzfeld, R.J. Temkin and R.G. Griffin 2008. 
Dynamic nuclear polarization at high magnetic fields. J. Chem. Phys. 128, 052211. 
  
240 
 
Bibliography 
Abu-Baker, S. and G.A. Lorigan 2006. Phospholamban and its phosphorylated form 
interact differently with lipid bilayers: A 31P, 2H, and 13C solid-state NMR 
spectroscopic study. Biochemistry. 45, 13312-13322. 
Abu-Baker, S., J.X. Lu, S. Chu, C.C. Brinn, C.A. Makaroff and G.A. Lorigan 2007. Side 
chain and backbone dynamics of phospholamban in phospholipid bilayers utilizing 
(2)h and (15)n solid-state NMR spectroscopy. Biochemistry. 46, 11695-11706. 
Ader, C., R. Schneider, S. Hornig, P. Velisetty, E.M. Wilson, A. Lange, K. Giller, I. 
Ohmert, M.F. Martin-Eauclaire, D. Trauner, S. Becker, O. Pongs and M. Baldus 
2008. A structural link between inactivation and block of a K+ channel. Nat. Struct. 
Mol. Biol. 15, 605-612. 
Ader, C., R. Schneider, K. Seidel, M. Etzkorn, S. Becker and M. Baldus 2009. Structural 
rearrangements of membrane proteins probed by water-edited solid-state NMR 
spectroscopy. J. Am. Chem. Soc. 131, 170-176. 
Afara, M. R., C.A. Trieber, J.P. Glaves and H.S. Young 2006. Rational design of peptide 
inhibitors of the sarcoplasmic reticulum calcium pump. Biochemistry. 45, 8617-8627. 
Al-Hashimi, H. M., P.J. Bolon and J.H. Prestegard 2000a. Molecular symmetry as an aid 
to geometry determination in ligand protein complexes. J. Magn. Reson. 142, 153-
158. 
Al-Hashimi, H. M., H. Valafar, M. Terrell, E.R. Zartler, M.K. Eidsness and J.H. 
Prestegard 2000b. Variation of molecular alignment as a means of resolving 
orientational ambiguities in protein structures from dipolar couplings. J. Magn. 
Reson. 143, 402-406. 
Andronesi, O. C., S. Becker, K. Seidel, H. Heise, H.S. Young and M. Baldus 2005. 
Determination of membrane protein structure and dynamics by magic-angle-spinning 
solid-state NMR spectroscopy. J. Am. Chem. Soc. 127, 12965-12974. 
Asahi, M., N.M. Green, K. Kurzydlowski, M. Tada and D.H. MacLennan 2001. 
Phospholamban domain IB forms an interaction site with the loop between 
transmembrane helices M6 and M7 of sarco(endo)plasmic reticulum Ca2+ ATPases. 
Proc Natl Acad Sci U S A. 98, 10061-6. 
Asahi, M., E. McKenna, K. Kurzydlowski, M. Tada and D.H. MacLennan 2000. Physical 
interactions between phospholamban and sarco(endo)plasmic reticulum Ca2+-
ATPases are dissociated by elevated Ca2+, but not by phospholamban 
phosphorylation, vanadate, or thapsigargin, and are enhanced by ATP. J Biol Chem. 
275, 15034-8. 
Bajaj, V. S., M.L. Mak-Jurkauskas, M. Belenky, J. Herzfeld and R.G. Griffin 2009. 
Functional and shunt states of bacteriorhodopsin resolved by 250 GHz dynamic 
nuclear polarization-enhanced solid-state NMR. Proc. Natl. Acad. Sci. U. S. A. 106, 
9244-9249. 
Bakheet, T. M. and A.J. Doig 2009. Properties and identification of human protein drug 
targets. Bioinformatics. 25, 451-457. 
241 
 
Baldwin, A. J., D.F. Hansen, P. Vallurupalli and L.E. Kay 2009. Measurement of methyl 
axis orientations in invisible, excited states of proteins by relaxation dispersion NMR 
spectroscopy. J. Am. Chem. Soc. 131, 11939-11948. 
Battiste, J. L. and G. Wagner 2000. Utilization of site-directed spin labeling and high-
resolution heteronuclear nuclear magnetic resonance for global fold determination of 
large proteins with limited nuclear overhauser effect data. Biochemistry. 39, 5355-
5365. 
Bax, A., G. Kontaxis and N. Tjandra 2001. Dipolar coupling in macromolecular structure 
determination. Methods in Enzymology. 339, 127-174. 
Becucci, L., A. Cembran, C.B. Karim, D.D. Thomas, R. Guidelli, J. Gao and G. Veglia 
2009. On the function of pentameric phospholamban: Ion channel or storage form? 
Biophys. J. 96, L60-2. 
Bennett, A. E., C.M. Rienstra, M. Auger, K.V. Lakshmi and R.G. Griffin 1995. 
Heteronuclear decoupling in rotating solids. J Chem Phys. 103, 6951-8. 
Berardi, M. J., W.M. Shih, S.C. Harrison and J.J. Chou 2011. Mitochondrial uncoupling 
protein 2 structure determined by NMR molecular fragment searching. Nature. 476, 
109-113. 
Bers, D. M. 2008. Calcium cycling and signaling in cardiac myocytes. Annu. Rev. 
Physiol. 70, 23-49. 
Bers, D. M. 2002. Cardiac excitation-contraction coupling. Nature. 415, 198-205. 
Bertelsen, E. B., L. Chang, J.E. Gestwicki and E.R. Zuiderweg 2009. Solution 
conformation of wild-type E. coli Hsp70 (DnaK) chaperone complexed with ADP and 
substrate. Proc. Natl. Acad. Sci. U. S. A. 106, 8471-8476. 
Bertini, I., Y.K. Gupta, C. Luchinat, G. Parigi, M. Peana, L. Sgheri and J. Yuan 2007. 
Paramagnetism-based NMR restraints provide maximum allowed probabilities for the 
different conformations of partially independent protein domains. J. Am. Chem. Soc. 
129, 12786-12794. 
Bhabha, G., J. Lee, D.C. Ekiert, J. Gam, I.A. Wilson, H.J. Dyson, S.J. Benkovic and P.E. 
Wright 2011. A dynamic knockout reveals that conformational fluctuations influence 
the chemical step of enzyme catalysis. Science. 332, 234-238. 
Bick, R. J., L.M. Buja, W.B. Van Winkle and G.E. Taffet 1998. Membrane asymmetry in 
isolated canine cardiac sarcoplasmic reticulum: Comparison with skeletal muscle 
sarcoplasmic reticulum. J. Membr. Biol. 164, 169-175. 
Birmachu, W., F.L. Nisswandt and D.D. Thomas 1989. Conformational transitions in the 
calcium adenosinetriphosphatase studied by time-resolved fluorescence resonance 
energy transfer. Biochemistry. 28, 3940-3947. 
Boehr, D. D., R. Nussinov and P.E. Wright 2009. The role of dynamic conformational 
ensembles in biomolecular recognition. Nat. Chem. Biol. 5, 789-796. 
Bogdanov, M., P. Heacock, Z. Guan and W. Dowhan 2010. Plasticity of lipid-protein 
interactions in the function and topogenesis of the membrane protein lactose 
permease from escherichia coli. Proc. Natl. Acad. Sci. U. S. A. 107, 15057-15062. 
242 
 
Brini, M. and E. Carafoli 2009. Calcium pumps in health and disease. Physiol. Rev. 89, 
1341-1378. 
Buck, B., J. Zamoon, T.L. Kirby, T.M. DeSilva, C. Karim, D. Thomas and G. Veglia 2003. 
Overexpression, purification, and characterization of recombinant ca-ATPase 
regulators for high-resolution solution and solid-state NMR studies. Protein Expr 
Purif. 30, 253-61. 
Buechler, J. A., J.A. Toner-Webb and S.S. Taylor 1991. Carbodiimides as probes for 
protein kinase structure and function. Methods Enzymol. 200, 487-500. 
Buffy, J. J., N.J. Traaseth, A. Mascioni, P.L. Gor'kov, E.Y. Chekmenev, W.W. Brey and 
G. Veglia 2006. Two-dimensional solid-state NMR reveals two topologies of 
sarcolipin in oriented lipid bilayers. Biochemistry. 45, 10939-10946. 
Cady, S. D., K. Schmidt-Rohr, J. Wang, C.S. Soto, W.F. Degrado and M. Hong 2010. 
Structure of the amantadine binding site of influenza M2 proton channels in lipid 
bilayers. Nature. 463, 689-692. 
Caffrey, M. and G.W. Feigenson 1981. Fluorescence quenching in model membranes. 
3. relationship between calcium adenosinetriphosphatase enzyme activity and the 
affinity of the protein for phosphatidylcholines with different acyl chain characteristics. 
Biochemistry. 20, 1949-1961. 
Castellani, F., B. van Rossum, A. Diehl, M. Schubert, K. Rehbein and H. Oschkinat 
2002. Structure of a protein determined by solid-state magic-angle-spinning NMR 
spectroscopy. Nature. 420, 98-102. 
Chen, Z., B.L. Akin and L.R. Jones 2007. Mechanism of reversal of phospholamban 
inhibition of the cardiac Ca2+-ATPase by protein kinase A and by anti-
phospholamban monoclonal antibody 2D12. J. Biol. Chem. 282, 20968-20976. 
Cherezov, V., D.M. Rosenbaum, M.A. Hanson, S.G. Rasmussen, F.S. Thian, T.S. 
Kobilka, H.J. Choi, P. Kuhn, W.I. Weis, B.K. Kobilka and R.C. Stevens 2007. High-
resolution crystal structure of an engineered human beta2-adrenergic G protein-
coupled receptor. Science. 318, 1258-1265. 
Chill, J. H., J.M. Louis, F. Delaglio and A. Bax 2007. Local and global structure of the 
monomeric subunit of the potassium channel KcsA probed by NMR. Biochim. 
Biophys. Acta. 1768, 3260-3270. 
Chou, J. J., S. Gaemers, B. Howder, J.M. Louis and A. Bax 2001. Journal of Molecular 
Biology. 21, 377-382. 
Chou, J. J., J.D. Kaufman, S.J. Stahl, P.T. Wingfield and A. Bax 2002. Micelle-induced 
curvature in a water-insoluble HIV-1 env peptide revealed by NMR dipolar coupling 
measurement in stretched polyacrylamide gel. J. Am. Chem. Soc. 124, 2450-2451. 
Chu, G., J.W. Lester, K.B. Young, W. Luo, J. Zhai and E.G. Kranias 2000. A single site 
(Ser16) phosphorylation in phospholamban is sufficient in mediating its maximal 
cardiac responses to beta -agonists. J. Biol. Chem. 275, 38938-38943. 
Chu, S., S. Abu-Baker, J. Lu and G.A. Lorigan 2010. (15)N solid-state NMR 
spectroscopic studies on phospholamban at its phosphorylated form at ser-16 in 
aligned phospholipid bilayers. Biochim. Biophys. Acta. 1798, 312-317. 
243 
 
Cierpicki, T., B. Liang, L.K. Tamm and J.H. Bushweller 2006. Increasing the accuracy of 
solution NMR structures of membrane proteins by application of residual dipolar 
couplings. high-resolution structure of outer membrane protein A. J. Am. Chem. Soc. 
128, 6947-6951. 
Clayton, J. C., E. Hughes and D.A. Middleton 2005. Spectroscopic studies of 
phospholamban variants in phospholipid bilayers. Biochem. Soc. Trans. 33, 913-915. 
Clore, G. M. and J. Kuszewski 2003. Improving the accuracy of NMR structures of RNA 
by means of conformational database potentials of mean force as assessed by 
complete dipolar coupling cross-validation. J. Am. Chem. Soc. 125, 1518-1525. 
Clore, M. G., M.A. Gronenborn and A. Bax 1998a. A robust method for determining the 
magnitude of the fully asymmetric alignment tensor of oriented macromolecules in 
the absence of structural information. Journal of Magnetic Resonance. 133, 216-221. 
Clore, M. G., M.A. Gronenborn and N. Tjandra 1998b. Direct structure refinement 
against residual dipolar couplings in the presence of rhombicity of unknown 
magnitude. Journal of Magnetic Resonance. 131, 159-162. 
Cook, P. F., M.E. Neville, K.E. Vrana , F.T. Hartl and R. Roskoshi 1982. Adenosine 
cyclic 3'5'-monophosphate dependent protein kinase: Kinetic mechanism for the 
bovine skeletal muscle catalytic subunit. Biochemistry. 21, 5794-5799. 
Cornea, R. L., L.R. Jones, J.M. Autry and D.D. Thomas 1997. Mutation and 
phosphorylation change the oligomeric structure of phospholamban in lipid bilayers. 
Biochemistry. 36, 2960-7. 
Cornea, R. L. and D.D. Thomas 1994. Effects of membrane thickness on the molecular 
dynamics and enzymatic activity of reconstituted ca-ATPase. Biochemistry. 33, 
2912-2920. 
Cornell, R. B. and S.G. Taneva 2006. Amphipathic helices as mediators of the 
membrane interaction of amphitropic proteins, and as modulators of bilayer physical 
properties. Curr. Protein Pept. Sci. 7, 539-552. 
Cornilescu, G., F. Delaglio and A. Bax 1999. Protein backbone angle restraints from 
searching a database for chemical shift and sequence homology. J Biomol NMR. 13, 
289-302. 
Csermely, P., R. Palotai and R. Nussinov 2010. Induced fit, conformational selection and 
independent dynamic segments: An extended view of binding events. Trends 
Biochem. Sci. 35, 539-546. 
Cui, Q. and M. Karplus 2008. Allostery and cooperativity revisited. Protein Sci. 17, 1295-
1307. 
Davis, J., M.V. Westfall, D. Townsend, M. Blankinship, T.J. Herron, G. Guerrero-Serna, 
W. Wang, E. Devaney and J.M. Metzger 2008. Designing heart performance by gene 
transfer. Physiol. Rev. 88, 1567-1651. 
De Angelis, A. A., S.C. Howell, A.A. Nevzorov and S.J. Opella 2006. Structure 
determination of a membrane protein with two trans-membrane helices in aligned 
phospholipid bicelles by solid-state NMR spectroscopy. J. Am. Chem. Soc. 128, 
12256-12267. 
244 
 
De Angelis, A. A., D.H. Jones, C.V. Grant, S.H. Park, M.F. Mesleh and S.J. Opella 2005. 
NMR experiments on aligned samples of membrane proteins. Methods Enzymol. 
394, 350-82. 
De Angelis, A. A. and S.J. Opella 2007. Bicelle samples for solid-state NMR of 
membrane proteins. Nat. Protoc. 2, 2332-2338. 
de Planque, M. R., D.T. Rijkers, J.I. Fletcher, R.M. Liskamp and F. Separovic 2004. The 
alphaM1 segment of the nicotinic acetylcholine receptor exhibits conformational 
flexibility in a membrane environment. Biochim. Biophys. Acta. 1665, 40-47. 
De Simone, A., B. Richter, X. Salvatella and M. Vendruscolo 2009. Toward an accurate 
determination of free energy landscapes in solution states of proteins. J. Am. Chem. 
Soc. 131, 3810-3811. 
Dedmon, M. M., K. Lindorff-Larsen, J. Christodoulou, M. Vendruscolo and C.M. Dobson 
2005. Mapping long-range interactions in alpha-synuclein using spin-label NMR and 
ensemble molecular dynamics simulations. J. Am. Chem. Soc. 127, 476-477. 
del Monte, F., S.E. Harding, G.W. Dec, J.K. Gwathmey and R.J. Hajjar 2002. Targeting 
phospholamban by gene transfer in human heart failure. Circulation. 105, 904-907. 
Delaglio, F., Grzesiek, S., Vuister, G. W., Zhu, G. Pfeifer, J., Bax,A. 1995. NMRPipe: A 
multidimensional spectral processing system based on UNIX pipes. J. Biomol. NMR. 
6, 277-293. 
Delaglio, F., S. Grzesiek, G.W. Vuister, G. Zhu, J. Pfeifer and A. Bax 1995. NMRPipe: A 
multidimensional spectral processing system based on UNIX pipes. J. Biomol. NMR. 
6, 277-293. 
Dominguez, C., R. Boelens and A.M. Bonvin 2003. HADDOCK: A protein-protein 
docking approach based on biochemical or biophysical information. J. Am. Chem. 
Soc. 125, 1731-1737. 
D'Onofrio, M., L. Ragona, D. Fessas, M. Signorelli, R. Ugolini, M. Pedo, M. Assfalg and 
H. Molinari 2009. NMR unfolding studies on a liver bile acid binding protein reveal a 
global two-state unfolding and localized singular behaviors. Arch. Biochem. Biophys. 
481, 21-29. 
Douglas, S. M., J.J. Chou and W.M. Shih 2007. DNA-nanotube-induced alignment of 
membrane proteins for NMR structure determination. Proc. Natl. Acad. Sci. U. S. A. 
104, 6644-6648. 
Dowhan, W. and M. Bogdanov 2011. Lipid-protein interactions as determinants of 
membrane protein structure and function. Biochem. Soc. Trans. 39, 767-774. 
Doyle, D. A., J.M. Cabral, R.A. Pfuetzner, A. Kuo, J.M. Gulbis, S.L. Cohen, B.T. Chait 
and R. Mackinnon 1998. The structure of the potassium channel : Molecular basis of 
K+ conduction and selectivity. Science. 280, 69-77. 
Dyson, H. J. and P.E. Wright 2004. Unfolded proteins and protein folding studied by 
NMR. Chem. Rev. 104, 3607-3622. 
Dyson, H. J. and P.E. Wright 2001. Nuclear magnetic resonance methods for elucidation 
of structure and dynamics in disordered states. Methods Enzymol. 339, 258-271. 
245 
 
Dyson, H. J. and P.E. Wright 1998. Equilibrium NMR studies of unfolded and partially 
folded proteins. Nat Struct Biol., 499-503. 
Engelman, D. M. 2005. Membranes are more mosaic than fluid. Nature. 438, 578-580. 
Engelman, D. M., Y. Chen, C.N. Chin, A.R. Curran, A.M. Dixon, A.D. Dupuy, A.S. Lee, 
U. Lehnert, E.E. Matthews, Y.K. Reshetnyak, A. Senes and J.L. Popot 2003. 
Membrane protein folding: Beyond the two stage model. FEBS Lett. 555, 122-125. 
Espinoza-Fonseca, L. M. and D.D. Thomas 2011. Atomic-level characterization of the 
activation mechanism of SERCA by calcium. PLoS One. 6, e26936. 
Fabiato, A. and F. Fabiato 1978. Calcium-induced release of calcium from the 
sarcoplasmic reticulum of skinned cells from adult human, dog, cat, rabbit, rat, and 
frog hearts and from fetal and new-born rat ventricles. Ann. N. Y. Acad. Sci. 307, 
491-522. 
Farias, R. N., B. Bloj, R.D. Morero, F. Sineriz and R.E. Trucco 1975. Regulation of 
allosteric membrane-bound enzymes through changes in membrane lipid 
compostition. Biochim. Biophys. Acta. 415, 231-251. 
Farrow, N. A., R. Muhandiram, A.U. Singer, S.M. Pascal, C.M. Kay, G. Gish, S.E. 
Shoelson, T. Pawson, J.D. Forman-Kay and L.E. Kay 1994. Backbone dynamics of a 
free and phosphopeptide-complexed src homology 2 domain studied by 15N NMR 
relaxation. Biochemistry. 33, 5984-6003. 
Ferrington, D. A., Q. Yao, T.C. Squier and D.J. Bigelow 2002. Comparable levels of ca-
ATPase inhibition by phospholamban in slow-twitch skeletal and cardiac 
sarcoplasmic reticulum. Biochemistry. 41, 13289-13296. 
Fersht, A. 1999. Structure and Mechanism in Protein Science. W.H. Freeman & Co., 
New York. 
Fischer, M. W. F., J.A. Losonczi, J.L. Weaver and J.H. Prestegard 1999. Domain 
orientation and dynamics in multidomain proteins from residual dipolar couplings. 
Biochemistry. 38, 9013-9022. 
Franzin, C. M., P. Teriete and F.M. Marassi 2007. Structural similarity of a membrane 
protein in micelles and membranes. J. Am. Chem. Soc. 129, 8078-8079. 
Froud, R. J., C.R. Earl, J.M. East and A.G. Lee 1986. Effects of lipid fatty acyl chain 
structure on the activity of the (Ca2+ + Mg2+)-ATPase. Biochim. Biophys. Acta. 860, 
354-360. 
Fu, S., L. Yang, P. Li, O. Hofmann, L. Dicker, W. Hide, X. Lin, S.M. Watkins, A.R. Ivanov 
and G.S. Hotamisligil 2011. Aberrant lipid metabolism disrupts calcium homeostasis 
causing liver endoplasmic reticulum stress in obesity. Nature. 473, 528-531. 
Goddard, T. D., Kneller,D.G. 1999. SPARKY 3.University of California. 
Goddard, T. D. and D.G. Kneller SPARKY 3. University of California, San Francisco. 
Gustavsson, M., N.J. Traaseth, C.B. Karim, E.L. Lockamy, D.D. Thomas and G. Veglia 
2011a. Lipid-mediated Folding/Unfolding of phospholamban as a regulatory 
mechanism for the sarcoplasmic reticulum ca(2+)-ATPase. J. Mol. Biol. 408, 755-
765. 
246 
 
Gustavsson, M., N.T. Traaseth and G. Veglia 2011b. Probing ground and excited states 
of phospholamban in model and native lipid membranes by magic angle spinning 
NMR spectroscopy. Biochim. Biophys. Acta. 1818. 
Ha, K. N., L.R. Masterson, Z. Hou, R. Verardi, N. Walsh, G. Veglia and S.L. Robia 2011. 
Lethal Arg9Cys phospholamban mutation hinders Ca2+-ATPase regulation and 
phosphorylation by protein kinase A. Proc. Natl. Acad. Sci. U. S. A. 108, 2735-2740. 
Ha, K. N., N.J. Traaseth, R. Verardi, J. Zamoon, A. Cembran, C.B. Karim, D.D. Thomas 
and G. Veglia 2007. Controlling the inhibition of the sarcoplasmic Ca2+-ATPase by 
tuning phospholamban structural dynamics. J. Biol. Chem. 282, 37205-37214. 
Hadri, L. and R.J. Hajjar 2011. Calcium cycling proteins and their association with heart 
failure. Clin. Pharmacol. Ther. 90, 620-624. 
Haghighi, K., K.N. Gregory and E.G. Kranias 2004. Sarcoplasmic reticulum ca-ATPase-
phospholamban interactions and dilated cardiomyopathy. Biochem. Biophys. Res. 
Commun. 322, 1214-1222. 
Haghighi, K., F. Kolokathis, A.O. Gramolini, J.R. Waggoner, L. Pater, R.A. Lynch, G.C. 
Fan, D. Tsiapras, R.R. Parekh, G.W. Dorn 2nd, D.H. MacLennan, D.T. Kremastinos 
and E.G. Kranias 2006. A mutation in the human phospholamban gene, deleting 
arginine 14, results in lethal, hereditary cardiomyopathy. Proc. Natl. Acad. Sci. U. S. 
A. 103, 1388-1393. 
Haghighi, K., F. Kolokathis, L. Pater, R.A. Lynch, M. Asahi, A.O. Garmolini, G. Fan, D. 
Tsiapras, H.S. Hahn, S. Adamopoulos, S.B. Liggett, G.W.I. Dorn, D.H. Mac Lennan, 
D.T. Kremastinos and E.G. Kranias 2003. Human phospholamban null results in 
lethal dilated cardiomyopathy revealing a critical difference between mouse and 
human. J Clin Invest. 111, 869-876. 
Haghighi, K., A.G. Schmidt, B.D. Hoit, A.G. Brittsan, A. Yatani, J.W. Lester, J. Zhai, Y. 
Kimura, G.W. Dorn 2nd, D.H. MacLennan and E.G. Kranias 2001. Superinhibition of 
sarcoplasmic reticulum function by phospholamban induces cardiac contractile 
failure. J. Biol. Chem. 276, 24145-24152. 
Hakizimana, P., M. Masureel, B. Gbaguidi, J.M. Ruysschaert and C. Govaerts 2008. 
Interactions between phosphatidylethanolamine headgroup and LmrP, a multidrug 
transporter: A conserved mechanism for proton gradient sensing? J. Biol. Chem. 
283, 9369-9376. 
Hicks, M. J., M. Shigekawa and A.M. Katz 1979. Mechanism by which cyclic adenosine 
3':5'-monophosphate-dependent protein kinase stimulates calcium transport in 
cardiac sarcoplasmic reticulum. Circ Res. 44, 384-91. 
Hiller, S., R.G. Garces, T.J. Malia, V.Y. Orekhov, M. Colombini and G. Wagner 2008. 
Solution structure of the integral human membrane protein VDAC-1 in detergent 
micelles. Science. 321, 1206-1210. 
Hohwy, M., C.M. Rienstra, C.P. Jaroniec and R.G. Griffin 1999. Fivefold symmetric 
homonuclear dipolar recoupling in rotating solids: Application to double quantum 
spectroscopy. J Chem Phys. 110, 7983-7992. 
247 
 
Hong, M., Y. Zhang and F. Hu 2012. Membrane protein structure and dynamics from 
NMR spectroscopy. Annu. Rev. Phys. Chem. 63, 1-24. 
Hoshijima, M., Y. Ikeda, Y. Iwanaga, S. Minamisawa, M.O. Date, Y. Gu, M. Iwatate, M. 
Li, L. Wang, J.M. Wilson, Y. Wang, J. Ross Jr and K.R. Chien 2002. Chronic 
suppression of heart-failure progression by a pseudophosphorylated mutant of 
phospholamban via in vivo cardiac rAAV gene delivery. Nat. Med. 8, 864-871. 
Hoshijima, M., R. Knoll, M. Pashmforoush and K.R. Chien 2006. Reversal of calcium 
cycling defects in advanced heart failure toward molecular therapy. J. Am. Coll. 
Cardiol. 48, A15-23. 
Hou, Z., Z. Hu, D.J. Blackwell, T.D. Miller, D.D. Thomas and S.L. Robia 2012. 2-color 
calcium pump reveals closure of the cytoplasmic headpiece with calcium binding. 
PLoS One. 7, e40369. 
Hubbard, J. A., L.K. MacLachlan, E. Meenan, C.J. Salter, D.G. Reid, P. Lahouratate, J. 
Humphries, N. Stevens, D. Bell and W.A. Neville 1994. Conformation of the 
cytoplasmic domain of phospholamban by NMR and CD. Mol. Membr. Biol. 11, 263-
269. 
Huggins, J. P. and P.J. England 1987. Evidence for a phosphorylation-induced 
conformational change in phospholamban from the effects of three proteases. FEBS 
Lett. 217, 32-36. 
Hughes, E., J.C. Clayton and D.A. Middleton 2009. Cytoplasmic residues of 
phospholamban interact with membrane surfaces in the presence of SERCA: A new 
role for phospholipids in the regulation of cardiac calcium cycling? Biochim. Biophys. 
Acta. 1788, 559-566. 
Hunter, G. W., S. Negash and T.C. Squier 1999. Phosphatidylethanolamine modulates 
ca-ATPase function and dynamics. Biochemistry. 38, 1356-1364. 
Hus, J. C., L. Salmon, G. Bouvignies, J. Lotze, M. Blackledge and R. Bruschweiler 2008. 
16-fold degeneracy of peptide plane orientations from residual dipolar couplings: 
Analytical treatment and implications for protein structure determination. J. Am. 
Chem. Soc. 130, 15927-15937. 
Hwang, T. L., P.C. van Zijl and S. Mori 1998. Accurate quantitation of water-amide 
proton exchange rates using the phase-modulated CLEAN chemical EXchange 
(CLEANEX-PM) approach with a fast-HSQC (FHSQC) detection scheme. J. Biomol. 
NMR. 11, 221-226. 
Inesi, G., A.M. Prasad and R. Pilankatta 2008. The Ca2+ ATPase of cardiac 
sarcoplasmic reticulum: Physiological role and relevance to diseases. Biochem. 
Biophys. Res. Commun. 369, 182-187. 
Ishikawa, K., L. Tilemann, K. Fish and R.J. Hajjar 2011. Gene delivery methods in 
cardiac gene therapy. J. Gene Med. 13, 566-572. 
James, P., M. Inui, M. Tada, M. Chiesi and E. Carafoli 1989. Nature and site of 
phospholamban regulation of the Ca2+ pump of sarcoplasmic reticulum. Nature. 
342, 90-2. 
248 
 
Jensen, M. R. and M. Blackledge 2008. On the origin of NMR dipolar waves in transient 
helical elements of partially folded proteins. J. Am. Chem. Soc. 130, 11266-11267. 
Jessup, M., B. Greenberg, D. Mancini, T. Cappola, D.F. Pauly, B. Jaski, A. Yaroshinsky, 
K.M. Zsebo, H. Dittrich, R.J. Hajjar and Calcium Upregulation by Percutaneous 
Administration of Gene Therapy in Cardiac Disease (CUPID) Investigators 2011. 
Calcium upregulation by percutaneous administration of gene therapy in cardiac 
disease (CUPID): A phase 2 trial of intracoronary gene therapy of sarcoplasmic 
reticulum Ca2+-ATPase in patients with advanced heart failure. Circulation. 124, 
304-313. 
Jha, A. K., A. Colubri, K.F. Freed and T.R. Sosnick 2005. Statistical coil model of the 
unfolded state: Resolving the reconciliation problem. Proc. Natl. Acad. Sci. U. S. A. 
102, 13099-13104. 
Johnson, B. A. 2004. Using NMRView to visualize and analyze the NMR spectra of 
macromolecules. Methods Mol. Biol. 278, 313-352. 
Johnson, D. A., P. Akamine, E. Radzio-Andzelm, M. Madhusudan and S.S. Taylor 2001. 
Dynamics of cAMP-dependent protein kinase. Chem. Rev. 101, 2243-2270. 
Johnson, J. E. and R.B. Cornell 1999. Amphitropic proteins: Regulation by reversible 
membrane interactions (review). Mol. Membr. Biol. 16, 217-235. 
Johnson, L. N. 2009. The regulation of protein phosphorylation. Biochem. Soc. Trans. 
37, 627-641. 
Jones, L. R., R.L. Cornea and Z. Chen 2002. Close proximity between residue 30 of 
phospholamban and cysteine 318 of the cardiac Ca2+ pump revealed by 
intermolecular thiol cross-linking. J Biol Chem. 277, 28319-29. 
Juretic, D., R.W. Hendler, F. Kamp, W.S. Caughey, M. Zasloff and H.V. Westerhoff 
1994. Magainin oligomers reversibly dissipate delta microH+ in cytochrome oxidase 
liposomes. Biochemistry. 33, 4562-4570. 
Kairouz, V., L. Lipskaia, R.J. Hajjar and E.R. Chemaly 2012. Molecular targets in heart 
failure gene therapy: Current controversies and translational perspectives. Ann. N. Y. 
Acad. Sci. 1254, 42-50. 
Karim, C. B., T.L. Kirby, Z. Zhang, Y. Nesmelov and D.D. Thomas 2004. 
Phospholamban structural dynamics in lipid bilayers probed by a spin label rigidly 
coupled to the peptide backbone. Proc Natl Acad Sci U S A. 101, 14437-42. 
Karim, C. B., C.G. Marquardt, J.D. Stamm, G. Barany and D.D. Thomas 2000. Synthetic 
null-cysteine phospholamban analogue and the corresponding transmembrane 
domain inhibit the ca-ATPase. Biochemistry. 39, 10892-7. 
Karim, C. B., Z. Zhang, E.C. Howard, K.D. Torgersen and D.D. Thomas 2006. 
Phosphorylation-dependent conformational switch in spin-labeled phospholamban 
bound to SERCA. J. Mol. Biol. 358, 1032-1040. 
Kawase, Y., D. Ladage and R.J. Hajjar 2011. Rescuing the failing heart by targeted gene 
transfer. J. Am. Coll. Cardiol. 57, 1169-1180. 
249 
 
Kay, L. E., E. Keifer and T. Saarinen 1992. Pure absorption gradient enhanced 
heteronuclear single quantum correlation spectroscopy with improved sensitivity. J. 
Am. Chem. Soc. 114, 10663-10665. 
Kay, L. E., D.A. Torchia and A. Bax 1989. Backbone dynamics of proteins as studied by 
15N inverse detected heteronuclear NMR spectroscopy: Application to 
staphylococcal nuclease. Biochemistry. 28, 8972-8979. 
Kaye, D. M., M. Hoshijima and K.R. Chien 2008. Reversing advanced heart failure by 
targeting Ca2+ cycling. Annu. Rev. Med. 59, 13-28. 
Kaye, D. M., A. Preovolos, T. Marshall, M. Byrne, M. Hoshijima, R. Hajjar, J.A. Mariani, 
S. Pepe, K.R. Chien and J.M. Power 2007. Percutaneous cardiac recirculation-
mediated gene transfer of an inhibitory phospholamban peptide reverses advanced 
heart failure in large animals. J. Am. Coll. Cardiol. 50, 253-260. 
Kelly, E. M., Z. Hou, J. Bossuyt, D.M. Bers and S.L. Robia 2008. Phospholamban 
oligomerization, quaternary structure, and sarco(endo)plasmic reticulum calcium 
ATPase binding measured by fluorescence resonance energy transfer in living cells. 
J. Biol. Chem. 283, 12202-12211. 
Kern, D. and E.R. Zuiderweg 2003. The role of dynamics in allosteric regulation. Curr. 
Opin. Struct. Biol. 13, 748-757. 
Ketchem, R. R., W. Hu and T.A. Cross 1993. High-resolution conformation of gramicidin 
A in a lipid bilayer by solid-state NMR. Science. 261, 1457-1460. 
Kimura, Y., M. Asahi, K. Kurzydlowski, M. Tada and D.H. MacLennan 1998. 
Phospholamban domain ib mutations influence functional interactions with the Ca2+-
ATPase isoform of cardiac sarcoplasmic reticulum. J Biol Chem. 273, 14238-41. 
Kimura, Y., K. Kurzydlowski, M. Tada and D.H. MacLennan 1997. Phospholamban 
inhibitory function is activated by depolymerization. J Biol Chem. 272, 15061-4. 
Kirby, T. L., C.B. Karim and D.D. Thomas 2004. Electron paramagnetic resonance 
reveals a large-scale conformational change in the cytoplasmic domain of 
phospholamban upon binding to the sarcoplasmic reticulum ca-ATPase. 
Biochemistry. 43, 5842-52. 
Knighton, D. R., J. Zheng, L.F.T. Eyck, N.H. Xuong, S.S. Taylor and J.M. Sowadski 
1991. Structure of a peptide inhibitor bound to the catalytic subunit of cyclic 
adenosine monophosphate-dependent protein kinase. Science. 253, 414-420. 
Koshland, D. E.,Jr, G. Nemethy and D. Filmer 1966. Comparison of experimental 
binding data and theoretical models in proteins containing subunits. Biochemistry. 5, 
365-385. 
Krainev, A. G., D.A. Ferrington, T.D. Williams, T.C. Squier and D.J. Bigelow 1995. 
Adaptive changes in lipid composition of skeletal sarcoplasmic reticulum membranes 
associated with aging. Biochim. Biophys. Acta. 1235, 406-418. 
Ladokhin, A. S. and S.H. White 1999. Folding of amphipathic alpha-helices on 
membranes: Energetics of helix formation by melittin. J. Mol. Biol. 285, 1363-1369. 
250 
 
Lakomek, N. A., T. Carlomagno, S. Becker, C. Griesinger and J. Meiler 2006. A 
thorough dynamic interpretation of residual dipolar couplings in ubiquitin. J. Biomol. 
NMR. 34, 101-115. 
Lamberth, S., H. Schmid, M. Muenchbach, T. Vorherr, J. Krebs, E. Carafoli and C. 
Griesinger 2000. NMR solution structure of phospholamban. Helvetica Chimica Acta. 
83, 2141-2151. 
Lange, V., J. Becker-Baldus, B. Kunert, B.J. van Rossum, F. Casagrande, A. Engel, Y. 
Roske, F.M. Scheffel, E. Schneider and H. Oschkinat 2010. A MAS NMR study of 
the bacterial ABC transporter ArtMP. Chembiochem. 11, 547-555. 
Langen, R., K.J. Oh, D. Cascio and W.L. Hubbell 2000. Crystal structures of spin labeled 
T4 lysozyme mutants: Implications for the interpretation of EPR spectra in terms of 
structure. Biochemistry. 39, 8396-8405. 
Lee, A. G. 2003. Lipid-protein interactions in biological membranes: A structural 
perspective. Biochim. Biophys. Acta. 1612, 1-40. 
Lee, A. G. 1998. How lipids interact with an intrinsic membrane protein: The case of the 
calcium pump. Biochim. Biophys. Acta. 1376, 381-390. 
Lee, A. G. and J.M. East 1998. The effects of phospholipid structure on the function of a 
calcium pump. Biochem. Soc. Trans. 26, 359-365. 
Levitt, M. H. 2001. Spin dynamics. John Wiley & sons, New York. 
Levy, D., A. Gulik, A. Bluzat and J.L. Rigaud 1992. Reconstitution of the sarcoplasmic 
reticulum ca(2+)-ATPase: Mechanisms of membrane protein insertion into liposomes 
during reconstitution procedures involving the use of detergents. Biochim. Biophys. 
Acta. 1107, 283-298. 
Li, J., C.B. Boschek, Y. Xiong, C.A. Sacksteder, T.C. Squier and D.J. Bigelow 2005. 
Essential role for Pro21 in phospholamban for optimal inhibition of the ca-ATPase. 
Biochemistry. 44, 16181-16191. 
Li, J., Z.M. James, X. Dong, C.B. Karim and D.D. Thomas 2012. Structural and 
functional dynamics of an integral membrane protein complex modulated by lipid 
headgroup charge. J. Mol. Biol. 418, 379-389. 
Li, P., I.R. Martins, G.K. Amarasinghe and M.K. Rosen 2008. Internal dynamics control 
activation and activity of the autoinhibited vav DH domain. Nat. Struct. Mol. Biol. 15, 
613-618. 
Liang, B., J.H. Bushweller and L.K. Tamm 2006. Site-directed parallel spin-labeling and 
paramagnetic relaxation enhancement in structure determination of membrane 
proteins by solution NMR spectroscopy. J. Am. Chem. Soc. 128, 4389-4397. 
Lin, D., K.H. Sze, Y. Cui and G. Zhu 2002. Clean SEA-HSQC: A method to map solvent 
exposed amides in large non-deuterated proteins with gradient-enhanced HSQC. J. 
Biomol. NMR. 23, 317-322. 
Linser, R., M. Dasari, M. Hiller, V. Higman, U. Fink, J.M. Lopez Del Amo, S. Markovic, L. 
Handel, B. Kessler, P. Schmieder, D. Oesterhelt, H. Oschkinat and B. Reif 2011. 
251 
 
Proton-detected solid-state NMR spectroscopy of fibrillar and membrane proteins. 
Angew. Chem. Int. Ed Engl. 50, 4508-4512. 
Lockwood, N. A., R.S. Tu, Z. Zhang, M.V. Tirrell, D.D. Thomas and C.B. Karim 2003. 
Structure and function of integral membrane protein domains resolved by peptide-
amphiphiles: Application to phospholamban. Biopolymers. 69, 283-92. 
Lorieau, J., L. Yao and A. Bax 2008. Liquid crystalline phase of G-tetrad DNA for NMR 
study of detergent-solubilized proteins. J. Am. Chem. Soc. 130, 7536-7537. 
Losonczi, J. A., M. Andrec, M.W. Fischer and J.H. Prestegard 1999. Order matrix 
analysis of residual dipolar coupling using singular value decomposition. Journal of 
Magnetic Resonance. 138, 334-342. 
Luo, W., S.D. Cady and M. Hong 2009. Immobilization of the influenza A M2 
transmembrane peptide in virus envelope-mimetic lipid membranes: A solid-state 
NMR investigation. Biochemistry. 48, 6361-6368. 
Lygren, B., C.R. Carlson, K. Santamaria, V. Lissandron, T. McSorley, J. Litzenberg, D. 
Lorenz, B. Wiesner, W. Rosenthal, M. Zaccolo, K. Tasken and E. Klussmann 2007. 
AKAP complex regulates Ca2+ re-uptake into heart sarcoplasmic reticulum. EMBO 
Rep. 8, 1061-1067. 
Ma, B. and R. Nussinov 2010. Enzyme dynamics point to stepwise conformational 
selection in catalysis. Curr. Opin. Chem. Biol. 14, 652-659. 
Ma, C. and S.J. Opella 2000. Lanthanide ions bind specifically to an added "EF-hand" 
and orient a membrane protein in micelles for solution NMR spectroscopy. J. Magn. 
Reson. 146, 381-384. 
Maclennan, D. H. 2004. Interactions of the calcium ATPase with phospholamban and 
sarcolipin: Structure, physiology and pathophysiology. J. Muscle Res. Cell. Motil. 25, 
600-601. 
MacLennan, D. H., Y. Kimura and T. Toyofuku 1998. Sites of regulatory interaction 
between calcium ATPases and phospholamban. Ann N Y Acad Sci. 853, 31-42. 
MacLennan, D. H. and E.G. Kranias 2003. Phospholamban: A crucial regulator of 
cardiac contractility. Nat Rev Mol Cell Biol. 4, 566-77. 
Mahaney, J. E., J.M. Autry and L.R. Jones 2000. Kinetics studies of the cardiac ca-
ATPase expressed in Sf21 cells: New insights on ca-ATPase regulation by 
phospholamban. Biophys. J. 78, 1306-1323. 
Maly, T., G.T. Debelouchina, V.S. Bajaj, K.N. Hu, C.G. Joo, M.L. Mak-Jurkauskas, J.R. 
Sirigiri, P.C. van der Wel, J. Herzfeld, R.J. Temkin and R.G. Griffin 2008. Dynamic 
nuclear polarization at high magnetic fields. J. Chem. Phys. 128, 052211. 
Marsh, J. A. and J.D. Forman-Kay 2009. Structure and disorder in an unfolded state 
under nondenaturing conditions from ensemble models consistent with a large 
number of experimental restraints. J. Mol. Biol. 391, 359-374. 
Mascioni, A., B.L. Eggimann and G. Veglia 2004. Determination of helical membrane 
protein topology using residual dipolar couplings and exhaustive search algorithm: 
Application to phospholamban. Chem. Phys. Lipids. 132, 133-144. 
252 
 
Mascioni, A., C. Karim, J. Zamoon, D.D. Thomas and G. Veglia 2002. Solid-state NMR 
and rigid body molecular dynamics to determine domain orientations of monomeric 
phospholamban. J. Am. Chem. Soc. 124, 9392-9393. 
Mascioni, A. and G. Veglia 2003. Theoretical analysis of residual dipolar coupling 
patterns in regular secondary structures of proteins. J. Am. Chem. Soc. 125, 12520-
12526. 
Masterson, L. R., N. Bortone, T. Yu, K.N. Ha, E.C. Gaffarogullari, O. Nguyen and G. 
Veglia 2009. Expression and purification of isotopically labeled peptide inhibitors and 
substrates of cAMP-dependant protein kinase A for NMR analysis. Protein Expr. 
Purif. 64, 231-236. 
Masterson, L. R., C. Cheng, T. Yu, M. Tonelli, A.P. Kornev, S.S. Taylor and G. Veglia 
2010. Dynamics connect substrate recognition to catalysis in protein kinase A. Nat 
Chem Biol. 6, 821-828. 
Masterson, L. R., A. Mascioni, N.J. Traaseth, S.S. Taylor and G. Veglia 2008. Allosteric 
cooperativity in protein kinase A. Proc Natl Acad Sci U S A. 105, 506-511. 
Masterson, L. R., L. Shi, E. Metcalfe, J. Gao, S.S. Taylor and G. Veglia 2011a. 
Dynamically committed, uncommitted, and quenched states encoded in protein 
kinase A revealed by NMR spectroscopy. Proc. Natl. Acad. Sci. U. S. A. 108, 6969-
6974. 
Masterson, L. R., T. Yu, L. Shi, Y. Wang, M. Gustavsson, M.M. Mueller and G. Veglia 
2011b. cAMP-dependent protein kinase A selects the excited state of the membrane 
substrate phospholamban. J. Mol. Biol. 412, 155-164. 
Matsuzaki, K. 1999. Why and how are peptide-lipid interactions utilized for self-defense? 
magainins and tachyplesins as archetypes. Biochim. Biophys. Acta. 1462, 1-10. 
McDermott, A. 2009. Structure and dynamics of membrane proteins by magic angle 
spinning solid-state NMR. Annu. Rev. Biophys. 38, 385-403. 
McDermott, A. and T. Polenova 2007. Solid state NMR: New tools for insight into 
enzyme function. Curr. Opin. Struct. Biol. 17, 617-622. 
Medeiros, A., D.G. Biagi, T.J. Sobreira, P.S. de Oliveira, C.E. Negrao, A.J. Mansur, J.E. 
Krieger, P.C. Brum and A.C. Pereira 2011. Mutations in the human phospholamban 
gene in patients with heart failure. Am. Heart J. 162, 1088-1095.e1. 
Meier, S., M. Blackledge and S. Grzesiek 2008. Conformational distributions of unfolded 
polypeptides from novel NMR techniques. J. Chem. Phys. 128, 052204. 
Mesleh, M. F. and S.J. Opella 2003. Dipolar waves as NMR maps of helices in proteins. 
J. Magn. Reson. 163, 288-299. 
Mesleh, M. F., G. Veglia, T.M. DeSilva, F.M. Marassi and S.J. Opella 2002. Dipolar 
waves as NMR maps of protein structure. J. Am. Chem. Soc. 124, 4206-4207. 
Metcalfe, E. E., N.J. Traaseth and G. Veglia 2005. Serine 16 phosphorylation induces an 
order-to-disorder transition in monomeric phospholamban. Biochemistry. 44, 4386-
4396. 
253 
 
Metcalfe, E. E., J. Zamoon, D.D. Thomas and G. Veglia 2004. (1)H/(15)N heteronuclear 
NMR spectroscopy shows four dynamic domains for phospholamban reconstituted in 
dodecylphosphocholine micelles. Biophys. J. 87, 1205-1214. 
Mills, F. D., V.C. Antharam, O.K. Ganesh, D.W. Elliott, S.A. McNeill and J.R. Long 2008. 
The helical structure of surfactant peptide KL4 when bound to POPC: POPG lipid 
vesicles. Biochemistry. 47, 8292-8300. 
Mittag, T., L.E. Kay and J.D. Forman-Kay 2010. Protein dynamics and conformational 
disorder in molecular recognition. J. Mol. Recognit. 23, 105-116. 
Moe, P. and P. Blount 2005. Assessment of potential stimuli for mechano-dependent 
gating of MscL: Effects of pressure, tension, and lipid headgroups. Biochemistry. 44, 
12239-12244. 
Moller, J. V., C. Olesen, A.M. Winther and P. Nissen 2010. The sarcoplasmic Ca2+-
ATPase: Design of a perfect chemi-osmotic pump. Q. Rev. Biophys. 43, 501-566. 
Monod, J., J. Wyman and J.P. Changeux 1965. On the nature of allosteric transitions: A 
plausible model. J Mol Biol. 12, 88-118. 
Mori, S., J.M. Berg and P.C. van Zijl 1996. Separation of intramolecular NOE and 
exchange peaks in water exchange spectroscopy using spin-echo filters. J. Biomol. 
NMR. 7, 77-82. 
Morris, G. A. and R.J. Freeman 1979. Enhancement of nuclear magnetic resonance 
signals by polarization transfer. J. Am. Chem. Soc. 101, 760-762. 
Mrak, R. E. and S. Fleischer 1982. Lipid composition of sarcoplasmic reticulum from 
mice with muscular dystrophy. Muscle Nerve. 5, 439-446. 
Mueller, B., C.B. Karim, I.V. Negrashov, H. Kutchai and D.D. Thomas 2004. Direct 
detection of phospholamban and sarcoplasmic reticulum ca-ATPase interaction in 
membranes using fluorescence resonance energy transfer. Biochemistry. 43, 8754-
65. 
Mueller, G. A., W.Y. Choy, D. Yang, J.D. Forman-Kay, R.A. Venters and L.E. Kay 2000. 
Global folds of proteins with low densities of NOEs using residual dipolar couplings: 
Application to the 370-residue maltodextrin-binding protein. J. Mol. Biol. 300, 197-
212. 
Nash, A. I., W.H. Ko, S.M. Harper and K.H. Gardner 2008. A conserved glutamine plays 
a central role in LOV domain signal transmission and its duration. Biochemistry. 47, 
13842-13849. 
Nesmelov, Y. E., C.B. Karim, L. Song, P.G. Fajer and D.D. Thomas 2007. Rotational 
dynamics of phospholamban determined by multifrequency electron paramagnetic 
resonance. Biophys. J. 93, 2805-2812. 
Nodet, G., L. Salmon, V. Ozenne, S. Meier, M.R. Jensen and M. Blackledge 2009. 
Quantitative description of backbone conformational sampling of unfolded proteins at 
amino acid resolution from NMR residual dipolar couplings. J. Am. Chem. Soc. 131, 
17908-17918. 
254 
 
Obara, K., N. Miyashita, C. Xu, I. Toyoshima, Y. Sugita, G. Inesi and C. Toyoshima 
2005. Structural role of countertransport revealed in ca(2+) pump crystal structure in 
the absence of ca(2+). Proc. Natl. Acad. Sci. U. S. A. 102, 14489-14496. 
Olesen, C., T.L. Sorensen, R.C. Nielsen, J.V. Moller and P. Nissen 2004. 
Dephosphorylation of the calcium pump coupled to counterion occlusion. Science. 
306, 2251-2255. 
Oxenoid, K. and J.J. Chou 2005. The structure of phospholamban pentamer reveals a 
channel-like architecture in membranes. Proc. Natl. Acad. Sci. U. S. A. 102, 10870-
10875. 
Palmer, A. G.,3rd, C.D. Kroenke and J.P. Loria 2001. Nuclear magnetic resonance 
methods for quantifying microsecond-to-millisecond motions in biological 
macromolecules. Methods Enzymol. 339, 204-238. 
Park, S. H., B.B. Das, F. Casagrande, Y. Tian, H.J. Nothnagel, M. Chu, H. Kiefer, K. 
Maier, A.A. De Angelis, F.M. Marassi and S.J. Opella 2012. Structure of the 
chemokine receptor CXCR1 in phospholipid bilayers. Nature. 
Park, S. H., S. Prytulla, A.A. De Angelis, J.M. Brown, H. Kiefer and S.J. Opella 2006. 
High-resolution NMR spectroscopy of a GPCR in aligned bicelles. J. Am. Chem. Soc. 
128, 7402-7403. 
Periasamy, M. and A. Kalyanasundaram 2007. SERCA pump isoforms: Their role in 
calcium transport and disease. Muscle Nerve. 
Permi, P. and A. Annila 2000. Transverse relaxation optimised spin-state selective NMR 
experiments for measurement of residual dipolar couplings. J. Biomol. NMR. 16, 
221-227. 
Poget, S. F., S.M. Cahill and M.E. Girvin 2007. Isotropic bicelles stabilize the functional 
form of a small multidrug-resistance pump for NMR structural studies. J. Am. Chem. 
Soc. 129, 2432-2433. 
Pollesello, P., A. Annila and M. Ovaska 1999. Structure of the 1-36 amino-terminal 
fragment of human phospholamban by nuclear magnetic resonance and modeling of 
the phospholamban pentamer. Biophys J. 76, 1784-95. 
Prestegard, J. H. 1998. New techniques in structural NMR - anisotropic interactions. 
Nature Structural Biology., 517. 
Prestegard, J. H., H.M. Al-Hashimi and J.R. Tolman 2000. NMR structures of 
biomolecules using field oriented media and residual dipolar couplings. Quarterly 
Review in Biophysics. 33, 371-424. 
Qiang, W., Y. Sun and D.P. Weliky 2009. A strong correlation between fusogenicity and 
membrane insertion depth of the HIV fusion peptide. Proc. Natl. Acad. Sci. U. S. A. 
106, 15314-15319. 
Rand, R. P., N. Fuller, V.A. Parsegian and D.C. Rau 1988. Variation in hydration forces 
between neutral phospholipid bilayers: Evidence for hydration attraction. 
Biochemistry. 27, 7711-7722. 
255 
 
Rasmussen, S. G., H.J. Choi, D.M. Rosenbaum, T.S. Kobilka, F.S. Thian, P.C. Edwards, 
M. Burghammer, V.R. Ratnala, R. Sanishvili, R.F. Fischetti, G.F. Schertler, W.I. Weis 
and B.K. Kobilka 2007. Crystal structure of the human beta2 adrenergic G-protein-
coupled receptor. Nature. 450, 383-387. 
Reddy, L. G., R.L. Cornea, D.L. Winters, E. McKenna and D.D. Thomas 2003. Defining 
the molecular components of calcium transport regulation in a reconstituted 
membrane system. Biochemistry. 42, 4585-92. 
Reddy, L. G., L.R. Jones, S.E. Cala, J.J. O'Brian, S.A. Tatulian and D.L. Stokes 1995. 
Functional reconstitution of recombinant phospholamban with rabbit skeletal ca(2+)-
ATPase. J Biol Chem. 270, 9390-7. 
Reddy, L. G., L.R. Jones and D.D. Thomas 1999. Depolymerization of phospholamban 
in the presence of calcium pump: A fluorescence energy transfer study. 
Biochemistry. 38, 3954-62. 
Religa, T. L., A.M. Ruschak, R. Rosenzweig and L.E. Kay 2011. Site-directed methyl 
group labeling as an NMR probe of structure and dynamics in supramolecular protein 
systems: Applications to the proteasome and to the ClpP protease. J. Am. Chem. 
Soc. 133, 9063-9068. 
Renault, M., R. Tommassen-van Boxtel, M.P. Bos, J.A. Post, J. Tommassen and M. 
Baldus 2012. Cellular solid-state nuclear magnetic resonance spectroscopy. Proc. 
Natl. Acad. Sci. U. S. A. 109, 4863-4868. 
Roach, C., S.E. Feller, J.A. Ward, S.R. Shaikh, M. Zerouga and W. Stillwell 2004. 
Comparison of cis and trans fatty acid containing phosphatidylcholines on membrane 
properties. Biochemistry. 43, 6344-6351. 
Robia, S. L., K.S. Campbell, E.M. Kelly, Z. Hou, D.L. Winters and D.D. Thomas 2007. 
Forster transfer recovery reveals that phospholamban exchanges slowly from 
pentamers but rapidly from the SERCA regulatory complex. Circ. Res. 101, 1123-
1129. 
Roger, V. L., A.S. Go, D.M. Lloyd-Jones, E.J. Benjamin, J.D. Berry, W.B. Borden, D.M. 
Bravata, S. Dai, E.S. Ford, C.S. Fox, H.J. Fullerton, C. Gillespie, S.M. Hailpern, J.A. 
Heit, V.J. Howard, B.M. Kissela, S.J. Kittner, D.T. Lackland, J.H. Lichtman, L.D. 
Lisabeth, D.M. Makuc, G.M. Marcus, A. Marelli, D.B. Matchar, C.S. Moy, D. 
Mozaffarian, M.E. Mussolino, G. Nichol, N.P. Paynter, E.Z. Soliman, P.D. Sorlie, N. 
Sotoodehnia, T.N. Turan, S.S. Virani, N.D. Wong, D. Woo, M.B. Turner and 
American Heart Association Statistics Committee and Stroke Statistics 
Subcommittee 2012. Executive summary: Heart disease and stroke statistics--2012 
update: A report from the american heart association. Circulation. 125, 188-197. 
Saito, H. and A. Naito 2007. NMR studies on fully hydrated membrane proteins, with 
emphasis on bacteriorhodopsin as a typical and prototype membrane protein. 
Biochim. Biophys. Acta. 1768, 3145-3161. 
Saito-Nakatsuka, K., T. Yamashita, I. Kubota and M. Kawakita 1987. Reactive sulfhydryl 
groups of sarcoplasmic reticulum ATPase. I. location of a group which is most 
reactive with N-ethylmaleimide. J. Biochem. 101, 365-376. 
256 
 
Salmon, L., G. Nodet, V. Ozenne, G. Yin, M.R. Jensen, M. Zweckstetter and M. 
Blackledge 2010. NMR characterization of long-range order in intrinsically disordered 
proteins. J. Am. Chem. Soc. 132, 8407-8418. 
Salvatella, X., B. Richter and M. Vendruscolo 2008. Influence of the fluctuations of the 
alignment tensor on the analysis of the structure and dynamics of proteins using 
residual dipolar couplings. J. Biomol. NMR. 40, 71-81. 
Sammalkorpi, M. and T. Lazaridis 2007. Modeling a spin-labeled fusion peptide in a 
membrane: Implications for the interpretation of EPR experiments. Biophys. J. 92, 
10-22. 
Scarlata, S. and S.M. Gruner 1997. Role of phosphatidylethanolamine lipids in the 
stabilization of protein-lipid contacts. Biophys. Chem. 67, 269-279. 
Schmidt, A. G., I. Edes and E.G. Kranias 2001. Phospholamban: A promising 
therapeutic target in heart failure? Cardiovasc Drugs Ther. 15, 387-96. 
Schmidt, A. G., J. Zhai, A.N. Carr, M.J. Gerst, J.N. Lorenz, P. Pollesello, A. Annila, B.D. 
Hoit and E.G. Kranias 2002. Structural and functional implications of the 
phospholamban hinge domain: Impaired SR Ca2+ uptake as a primary cause of 
heart failure. Cardiovasc Res. 56, 248-59. 
Schmitt, J. P., F. Ahmad, K. Lorenz, L. Hein, S. Schulz, M. Asahi, D.H. Maclennan, C.E. 
Seidman, J.G. Seidman and M.J. Lohse 2009. Alterations of phospholamban 
function can exhibit cardiotoxic effects independent of excessive sarcoplasmic 
reticulum Ca2+-ATPase inhibition. Circulation. 119, 436-444. 
Schmitt, J. P., M. Kamisago, M. Asahi, G.H. Li, F. Ahmad, U. Mende, E.G. Kranias, D.H. 
MacLennan, J.G. Seidman and C.E. Seidman 2003. Dilated cardiomyopathy and 
heart failure caused by a mutation in phospholamban. Science. 299, 1410-3. 
Schwieters, C. D., J.J. Kuszewski, N. Tjandra and G.M. Clore 2003. The xplor-NIH NMR 
molecular structure determination package. J. Magn. Reson. 160, 65-73. 
Seidel, K., O.C. Andronesi, J. Krebs, C. Griesinger, H.S. Young, S. Becker and M. 
Baldus 2008. Structural characterization of ca(2+)-ATPase-bound phospholamban in 
lipid bilayers by solid-state nuclear magnetic resonance (NMR) spectroscopy. 
Biochemistry. 47, 4369-4376. 
Selvaratnam, R., S. Chowdhury, B. VanSchouwen and G. Melacini 2011. Mapping 
allostery through the covariance analysis of NMR chemical shifts. Proc. Natl. Acad. 
Sci. U. S. A. 108, 6133-6138. 
Sengupta, I., P.S. Nadaud, J.J. Helmus, C.D. Schwieters and C.P. Jaroniec 2012. 
Protein fold determined by paramagnetic magic-angle spinning solid-state NMR 
spectroscopy. Nat. Chem. 4, 410-417. 
Shanmugam, M., S. Gao, C. Hong, N. Fefelova, M.C. Nowycky, L.H. Xie, M. Periasamy 
and G.J. Babu 2011. Ablation of phospholamban and sarcolipin results in cardiac 
hypertrophy and decreased cardiac contractility. Cardiovasc. Res. 89, 353-361. 
Sharma, M., M. Yi, H. Dong, H. Qin, E. Peterson, D.D. Busath, H.X. Zhou and T.A. 
Cross 2010. Insight into the mechanism of the influenza A proton channel from a 
structure in a lipid bilayer. Science. 330, 509-512. 
257 
 
Shi, L., I. Kawamura, K.H. Jung, L.S. Brown and V. Ladizhansky 2011. Conformation of 
a seven-helical transmembrane photosensor in the lipid environment. Angew. Chem. 
Int. Ed Engl. 50, 1302-1305. 
Shi, L., N.J. Traaseth, R. Verardi, A. Cembran, J. Gao and G. Veglia 2009. A refinement 
protocol to determine structure, topology, and depth of insertion of membrane 
proteins using hybrid solution and solid-state NMR restraints. J. Biomol. NMR. 44, 
195-205. 
Shi, L., N.J. Traaseth, R. Verardi, M. Gustavsson, J. Gao and G. Veglia 2011. 
Paramagnetic-based NMR restraints lift residual dipolar coupling degeneracy in 
multidomain detergent-solubilized membrane proteins. J Am Chem Soc. 133, 2232-
2241. 
Sigalov, A. B. 2011. Uncoupled binding and folding of immune signaling-related 
intrinsically disordered proteins. Prog. Biophys. Mol. Biol. 106, 525-536. 
Simmerman, H. K., J.H. Collins, J.L. Theibert, A.D. Wegener and L.R. Jones 1986. 
Sequence analysis of phospholamban. identification of phosphorylation sites and two 
major structural domains. J Biol Chem. 261, 13333-41. 
Simmerman, H. K. and L.R. Jones 1998. Phospholamban: Protein structure, mechanism 
of action, and role in cardiac function. Physiol Rev. 78, 921-47. 
Simmerman, H. K., Y.M. Kobayashi, J.M. Autry and L.R. Jones 1996. A leucine zipper 
stabilizes the pentameric membrane domain of phospholamban and forms a coiled-
coil pore structure. J Biol Chem. 271, 5941-6. 
Singer, S. J. and G.L. Nicolson 1972. The fluid mosaic model of the structure of cell 
membranes. Science. 175, 720-731. 
Smock, R. G. and L.M. Gierasch 2009. Sending signals dynamically. Science. 324, 198-
203. 
Sonntag, Y., M. Musgaard, C. Olesen, B. Schiott, J.V. Moller, P. Nissen and L. 
Thogersen 2011. Mutual adaptation of a membrane protein and its lipid bilayer 
during conformational changes. Nat. Commun. 2, 304. 
Sorensen, T. L., J.V. Moller and P. Nissen 2004. Phosphoryl transfer and calcium ion 
occlusion in the calcium pump. Science. 304, 1672-1675. 
Starling, A. P., K.A. Dalton, J.M. East, S. Oliver and A.G. Lee 1996. Effects of 
phosphatidylethanolamines on the activity of the ca(2+)-ATPase of sarcoplasmic 
reticulum. Biochem. J. 320 ( Pt 1), 309-314. 
Stevenson, L. W. 2003. Clinical use of inotropic therapy for heart failure: Looking 
backward or forward? part II: Chronic inotropic therapy. Circulation., 492-497. 
Stokes, D. L. and N.M. Green 1990. Three-dimensional crystals of CaATPase from 
sarcoplasmic reticulum. symmetry and molecular packing. Biophys J. 57, 1-14. 
Stokes, D. L., A.J. Pomfret, W.J. Rice, J.P. Glaves and H.S. Young 2006. Interactions 
between Ca2+-ATPase and the pentameric form of phospholamban in two-
dimensional co-crystals. Biophys. J. 90, 4213-4223. 
258 
 
Su, Y., A.J. Waring, P. Ruchala and M. Hong 2010. Membrane-bound dynamic structure 
of an arginine-rich cell-penetrating peptide, the protein transduction domain of HIV 
TAT, from solid-state NMR. Biochemistry. 49, 6009-6020. 
Szymanska, G., H.W. Kim and E.G. Kranias 1991. Reconstitution of the skeletal 
sarcoplasmic reticulum Ca2(+)-pump: Influence of negatively charged phospholipids. 
Biochim. Biophys. Acta. 1091, 127-134. 
Tada, M. and M. Kadoma 1989. Regulation of the Ca2+ pump ATPase by cAMP-
dependent phosphorylation of phospholamban. Bioessays. 10, 157-63. 
Tada, M., T. Yamamoto and Y. Tonomura 1978. Molecular mechanism of active calcium 
transport by sarcoplasmic reticulum. Physiol. Rev. 58, 1-79. 
Taffet, G. E., T.T. Pham, D.L. Bick, M.L. Entman, H.J. Pownall and R.J. Bick 1993. The 
calcium uptake of the rat heart sarcoplasmic reticulum is altered by dietary lipid. J. 
Membr. Biol. 131, 35-42. 
Takegoshi, K., S. Nakamura and T. Terao 2001. 13C–1H dipolar-assisted rotational 
resonance in magic-angle spinning NMR. Chem. Phys. Lett. 344, 631. 
Tang, C., J. Iwahara and G.M. Clore 2006. Visualization of transient encounter 
complexes in protein-protein association. Nature. 444, 383-386. 
Tang, M., L.J. Sperling, D.A. Berthold, A.E. Nesbitt, R.B. Gennis and C.M. Rienstra 
2011. Solid-state NMR study of the charge-transfer complex between ubiquinone-8 
and disulfide bond generating membrane protein DsbB. J. Am. Chem. Soc. 133, 
4359-4366. 
Tjandra, N. and A. Bax 1997. Direct measurement of distances and angles in 
biomolecules by NMR in a dilute liquid crystalline medium. Science. 278, 1111-1114. 
Tjandra, N., J. Marquardt and Clore M. G. 2000. Direct refinement against proton-proton 
dipolar coupling in NMR structure of macromolecules. Journal of Magnetic 
Resonance. 142, 393-396. 
Tolman, J. R., J.M. Flanagan, M.A. Kennedy and J.H. Prestegard 1997. NMR evidence 
for slow collective motions in cyanometmyoglobin. Nat Struct Biol. 4, 292-7. 
Tolman, J. R., J.M. Flanagan, M.A. Kennedy and J.H. Prestegard 1995. Nuclear 
magnetic dipole interactions in field-oriented proteins: Information for structure 
determination in solution. Proceedings Natinal Academy Science U S A. 92, 9279-
9283. 
Tolman, J. R. and K. Ruan 2006. NMR residual dipolar couplings as probes of 
biomolecular dynamics. Chem. Rev. 106, 1720-1736. 
Tong, K. I., M. Yamamoto and T. Tanaka 2008. A simple method for amino acid 
selective isotope labeling of recombinant proteins in E. coli. J Biomol NMR. 42, 59-
67. 
Toyofuku, T., K. Kurzydlowski, M. Tada and D.H. MacLennan 1994. Amino acids lys-
asp-asp-lys-pro-val-402 in the Ca2+-ATPase of cardiac sarcoplasmic reticulum are 
critical for functional association with phospholamban. Journal Biological Chemistry. 
269, 22929-22932. 
259 
 
Toyoshima, C., M. Asahi, Y. Sugita, R. Khanna, T. Tsuda and D.H. MacLennan 2003. 
Modeling of the inhibitory interaction of phospholamban with the Ca2+ ATPase. Proc 
Natl Acad Sci U S A. 100, 467-72. 
Toyoshima, C. and G. Inesi 2004. Structural basis of ion pumping by Ca2+-ATPase of 
the sarcoplasmic reticulum. Annu. Rev. Biochem. 73, 269-292. 
Toyoshima, C., M. Nakasako, H. Nomura and H. Ogawa 2000. Crystal structure of the 
calcium pump of sarcoplasmic reticulum at 2.6 A resolution. Nature. 405, 647-55. 
Toyoshima, C. and H. Nomura 2002. Structural changes in the calcium pump 
accompanying the dissociation of calcium. Nature. 418, 605-11. 
Traaseth, N. J., J.J. Buffy, J. Zamoon and G. Veglia 2006. Structural dynamics and 
topology of phospholamban in oriented lipid bilayers using multidimensional solid-
state NMR. Biochemistry. 45, 13827-13834. 
Traaseth, N. J., K.N. Ha, R. Verardi, L. Shi, J.J. Buffy, L.R. Masterson and G. Veglia 
2008. Structural and dynamic basis of phospholamban and sarcolipin inhibition of 
ca(2+)-ATPase. Biochemistry. 47, 3-13. 
Traaseth, N. J., L. Shi, R. Verardi, D.G. Mullen, G. Barany and G. Veglia 2009. Structure 
and topology of monomeric phospholamban in lipid membranes determined by a 
hybrid solution and solid-state NMR approach. Proc. Natl. Acad. Sci. U. S. A. 106, 
10165-10170. 
Traaseth, N. J., D.D. Thomas and G. Veglia 2006. Effects of Ser16 phosphorylation on 
the allosteric transitions of phospholamban/Ca(2+)-ATPase complex. J. Mol. Biol. 
358, 1041-1050. 
Traaseth, N. J. and G. Veglia 2010. Probing excited states and activation energy for the 
integral membrane protein phospholamban by NMR CPMG relaxation dispersion 
experiments. Biochim. Biophys. Acta. 1798, 77-81. 
Traaseth, N. J. and G. Veglia 2009. Probing excited states and activation energy for the 
integral membrane protein phospholamban by NMR CPMG relaxation dispersion 
experiments. Biochim. Biophys. Acta. 
Traaseth, N. J., R. Verardi, K.D. Torgersen, C.B. Karim, D.D. Thomas and G. Veglia 
2007. Spectroscopic validation of the pentameric structure of phospholamban. Proc. 
Natl. Acad. Sci. U. S. A. 104, 14676-14681. 
Traaseth, N. J., R. Verardi and G. Veglia 2008. Asymmetric methyl group labeling as a 
probe of membrane protein homo-oligomers by NMR spectroscopy. J. Am. Chem. 
Soc. 130, 2400-2401. 
Trieber, C. A., M. Afara and H.S. Young 2009. Effects of phospholamban 
transmembrane mutants on the calcium affinity, maximal activity, and cooperativity of 
the sarcoplasmic reticulum calcium pump. Biochemistry. 48, 9287-9296. 
Trieber, C. A., J.L. Douglas, M. Afara and H.S. Young 2005. The effects of mutation on 
the regulatory properties of phospholamban in co-reconstituted membranes. 
Biochemistry. 44, 3289-3297. 
260 
 
Tsai, C. J., A. Del Sol and R. Nussinov 2009. Protein allostery, signal transmission and 
dynamics: A classification scheme of allosteric mechanisms. Mol. Biosyst. 5, 207-
216. 
Tugarinov, V. and L.E. Kay 2004. An isotope labeling strategy for methyl TROSY 
spectroscopy. J Biomol NMR. 28, 165-72. 
Tugarinov, V. and L.E. Kay 2003. Ile, leu, and val methyl assignments of the 723-residue 
malate synthase G using a new labeling strategy and novel NMR methods. J Am 
Chem Soc. 125, 13868-78. 
Tycko, R., F.J. Blanco and Y. Ishii 2000. Alignment of biopolymers in strained gels: A 
new way to create detectable dipole-dipole couplings in high-resolution biomolecular 
NMR. Journal of the American Chemical Society. 122, 9340-9341. 
Tzeng, S. R. and C.G. Kalodimos 2009. Dynamic activation of an allosteric regulatory 
protein. Nature. 462, 368-372. 
Vafiadaki, E., D. Sanoudou, D.A. Arvanitis, D.H. Catino, E.G. Kranias and A. 
Kontrogianni-Konstantopoulos 2007. Phospholamban interacts with HAX-1, a 
mitochondrial protein with anti-apoptotic function. J. Mol. Biol. 367, 65-79. 
Vallurupalli, P., D.F. Hansen, E. Stollar, E. Meirovitch and L.E. Kay 2007. Measurement 
of bond vector orientations in invisible excited states of proteins. Proc. Natl. Acad. 
Sci. U. S. A. 104, 18473-18477. 
Van den Berg, B., W.M. Clemons Jr, I. Collinson, Y. Modis, E. Hartmann, S.C. Harrison 
and T.A. Rapoport 2004. X-ray structure of a protein-conducting channel. Nature. 
427, 36-44. 
Van Horn, W. D., H.J. Kim, C.D. Ellis, A. Hadziselimovic, E.S. Sulistijo, M.D. Karra, C. 
Tian, F.D. Sonnichsen and C.R. Sanders 2009. Solution nuclear magnetic resonance 
structure of membrane-integral diacylglycerol kinase. Science. 324, 1726-1729. 
van Meer, G., D.R. Voelker and G.W. Feigenson 2008. Membrane lipids: Where they are 
and how they behave. Nat. Rev. Mol. Cell Biol. 9, 112-124. 
Vandecaetsbeek, I., M. Trekels, M. De Maeyer, H. Ceulemans, E. Lescrinier, L. 
Raeymaekers, F. Wuytack and P. Vangheluwe 2009. Structural basis for the high 
Ca2+ affinity of the ubiquitous SERCA2b Ca2+ pump. Proc. Natl. Acad. Sci. U. S. A. 
106, 18533-18538. 
Vangheluwe, P., K.R. Sipido, L. Raeymaekers and F. Wuytack 2006. New perspectives 
on the role of SERCA2's Ca2+ affinity in cardiac function. Biochim. Biophys. Acta. 
1763, 1216-1228. 
Veglia, G., K.N. Ha, L. Shi, R. Verardi and N.J. Traaseth 2010. What can we learn from 
a small regulatory membrane protein? Methods Mol. Biol. 654, 303-319. 
Veglia, G. and S.J. Opella 2000. Journal of the American Chemical Society., 11733-
11734. 
Veglia, G., A.C. Zeri, C. Ma and S.J. Opella 2002. Deuterium/hydrogen exchange factors 
measured by solution nuclear magnetic resonance spectroscopy as indicators of the 
structure and topology of membrane proteins. Biophys. J. 82, 2176-2183. 
261 
 
Velyvis, A., Y.R. Yang, H.K. Schachman and L.E. Kay 2007. A solution NMR study 
showing that active site ligands and nucleotides directly perturb the allosteric 
equilibrium in aspartate transcarbamoylase. Proc. Natl. Acad. Sci. U. S. A. 104, 
8815-8820. 
Verardi, R., L. Shi, N.J. Traaseth, N. Walsh and G. Veglia 2011. Structural topology of 
phospholamban pentamer in lipid bilayers by a hybrid solution and solid-state NMR 
method. Proc Natl Acad Sci U S A. 108, 9101-9106. 
Volkov, A. N., J.A. Worrall, E. Holtzmann and M. Ubbink 2006. Solution structure and 
dynamics of the complex between cytochrome c and cytochrome c peroxidase 
determined by paramagnetic NMR. Proc. Natl. Acad. Sci. U. S. A. 103, 18945-18950. 
von Heijne, G. 2011. Introduction to theme "membrane protein folding and insertion". 
Annu. Rev. Biochem. 80, 157-160. 
von Heijne, G. 2006. Membrane-protein topology. Nat. Rev. Mol. Cell Biol. 7, 909-918. 
Wallin, E. and G. von Heijne 1998. Genome-wide analysis of integral membrane proteins 
from eubacterial, archaean, and eukaryotic organisms. Protein Sci. 7, 1029-1038. 
Walsh, J. D. and Y.X. Wang 2005. Periodicity, planarity, residual dipolar coupling, and 
structures. J. Magn. Reson. 174, 152-162. 
Warren, J. J. and P.B. Moore 2001. A maximum likelihood method ofr determining da 
and R for sets of dipolar coupling data. Journal of Magnetic Resonance. 149, 271-
275. 
Wegener, A. D., H.K. Simmerman, J.P. Lindemann and L.R. Jones 1989. 
Phospholamban phosphorylation in intact ventricles. phosphorylation of serine 16 
and threonine 17 in response to beta-adrenergic stimulation. Journal Biological 
Chemistry. 264, 11468-11474. 
White, S. H. and W.C. Wimley 1999. Membrane protein folding and stability : Physical 
principles. Annual Review Biophysics Biomolecular Structures. 28, 319-365. 
Wimley, W. C. 2003. The versatile beta-barrel membrane protein. Curr. Opin. Struct. 
Biol. 13, 404-411. 
Winters, D. L., J.M. Autry, B. Svensson and D.D. Thomas 2008. Interdomain 
fluorescence resonance energy transfer in SERCA probed by cyan-fluorescent 
protein fused to the actuator domain. Biochemistry. 47, 4246-4256. 
Wohnert, J., K.J. Franz, M. Nitz, B. Imperiali and H. Schwalbe 2003. Protein alignment 
by a coexpressed lanthanide-binding tag for the measurement of residual dipolar 
couplings. J. Am. Chem. Soc. 125, 13338-13339. 
Wright, P. E. and H.J. Dyson 2009. Linking folding and binding. Curr. Opin. Struct. Biol. 
19, 31-38. 
Yao, X., M.K. Rosen and K.H. Gardner 2008. Estimation of the available free energy in a 
LOV2-J alpha photoswitch. Nat. Chem. Biol. 4, 491-497. 
Yonemoto, W. M., M.L. McGlone, L.W. Slice and S.S. Taylor 1991. Prokaryotic 
expression of catalytic subunit of adenosine cyclic monophosphate-dependent 
protein kinase. Methods Enzymol. 200, 581-596. 
262 
 
Young, H. S., L.R. Jones and D.L. Stokes 2001. Locating phospholamban in co-crystals 
with ca(2+)-ATPase by cryoelectron microscopy. Biophys J. 81, 884-94. 
Young, H. S., L.G. Reddy, L.R. Jones and D.L. Stokes 1998. Co-reconstitution and co-
crystallization of phospholamban and ca(2+)-ATPase. Ann. N. Y. Acad. Sci. 853, 
103-115. 
Young, H. S., J.L. Rigaud, J.J. Lacapere, L.G. Reddy and D.L. Stokes 1997. How to 
make tubular crystals by reconstitution of detergent-solubilized Ca2(+)-ATPase. 
Biophys. J. 72, 2545-2558. 
Zamoon, J., A. Mascioni, D.D. Thomas and G. Veglia 2003. NMR solution structure and 
topological orientation of monomeric phospholamban in dodecylphosphocholine 
micelles. Biophys. J. 85, 2589-2598. 
Zamoon, J., F. Nitu, C. Karim, D.D. Thomas and G. Veglia 2005. Mapping the interaction 
surface of a membrane protein: Unveiling the conformational switch of 
phospholamban in calcium pump regulation. Proc. Natl. Acad. Sci. U. S. A. 102, 
4747-4752. 
Zech, S. G., A.J. Wand and A.E. McDermott 2005. Protein structure determination by 
high-resolution solid-state NMR spectroscopy: Application to microcrystalline 
ubiquitin. J. Am. Chem. Soc. 127, 8618-8626. 
Zhang, H., S. Neal and D.S. Wishart 2003. RefDB: A database of uniformly referenced 
protein chemical shifts. J. Biomol. NMR. 25, 173-195. 
Zhao, X., S. Hu, J. Li, Y. Mou, K. Bian, J. Sun and Z. Zhu 2008. rAAV-asPLB transfer 
attenuates abnormal sarcoplasmic reticulum Ca2+-ATPase activity and cardiac 
dysfunction in rats with myocardial infarction. European Journal of Heart Failure,. 10, 
47-54. 
Zhou, Y., T. Cierpicki, R.H. Jimenez, S.M. Lukasik, J.F. Ellena, D.S. Cafiso, H. 
Kadokura, J. Beckwith and J.H. Bushweller 2008a. NMR solution structure of the 
integral membrane enzyme DsbB: Functional insights into DsbB-catalyzed disulfide 
bond formation. Mol. Cell. 31, 896-908. 
Zhou, Y., T. Cierpicki, R.H. Jimenez, S.M. Lukasik, J.F. Ellena, D.S. Cafiso, H. 
Kadokura, J. Beckwith and J.H. Bushweller 2008b. NMR solution structure of the 
integral membrane enzyme DsbB: Functional insights into DsbB-catalyzed disulfide 
bond formation. Mol. Cell. 31, 896-908. 
 
 
 
